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Title of Study: GLUTAMATE RECEPTOR SUBUNITS IN THE RAT CORNEA 
Major Field: BIOMEDICAL SCIENCES 
Abstract:  
The purpose of this study was to identify if topical application of an ionotropic Glutamate 
receptor (iGluR) antagonist could effectively reduce pain in the cornea and to identify the 
presence and location of the 16 different iGluR subunits. Furthermore, we assessed the 
quality of the currently published iGluR literature using the ARRIVE guidelines. We 
identified DNQX as an effective iGluR antagonist when topically applied to the cornea, 
we identified the presence of each of the iGluR to the cornea and the trigeminal root 
ganglion, and we identified the lack of completeness in the currently published iGluR 
literature. From these results, further investigation of DNQX should be done to identify if 
it can be used as an effective treatment of corneal pain. Further studies including co-
localization of iGluR subunits should be done to identify receptor composition and 
functionality. Finally, a better reporting of the methods and results of published works 
should be done to increase translation of results from animal to human.   
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CHAPTER I 
INTRODUCTION AND REVIEW OF LITERATURE 
Introduction 
Pain can be detrimental to everyday events leading to decreased productivity within 
society, including family, social, and work life. To regulate pain in a way to help an individual 
remain or become a functional member of society would be a huge improvement to many lives 
and society as a whole. Specifically, the type of pain, acute or chronic, an individual has may 
influence how their life will proceed within the near and possibly distant future. Acute pain is 
common from the peripheral nervous system due to an extensive innervation of tissues by 
primary sensory afferent nerve fibers. The structure, innervation, and sensitivity of the tissue will 
determine the level of pain intensity that leads to nocifensive (adverse) responses.  
Nocifensive responses are present in vertebrates to help fend off adverse stimuli that may 
be detrimental to existence. In the eye, a noxious stimulus may produce a nocifensive response 
such as eye blinking. When an irritant has been introduced to the eye, primary sensory afferents 
of the cornea responsively fire action potentials to signal for a nocifensive response. It has been 
proposed that glutamate, an excitatory neurotransmitter, has a role in the transduction of external 
stimuli and a neuronal response (Miller et al. 2011). The action of glutamate occurs by activating 
Glutamate Receptors (GluRs): α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
(AMPAr), Kainate receptor, and N-Methyl-D-aspartic acid receptor (NMDAr) (Bleakman, Alt, 
& Nisenbaum, 2006). The following literature review will describe in more detail the 
background of these phenomena and introduce my research hypotheses and specific aims.  
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Literature Review 
1.1: Nociception: Nociception is a response to a noxious stimulus. A noxious stimulus is 
an adverse stimulus that can cause reflex withdrawals, autonomic responses, and pain 
(Sherrington, 1903). A noxious stimulus, via application or injection of glutamate (da Silva et al., 
2014; Michelotti et al., 2014; Nilsson et al., 2014; Sato et al., 2015; Shimada et al., 2015), 
mustard oil (Albin, Carstens, & Carstens, 2008; Bonjardim, da Silva, Gameiro, Tambeli, & 
Ferraz de Arruda Veiga, 2009; Claiborne, Nag, & Mokha, 2009; Merrill, Cuellar, Judd, Carstens, 
& Carstens, 2008; Ruparel, Patwardhan, Akopian, & Hargreaves, 2008; Sawyer, Carstens, & 
Carstens, 2009; Zhang et al., 2006), capsaicin (Burness & McCormack, 2016; Deba & Bessac, 
2015; Doll et al., 2016; Landmann et al., 2016; Li et al., 2016; Ruparel et al., 2008; Zakharov et 
al., 2015), and Freund's adjuvant (Atianjoh et al., 2010; Y. S. Lee, Lee, Lee, & Choi, 2013; J. S. 
Park et al., 2008; Peng et al., 2012), can initiate an action potential from primary sensory afferent 
nerve fibers innervating peripheral tissue. In order to prevent unwanted harm to a tissue, a 
reflexive response (including wiping, licking, moving, etc.) occurs to prevent the noxious 
stimulus from remaining on a tissue for a prolonged period of time (Rossignol, Dubuc, & 
Gossard, 2006). This type of stimulus also will elicit nociception, or pain. 
1.2: Nociceptors: Nociceptors are classified as Aδ and C primary afferent fibers, but as 
seen in table 1.1, primary afferent nerve fibers in general are classified as being large, medium, 
or small or as type A, B, and C respectively (Basbaum, Bautista, Scherrer, & Julius, 2009; 
Haines, 2012). Furthermore, table 1.1 represents a distinct breakdown of the classifications of 
neuron type that is dependent on axon diameter, nerve fiber velocity, and what tissue is supplied 
by nociceptors. 
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Peripheral nerve 
electrophysiologic 
classification 
Afferent 
Fibers 
group 
Fiber 
Diameter 
(µm) 
Conduction 
velocity 
(m/s) Receptor supplied 
Sensory Fiber         
Aα 
Ia and 
Ib 13 - 20 80-120 Primary muscle spindles, Golgi tendon organ 
Aβ II 6-12 35-75 Secondary muscle spindles, skin mechanoreceptors 
Aδ III 1-5 5-30 
Skin mechanoreceptors, thermal receptors, and 
nociceptors 
C IV 0.2-1.5 0.5-2 
Skin mechanoreceptors, thermal receptors, and 
nociceptors 
Motor Fiber         
Aα N/A 12-20 72-120 Extrafusal skeletal muscle fibers 
Aγ N/A 2-8 12-48 Intrafusal muscle fibers 
B N/A 1-3 6-18 Preganglionic autonomic fibers 
C N/A 0.2-2 0.5-2 Postganglionic autonomic fibers 
Table 1.1: Sensory and motor nerve fiber classification (Adapted from (Haines, 2012)). 
The nociceptors, or primary sensory afferent neurons, have four specific main parts: the 
peripheral nerve terminal, axon, neuronal cell body, and a central axon terminal (Woolf & Ma, 
2007). The peripheral nerve terminal is present in the peripheral tissue and responds to a noxious 
stimulus that can produce an axonal action potential to reach the next sensory neuron, a 
secondary sensory neuron (Mertens, Blond, David, & Rigoard, 2015). The neuronal cell body is 
located in the Trigeminal Root Ganglion (TRG) or the Dorsal Root Ganglion (DRG) depending 
if the peripheral tissue is located in the face or body, respectively. Furthermore, these primary 
sensory afferent neurons are classified as pseudounipolar with one axon from the neuronal cell 
body that divides to project peripherally and centrally (Ray, Singh, & Mehra, 2010). In order to 
convey a noxious signal to the secondary neuron, the central axon terminal produces synaptic 
release, i.e., exocytosis, of neurotransmitters to stimulate the secondary neuron (Mertens et al., 
2015). 
For a noxious signal to reach the brain, there are four sensory neurons organized in a 
sequence from the peripheral tissue to the cerebral cortex. The primary neuron, represented by 
figure 1.1, extends from the peripheral tissue to the brainstem or spinal cord depending if the 
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primary neuron innervates the face or the body, respectively. This is where a topical stimulus- 
can be applied to the cornea to start a signaling cascade. The primary neuron synapses on a 
secondary neuron located in a brainstem nucleus or spinal cord. This secondary neuron has an 
axon that ascends to the thalamus to synapse on a tertiary neuron present in the Ventral Posterior 
Medial (Noseda & Burstein, 2013) or Ventral Posterior Lateral (Mertens et al., 2015) nucleus 
dependent on the primary neuron innervating the face or the body, respectively. Finally, the 
thalamic neuron synapses on a fourth order neuron in the primary sensory cortex of the brain. 
The peripheral noxious stimulus will be interpreted cognitively in the cortex as pain (Mertens et 
al., 2015; Noseda & Burstein, 2013). At the same time, interneurons in the brainstem or spinal 
cord produce a fast noxious reflexive response before a full painful interpretation is made 
(Rossignol et al., 2006). This reflexive nocifensive response is an attempt to eliminate the 
noxious stimulus before it can cause any harm.  
 
 
Figure 1.1: Primary sensory afferent in the cornea. 
1.3: Glutamate as a neurotransmitter: L-glutamate is the major excitatory 
neurotransmitter within vertebrates (Miller, Hoffman, Sutharshan, & Schechter, 2011). Once 
bound to a Glutamate receptor (GluR), a conformational change of the receptor will occur 
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producing an influx and efflux of ions disrupting the basal, electrochemical balance (Greger, 
Ziff, & Penn, 2007). If the response is large enough, the neuronal membrane will depolarize to 
produce an action potential through its axon to signal for neurotransmitter, e.g., glutamate, 
release into the postsynaptic cleft (Greger et al., 2007). Release of glutamate has the potential to 
signal the postsynaptic neuron to trigger an action potential.  
1.4: Glutamate synthesis: Glutamate is the conjugate base of the amino acid glutamic 
acid. Glutamic acid is a non-essential amino acid owing to cells being able to synthesize 
glutamate from glutamine (Miller et al., 2012). Glutamine is a non-essential amino acid under 
normal conditions, but also is a conditionally essential amino acid when an individual is 
critically ill. During this critically ill, or stressed state, the individual will require an external 
source of glutamine to meet the requirements of the body (Lacey & Wilmore, 1990). In the 
nervous system, a constant store of glutamine, the substrate for glutamate synthesis, is present 
from the supporting cells, such as astrocytes and Schwann cells, so that neurons will have 
replenishment of glutamate following synaptic exocytosis (Miller et al., 2011).  
 As seen in figure 1.2, Glutamine (Gln), stored in the glial cells, can be released for 
presynaptic neuronal uptake (Popoli, Yan, McEwen, & Sanacora, 2012). Once in the presynaptic 
neuron, the catalyzing enzyme glutaminase will perform glutaminolysis by hydrolysis of the 
amide group of glutamine (Miller et al., 2011). This will produce glutamic acid which can 
convert to its conjugate base after deprotonation of a hydroxyl group, glutamate (Fazzari, Linher-
Melville, & Singh, 2016). Glutamate is transported into the synaptic vesicles within the 
presynaptic neuron by the vesicular glutamate transporter (vGluT) (Miller et al., 2011). Once 
glutamate is in the synaptic vesicle, the presynaptic neuron can synaptically release, i.e., 
exocytose, glutamate into the synaptic cleft. At this time, the glutamate can bind to and trigger a 
conformational change of glutamate receptors on the post synaptic neuron causing membrane 
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depolarization and action potential production in the secondary neuron. Glutamate is recycled 
back into the Schwann or satellite cells by cell membrane glutamate transporters. Glutamate is 
converted back into glutamine by the enzyme glutamine synthetase (Miller et al., 2011) to 
continue the cycle between glutamine and glutamate. 
 
Figure 1.2: Postsynaptic neurotransmitter interactions. (Adapted from Thomas Splettstoesser (www.scistyle.com) - 
Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=41349083) 
1.5 Glutamate receptors: Ionotropic glutamate receptors (iGluRs) are present in the post 
synaptic neurons for regulation of neuronal depolarization and subsequent generation of action 
potentials (Mayer, 2005b). These iGluRs are also present on the peripheral tissue epithelium and 
the peripheral nerve terminals of primary afferents (Hatziefthimiou, Gourgoulianis, & Molyvdas, 
2002). Currently, there are three recognized iGluRs known in vertebrates: α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAr), Kainate receptor, and N-Methyl-D-aspartic 
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acid receptor (NMDAr) (Bleakman et al., 2006). A fourth type of iGluR, the Delta receptor, 
recently has been described and is currently undergoing characterization (Miyoshi et al., 2014; 
Yuzaki & Aricescu, 2017). The AMPA, Kainate, and NMDA receptors are all tetramers 
(Bleakman et al., 2006; Mayer, 2005b), as seen in figure 1.3, meaning four separate subunits 
combine to make a functional receptor (Popoli et al., 2012). These receptors can all be either 
heterotetramers, meaning that more than one receptor subtype produce a receptor, or 
homotetramers, which means that four of the same type of subunit produce a functional receptor 
(Bleakman et al., 2006).  
Even though AMPA, Kainate, and NMDA subunits are all iGluRs, a functional receptor 
can only be formed when four subunits combine within their respective type. AMPA receptors 
can also form homotetramers by dimerizing two dimers that both consist of the same type of 
subunits (Greger et al., 2007). Some of the combinations of AMPA subunits may not be fully 
functional, so receptor subunit expression is tightly controlled and specific combinations on the 
cellular membrane will be present (Coleman et al., 2010). 
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Figure 1.3: Conformation of the glutamate receptor before (Left) and after (Right) a conformational change. 
Represented by the GluN1–GluN2B NMDA receptor. (By Curtis Neveu - Own work, CC BY-SA 3.0, 
https://commons.wikimedia.org/w/index.php?curid=16583388) 
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Table 1.2: Nomenclature of the glutamate receptor subunits. 
1.6 AMPA receptors: AMPA receptors can be present in the form of homotetramers or 
heterotetramers, increasing the diversity in the construct of a functioning AMPA receptor 
(Greger et al., 2007; Mayer, 2005b). The AMPA receptors have four subunits that include 
GluA1, GluA2, GluA3, and GluA4 (Greger et al., 2007). In the vertebrate nervous system, there 
appears to be a limit to subunit combinations (Traynelis et al., 2010). Our current knowledge 
indicates that two of the four AMPA subunits dimerize, then, when forming a heterotetramer, 
form as a dimer of dimers (Greger et al., 2007). These dimers will then dimerize with another 
dimer to form a functional receptor with four subunits.  
A normally activated AMPA receptor will allow some calcium through the pore along 
with sodium from the extracellular space to intracellular (Traynelis et al., 2010). An exception to 
this rule is that the AMPA receptors can further increase diversity by substituting one amino acid 
for another to decrease calcium permeability (Traynelis et al., 2010). The Glutamine (Q) to 
Arginine (R) substitution that resides in the pore loop of the receptor dramatically reduces the 
calcium permeability of receptors containing modified GluA2 subunits (Greger et al., 2007). 
Furthermore, the GluA2-4 subunits can go through a Glycine (G) to Arginine (R) replacement in 
the ligand binding domain (LBD) that will allow for a quicker recovery of the receptor after 
depolarization (Lomeli et al., 1994).  
NMDA AMPA Kainate Delta
NR1 = GluN1 GluRA = GluR1 = GluA1 GluR5 = GLUK5 = GluK1 δ1 = GluD1
NR2A = GluN2A GluRB = GluR2 = GluA2 GluR6 = GLUK6 = GluK2 δ2 = GluD2
NR2B = GluN2B GluRC = GluR3 = GluA3 GluR7 = GLUK7 = GluK3
NR2C = GluN2C GluRD = GluR4 = GluA4 KA1 = GLUK1 = GluK4 
NR2D = GluN2D KA2 = GLUK2 = GluK5
NR3A = GluN3A
NR3B = GluN3B
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Another way that the AMPA receptors increase their diversity is by the production of two 
splicing variations called Flip and Flop (Pachernegg, Munster, Muth-Kohne, Fuhrmann, & 
Hollmann, 2015; Y. H. Park et al., 2016; Pei et al., 2009). The flip/flop splicing site of the 
AMPAr subunits (Krampfl et al., 2002; Lomeli et al., 1994; Pachernegg et al., 2015; Pei et al., 
2009) is found in the C-terminal loop between TMIII and TMIV (Greger et al., 2007). When 
spliced at the flip/flop site, only one of the two 115 base pair long sequences will be expressed 
(Pachernegg et al., 2015). The overall kinetics of the receptor show that the flip splice variant is 
activated faster and the desensitization of the receptors containing these subunit splice variants 
will be about four times slower than the flop splice variant (Pachernegg et al., 2015; Pei et al., 
2009).  
The type of AMPAr subunits present in a nerve terminal can help determine the roles 
they have during persistent, or chronic, pain (Latremoliere & Woolf, 2009; Tao, 2012). Central 
sensitization occurs as increased responsiveness of a second order, nociceptive neuron (Woolf & 
Salter, 2000). When NMDA receptors are activated postsynaptically, an increase influx of 
calcium activates protein kinase enzymes, protein kinase C (PKC), Ca2+/calmodulin-dependent 
protein kinase (CaMKII), protein kinase A (PKA), and extracellular signal–regulated kinases 
(ERK), that phosphorylate the GluA2 containing AMPA receptors and, in turn, causes 
endocytosis of the receptors. Furthermore, intracellular GluA1 containing AMPA receptors 
stored on vesicles will also become phosphorylated allowing them to be inserted into the 
membrane, replacing the GluA2 AMPAr. This allows for a much higher calcium influx further 
activating additional protein kinase pathways. These kinases produce phosphorylation of the 
scaffolding protein stargazin, increasing its affinity to postsynaptic density-95 (PSD-95), an 
auxiliary protein, and modifying its ectodomain (Latremoliere & Woolf, 2009). This allows for 
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an increased affinity of the GluA1 receptor subunit for glutamate and allows for higher channel 
opening probability to further increase the calcium influx (Latremoliere & Woolf, 2009). 
1.7 Kainate receptors: Kainate receptors consist of the subunits GluK1-5 and are also 
present as homotetramers and heterotetramers similar to AMPA and NMDA receptors 
(Bleakman et al., 2006), but not all of the Kainate receptor subunits can form homotetramers. 
The GluK1-3 receptor subunits can form homotetramers as well as heterotetramers. The GluK4 
and GluK5 subunits are only found in a heterotetrameric conformation and they need to form a 
heterotetramer with the GluK1-3 subunits (Mollerud, Frydenvang, Pickering, & Kastrup, 2017). 
The Kainate receptors are located both on pre-and post-synaptic terminals, whereas AMPA 
receptors are commonly located in post synaptic terminals only (Mollerud et al., 2017). 
Furthermore, the Kainate receptor subunits GluK4 and GluK5 have been shown to undergo a 
glutamine (Q) to an arginine (R) post-translational site editing causing a reduction in calcium 
permeability (Burnashev, Zhou, Neher, & Sakmann, 1995) similar to the AMPA receptors. 
The Kainate receptor binding domain of the GluK1 and GluK2 subunits have been 
described as 40% and 16% larger when compared to the GluA2 subunit (Mayer, 2005a). The 
larger volume of these Kainate receptor subunit binding domains allows for additional water 
molecules to become attached to the ligand binding domain (LBD) (Mayer, 2005a). Once the 
ligand glutamate comes into contact with the LBD, water molecules are displaced and an 
additional 11° greater domain closure of the GluK2 occurs, compared to the GluA2 subunit 
(Mayer, 2005a). This corresponds with the greater efficacy for ion gating that is seen by the 
Kainate receptors (Mayer, 2005a) as compared to the AMPA and NMDA receptors.  
Kainate receptor subunits have differing structural characteristics and responses when a 
ligand binds to the Kainate subunit LBD as compared to the AMPA subunit LBD. For example, 
Kainate receptors have a strong affinity for the specific ligand, Kainic acid, which causes a rapid 
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desensitization of the Kainate receptor but a nondesensitizing response at the AMPA receptors 
(Fleck, Cornell, & Mah, 2003; Patneau, Vyklicky, & Mayer, 1993). Furthermore, Kainate 
receptors recover from desensitization much slower than AMPA receptors (Fleck et al., 2003). 
Splice variation and RNA editing also occur for Kainate receptors to greatly increase variability 
similar to AMPA receptors (Bleakman et al., 2006). Lastly, Kainate receptors seem to play a key 
role in some diseases including epilepsy, schizophrenia, depression and bipolar disorder (Das et 
al., 2012; Ibrahim et al., 2000; Pickard et al., 2006).  
1.8 NMDA receptors: NMDA receptors occur as homotetramers and heterotetramers 
similar to that of the AMPA and Kainate receptors (Bleakman et al., 2006). There currently are 
seven NMDA receptor subunits which include GluN1, GluN2A-D, and GluN3A-B, (Bleakman 
et al., 2006). A major difference between NMDA receptors and the AMPA and Kainate receptors 
is that two GluN1 subunits are required to be present in all functional NMDA receptors. 
Additionally, these receptor subunits bind coagonists glycine or D-serine (Balu & Coyle, 2015; 
Mothet, Le Bail, & Billard, 2015). This provides additional complexity to the NMDA receptors 
since glutamate and a coagonist must be present to trigger a conformational change in the 
receptor. Furthermore, the GluN3A-B receptor subunits also use glycine or D-serine as a 
coagonist (Traynelis et al., 2010; Yao & Mayer, 2006). To form a functional GluN3 containing 
NMDA receptor, a GluN2 and 2 GluN1 subunits need to be present (Traynelis et al., 2010).  
NMDA receptors are unique from AMPA and Kainate receptors by having a basal, 
magnesium channel block preventing the flow of ions until it has been dislodged from the 
receptor (Mayer, Westbrook, & Guthrie, 1984; Nowak, Bregestovski, Ascher, Herbet, & 
Prochiantz, 1984). The magnesium block plays a large role in central sensitization by preventing 
calcium influx until proper membrane depolarization, often by GluA2 containing AMPA 
receptors (Latremoliere & Woolf, 2009). Once membrane depolarization occurs, magnesium is 
  
 
13 
 
dislodged allowing the influx of calcium ions through the NMDA receptor. The increased Ca++ 
will lead to the phosphorylation of GluA2 to cause a switching, endocytosis, of GluA2 
containing AMPA receptors to GluA1 containing receptors (Latremoliere & Woolf, 2009) as 
previously described during central sensitization. 
Splice variants also are present for GluN1, further increasing the diversity of NMDA 
receptors (Bleakman et al., 2006; Dingledine, Borges, Bowie, & Traynelis, 1999). The GluN1 
splice variants can be full length, missing exon 21, missing exon 22, or missing both and are 
represented as GluN1-1, GluN1-2, GluN1-3, GluN1-4, respectively (Dingledine et al., 1999). 
Furthermore, each of these splice variants can be further classified by inclusion or exclusion of 
exon 5 (Dingledine et al., 1999). 
1.9 Delta Receptors: Delta receptors are currently classified as glutamate receptors due 
to their similarity to the other three iGluRs, but they are not activated by glutamate (Miyoshi et 
al., 2014). The delta receptors have two subunits, GluD1 and GluD2, coded by the GRID2 gene 
(Miyoshi et al., 2014). The delta receptors will not be studied in our analysis. A complete 
summary of the iGluR nomenclature is present in table 1.2. 
1.10 Corneal Structure: The cornea is a transparent and avascular tissue that allows 
light to enter the eye for the retina (Parekh, Ferrari, Sheridan, Kaye, & Ahmad, 2016). The 
cornea consists of five main layers including the epithelial cell layer, Bowman’s layer, corneal 
stroma, Descemet’s layer, and endothelial cell layer. The corneal epithelium is stratified 
squamous epithelium. It consists of four to six cell layers in the human and is about 50 µm thick 
(Eghrari, Riazuddin, & Gottsch, 2015) as seen in figures 1.4. The corneal epithelium is the 
outermost cellular layer and is directly exposed to external irritants such as dust, chemicals, etc. 
The large number of tight junctions between corneal epithelial cells (Eghrari et al., 2015) helps 
to prevent adverse substances from crossing the epithelium to gain access to deeper corneal 
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structures. Under the epithelial layer is Bowman’s layer. Bowman’s layer is present in many 
species, but no major role has been found other than being the basement membrane of the 
corneal endothelial cells (Wilson & Hong, 2000). The stromal layer resides under Bowman’s 
layer as seen in Fig. 1.4. The stromal layer consists of about 90% of the thickness of the cornea, 
consisting of extra-cellular matrix proteins secreted by the epithelial and endothelial cells. The 
stroma has a key role of visual function due to the regular organization pattern of the collagen 
layers allowing for optimal passage of light (Xuan et al., 2016). The endothelial cells are the 
innermost layer of the cornea and Descemet’s membrane is the basement membrane for the 
endothelial cells (Parekh et al., 2016). The endothelial cells of the cornea have an incomplete 
zona occludens which allows nutrients to enter the cornea from the aqueous humor and allows 
water from the cornea to move towards the aqueous humor to keep the cornea slightly 
dehydrated to improve its transparency (Parekh et al., 2016). 
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Figure 1.4: Corneal layers (By Henry Vandyke Carter - Henry Gray (1918) Anatomy of the Human Body 
(See "Book" section below)Bartleby.com: Gray's Anatomy, Plate 871, Public Domain, 
https://commons.wikimedia.org/w/index.php?curid=566809) 
1.11: Corneal innervation: The cornea is innervated by the ophthalmic division of the 
trigeminal nerve (Cranial Nerve V1) (Marfurt & Del Toro, 1987). As seen in figure 1.5, the 
ophthalmic division of the trigeminal nerve enters the stroma and primary sensory afferents 
branch to innervate the corneal epithelium (Chan-Ling, 1989). The peripheral portion of the 
corneal epithelium is more highly innervated than the central (He, Bazan, & Bazan, 2010). 
Although glutamate and glutaminase have been reported in corneal afferent fibers (Miller & 
Ibitokun, 2011), there is a lack of knowledge about glutamate receptor subunit distribution in the 
corneal epithelium.  
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Figure 1.5: Sensory innervation of the cornea from the ophthalmic division of the trigeminal nerve. 
1.12: Glutamate in the Cornea: Glutamate is an effective agonist of iGluRs in the rat 
cornea. Although the corneal epithelial cells are held together by many tight junctions, topical 
application of glutamate is very effective at inducing a nocifensive response. In figure 1.6, the 
behavioral response, blinking, wiping, shaking, of Sprague Dawley rats is displayed when 
glutamate is introduced to the cornea in a topical solution. In figure 1.7, the glutamate dose 
response and the median effective dose (ED50) is presented (Ibitokun, 2012). The ED50 for 
glutamate-induced nocifensive responses was determined to be 0.5 M. Compared to the CNS, the 
high concentration of glutamate needed to induce an effective response is due to the tissue 
organization of the cornea, i.e., multiple cell layers and tight junctions. Since the topical solution 
of glutamate is applied directly to the eye, glutamate molecules reach the iGluRs by diffusion. In 
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addition, there is a thin layer of lubricating fluid, known as tear film, on the eye surface that 
dilutes the glutamate solution once applied.  
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   1.13: Glutamate receptor agonists: AMPA and Kainate are effective agonists of 
their respective iGluRs in the rat cornea. In our lab, AMPA and Kainate were applied to the 
rat cornea and the nocifensive response to these agonists is demonstrated in figures 1.8 and 1.9, 
respectively (Ibitokun, 2012). In figure 1.8 a topical application of AMPA was applied to the 
cornea and the ED50 was determined to be 0.5mM. In figure 1.9, a topical application of kainate 
was applied to the cornea and the ED50 was ascertained to be 0.1mM. This further supports that 
various shape and sizes of molecules can diffuse through the corneal epithelium to gain access to 
the sensory peripheral afferents.   
Figure 1.6. Glutamate dose response 
study. (From (Ibitokun, 2012))         
Figure 1.7. Glutamate dose response 
curve. (From (Ibitokun, 2012)) 
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1.14: Glutamate receptor antagonists: Antagonists of iGluR can be used to prevent 
activation of iGluRs to elicit action potentials (Alt et al., 2004). These iGluR antagonists include, 
but are not limited to: DNQX (Fedele & Raiteri, 1996; Lund et al., 2010), NBQX (Alt et al., 
2004; Dolman et al., 2005), and GYKI 53655 as AMPA/Kainate antagonists (Bleakman et al., 
1996; Bleakman, Ogden, Ornstein, & Hoo, 1999), LY382884 as a Kainate antagonist (Alt et al., 
2004), and AP5 as an NMDA antagonist (Lund et al., 2010). These iGluR antagonists 
competitively inhibit the iGluR by attaching to the ligand binding site making it less likely that 
the agonist, a glutamate molecule, will bind (Alt et al., 2004). By decreasing the likelihood of the 
iGluR activation, a reduction of nocifensive behavior can be observed and analyzed to determine 
the effectiveness of the antagonist (Bonnet et al., 2015).  
1.15: Glutamate subunit presence in the cornea: Immunohistochemistry supports the 
presence of NMDA receptors within the cornea. We have evaluated the presence of NMDA 
receptors using whole mounts and sagittal sections from the rat cornea (Ibitokun, 2012). Figure 
1.12 represents the immunoreactivity of corneal epithelial cells for GluN1 (NMDA subunit) 
demonstrated by the white arrows. The yellow arrows illustrate the immunoreactive granules that 
Figure 1.8. AMPA dose response curve. 
(From (Ibitokun, 2012))                       
Figure 1.9. Kainate dose response curve. 
(From (Ibitokun, 2012)) 
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are found within the nuclei and cell membranes of corneal epithelial cells. In figure 1.13, the 
white arrows represent the immunoreactivity of GluN1 on the corneal epithelial nerve fibers. 
This supports the hypothesis that the NMDA receptors are present in the cornea, but other 
specific NMDA subunits have not been studied. Furthermore, double labeling of NMDA 
subunits with nerve fiber specific proteins, e.g., peripherin, protein gene product 9.5, beta 
tubulin, have not been conducted. 
                                      
 
 
 
 
 
Immunohistochemistry supports the presence of AMPA receptors in the cornea. We have 
evaluated the presence of AMPA receptors using whole mount and sagittal sectioned corneas 
(Ibitokun, 2012). Figure 1.12 represents the whole mount immunoreactivity of AMPA GluA1 
receptor subunits represented by the white arrows. In figure 1.13, the white arrows demonstrate 
the GluA2/3 immunoreactivity within the cytoplasm of the corneal epithelial cells and the yellow 
arrows illustrate the immunoreactivity of GluA2/3 subunits around the nuclei of the epithelial 
Figure 1.10. NMDA GluN1 
immunoreactivity in cornea (whole 
mount). Corneal epithelial cell 
membranes are immunoreactive for 
NMDA GluN1 (white arrows), as well 
as scattered GluN1 immunoreactive 
granules within the nucleus (yellow 
arrows). (From (Ibitokun, 2012)) 
 
Figure 1.11. NMDA GluN1 
immunoreactivity in the rat cornea 
(10µm sagittal section). NMDA 
GluN1 immunoreactivity was 
observed on corneal epithelial 
nerve fibers (white arrows). These 
corneal afferent nerve fibers 
exhibited varicosities and traveled 
between the superficial corneal 
epithelial cells. (From (Ibitokun, 
2012)) 
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cells. This supports the hypothesis that AMPA receptors are present within the rat cornea, but the 
evaluation of other specific AMPA subunits is still understudied. Furthermore, the neuronal 
innervation associated with the AMPA receptors composition is lacking and can be further 
explained by double or triple labeling AMPA subunits alongside nerve fiber specific proteins 
(Ibitokun, 2012).  
                                   
 
 
 
 
 
1.16: Animal Research: Reporting of In Vivo Experiments (ARRIVE) Guidelines:  
To increase the quality of reporting preclinical trials, a set of standardized guidelines can 
be used. A set of guidelines commonly accepted for preclinical trials within a wide range of 
journals is called the Animal Research: Reporting In Vivo Experiments (ARRIVE) Guidelines 
(Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010). These guidelines were published in Plos 
Biology in 2010 to help standardize scientific reporting. Many journals have adopted the use of 
the ARRIVE guidelines to aid in the efforts to increase the quality of reporting. The ARRIVE 
guidelines are meant to be used during the process of constructing a study, but many 
Figure 1.12. AMPA GluA1 
immunoreactivity in cornea (whole 
mount). The cornea shows GluA1 
immunoreactivity in the subepithelial 
nerve plexus as indicated by the white 
arrows. (From (Ibitokun, 2012)) 
 
Figure 1.13. AMPA GluA2/3 
immunoreactivity in the rat cornea 
(10µm sagittal section). GluA2/3 
immunoreactivity occurred in corneal 
epithelial cells. The distribution is 
mainly within the cytoplasm (white 
arrows) of the epithelial cells with a 
clustering around the nucleus (yellow 
arrows). (From (Ibitokun, 2012)) 
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investigators encounter ARRIVE guidelines after the completion or initiation of research study 
and apply their study to the guidelines rather than applying the guidelines to their study.  
Preclinical trials in their current state have consistently underutilized the ARRIVE 
Guidelines (Baker, Lidster, Sottomayor, & Amor, 2014; Karp et al., 2015; Kilkenny et al., 2010). 
To increase the reporting of the standards set by the ARRIVE guidelines, in the current study we 
aim to identify the components that are lacking within the Excitatory Amino Acid Receptor 
(EAAR) literature, which includes the iGluR literature, so we can apply that knowledge to future 
preclinical trials. Figure 1.14 and 1.15 represents the first and second half ARRIVE guidelines 
with all of its components and descriptions, respectively.  
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Figure 1.14: The first half of the ARRIVE guidelines describing the recommended components of an 
animal research manuscript. (From (Kilkenny et al., 2010)) 
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Figure 1.15: The second half of the ARRIVE guidelines describing the recommended components of an 
animal research manuscript. (From (Kilkenny et al., 2010)) 
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1.17: Prospective implementations: Many previous experiments have used AMPA, 
Kainate, and NMDA receptor antagonists injected into tissue to test their effectiveness and 
examine if these antagonists can access peripheral receptors in the hind paw (J. S. Park et al., 
2008), sciatic nerve (Gong, Kung, Magni, Bhargava, & Jasmin, 2014), and masseter (Lund et al., 
2010). A missing element in this research on peripheral iGluRs is an examination of one of the 
most accessible tissues on the body, the cornea. Our study is novel in the sense that the treatment 
site is the direct application to the cornea. We also will use a iGluR antagonist that may be less 
selective when compared to other antagonists, but has a good chance of being effective in the 
cornea due to its low molecular weight. With this in mind, our study may yield a new 
pharmaceutical drug that can be easily applied to the cornea with a dropper. Furthermore, with a 
better understanding of the presence of the iGluR subunits in the cornea, more specific drugs can 
be used to target specific receptors that could have fewer side effects. 
1.18: Hypotheses and Specific Aims: 
Hypothesis for Aim 1: We hypothesize that the iGluRs can be antagonized with a topical 
application of the AMPA-kainate antagonist DNQX in the rat cornea.  
Specific Aim 1: To behaviorally evaluate the effect of DNQX, a selective AMPA and 
Kainate GluR antagonist, with co-application of glutamate to the Sprague Dawley rat 
cornea. In this study, a comprehensive evaluation of the nocifensive responses to glutamate 
when DNQX is co-administered will be carried out. Nocifensive responses to be recorded 
include: eye blinking, eye wiping, and eye scratching. The effectiveness of the antagonist will be 
evaluated by conducting an analysis of variance (ANOVA).  
Hypothesis for Aim 2: We hypothesize that specific iGluR subunits are present in the 
cornea and certain combinations of iGluR subunits contribute to the perception of pain of the 
cornea. 
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Specific Aim 2: To use Western blotting and immunohistochemical techniques to 
determine the presence and location of ionotropic GluR subunits within the Sprague 
Dawley rat cornea. In this study, Western blotting techniques and immunofluorescent imaging 
will be used to evaluate the specific subunits of iGluRs in relation to the corneal architecture. 
Localizing the specific iGluRs along with localizing nerve fibers will allow for a better 
understanding of the location, presence, and potential functionality of these iGluR subunits. 
Hypothesis for Aim 3: We hypothesize that there is an underreporting of the ARRIVE 
guidelines, particularly in methods sections, in the EAAR literature.  
Specific Aim 3: To evaluate Excitatory Amino Acid Receptor literature for the 
reporting of the ARRIVE guidelines components. In this study, the ARRIVE guidelines will 
be applied to the published EAAR literature. We will evaluate each of the ARRIVE guidelines to 
identify the components that are most severely underreported. This will allow for the proper 
reporting of results according to the ARRIVE guidelines for studies in our laboratory and 
hopefully other laboratories.  
 
 
 
 
 
 
 
  
 
26 
 
CHAPTER II  
 
6,7-DINITROQUINOXALINE-2,3-DIONE (DNQX) AS A TOPICAL EXCITATORY AMINO 
ACID RECEPTOR ANTAGONIST OF CORNEAL EPITHELIUM: A BEHAVIORAL STUDY 
 
Abstract 
Introduction: 6,7-dinitroquinoxaline-2,3-dione (DNQX) is an AMPA/Kainate antagonist that is 
water soluble. The aim of this study was to determine the effectiveness of DNQX when topically 
applied to the Sprague Dawley rat cornea stimulated by glutamate. 
Methods: A total of 36 rats were used to quantitatively evaluate the nocifensive behaviors. 
Glutamate, the ligand for AMPA and Kainate receptors, was used as the agonist. A co-
administration of Glutamate/DNQX was used to determine the effectiveness of DNQX as a 
competitive antagonist when directly applied to the cornea. The Animal Research: Reporting of 
In Vivo Experiments (ARRIVE) guidelines were used in the writing of this manuscript.  
Results: DNQX was shown to significantly (p < 0.05) antagonize the effects of glutamate in a 
dose dependent manner. The half maximal inhibitory concentration (IC50) was determined as 
1.18µM. 
Discussion: DNQX could potentially be beneficial in alleviating ophthalmic pain when topically 
applied to the cornea.  
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1. Introduction 
Ionotropic glutamate receptors (iGluR) are a class of receptors that are activated by 
glutamate (Johnson & Ascher, 1987; Kleckner & Dingledine, 1988), allowing for the flow of 
positively charged sodium and calcium ions to go from the exterior to interior cellular space 
(Dingledine et al., 1999; Traynelis et al., 2010). This influx of positively charged ions 
depolarizes neurons to trigger an intracellular cascade leading to an action potential 
(Latremoliere & Woolf, 2009; Miller et al., 2011; Tao, 2012; Woolf & Salter, 2000). While there 
is increasing research conducted in the central nervous system (CNS) (Zhuo, 2017), a better 
understanding of these iGluR is needed for peripheral tissues such as the cornea.  
 The iGluR are occur in four types: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptor, Kainate receptor, N-methyl-D-aspartate (NMDA) receptor, and Delta 
receptor. The AMPA, Kainate, NMDA, and Delta receptors are subdivided into 4 (GluA1-4), 5 
(GluK1-5), 7 (GluNA, GluNB1-4, GluNC1-2), and 2 (GluD1-2) subunits (Bleakman et al., 2006; 
Dingledine et al., 1999; Traynelis et al., 2010). These subunits will typically dimerize within 
their class, then form a dimer of those dimers to form a functional heterotetramer (Sobolevsky, 
Yelshansky, & Wollmuth, 2004; Traynelis et al., 2010) that will be activated by glutamate. 
Coagonists, glycine or D-Serine, bind to GluN1, GluN3A, or GluN3B containing NMDA 
receptors (Johnson & Ascher, 1987; Kleckner & Dingledine, 1988; Traynelis et al., 2010). 
The cornea is one of the most densely innervated tissues of the body (Eghrari et al., 2015; He 
et al., 2010) and glutamate receptors have been detected recently in the rat cornea (Ibitokun, 
2012). Glutamate was determined to produce dose dependent nocifensive behaviors when 
applied to the rat cornea (Ibitokun, 2012). These results identified a need for receptor specific 
antagonists to be directly applied to the cornea for inhibition of glutamate-induced nocifensive 
behavior. For example, 6,7-dinitroquinoxaline-2,3-dione (DNQX) is an AMPA and Kainate 
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receptor antagonist that is water soluble and it may easily penetrate the corneal epithelium to 
antagonize exogenously applied glutamate. These results will translate to human models in 
procedures such as Lasik Surgery. The animal model of choice was the rat which is superior to 
the mouse model for correlation to human disease (Iannaccone & Jacob, 2009). In the present 
study, our aim, therefore, is to determine if DNQX will antagonize nocifensive behaviors 
produced by the co-application of glutamate directly on the Sprague Dawley rat cornea. We 
hypothesize that the AMPA and Kainate specific antagonist, DNQX, will antagonize but not 
completely prevent nocifensive behavior when applied.  
2. Methods 
Ethical Guidelines 
 Experimental procedures were conducted in accordance to the guidelines from the 
National Institutes of Health (NIH Publications No. 80-23) and were approved by the Oklahoma 
State University Center for Health Sciences Institutional Animal Care and Use Committee. All 
experiments were structured so that the number of animals and the length of the study were kept 
to a minimum. This manuscript was written in accordance to the Animal Research: Reporting of 
In Vivo Experiments (ARRIVE) guidelines (Kilkenny et al., 2010). 
Animals 
 Thirty-six randomized naïve male and female Sprague-Dawley rats from Charles River 
Laboratories, Wilmington, MA, with an age of 3-5 months were used in this study. The exact 
number of animals in each group is displayed in the table in figure 2.1. The rats were housed as 
1-3 rats per transparent plastic cage (17in x 9.25in x 8.5in; L x W x H) with a metal grated top. A 
12-hour light/12-hour dark cycle was used at a temperature kept at 22-23 °C and humidity at 
38% in a USDA approved animal facility with standard housing conditions (not specific 
pathogen free). The rats had free access to Teklad 18% protein rat pellets (Envigo, Huntingdon, 
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United Kingdom) and purified water (Filter: Pentek C1 Carbon Filter Cartridge 2.5" X 9.75" 5 
Micron). All cages were bedded with Teklad Sani-Chips (Envigo, Huntingdon, United Kingdom) 
to cover the bottom of the cage 1 inch deep. The animals were allowed to habituate in the 
experimental apparatus by placing them in a transparent plexiglass observational chamber (12in 
x 11in x 10.25in; L x W x H) for exploration before application of any drugs, three consecutive 
days in advance of experimentation.  
Behavioral testing 
 All experiments were conducted in a quiet room between 1700 and 2300 hours. The 
animals were randomly assigned to at least one of 9 experimental groups and/or 2 control groups. 
Each rat was randomly chosen to participate in more than one experimental and/or control group. 
At least a week occurred between trials to allow for the 5-6 day period of corneal epithelium 
renewal before the next experiment was conducted. The experimenter was aware of what drug 
and concentration was used. All rats underwent welfare checks twice per week at the time of 
bedding replacement and by the experimenter immediately before the administration of the drug. 
Any changes in the rat health were noted. After all data was collected, all rats were euthanized 
with carbon dioxide (CO2).   
Drugs 
 L-Glutamic acid (Sigma, St. Louis, MO, FW= 169.1), 6,7-Dinitroquinoxaline-2,3-dione 
(DNQX) disodium salt (Tocris bioscience, Bristol, United Kingdom, FW= 252.14) and 
phosphate buffered saline PBS (pH:7.3) were used in this experiment. L-Glutamic acid was used 
as an agonist to the primary afferents to cause a nocifensive behavioral response (Ibitokun, 2012) 
and was considered the best iGluR agonist, being the natural ligand of the AMPA and Kainate 
receptors. The antagonist DNQX was used due to its low molecular weight compared to other 
AMPA and Kainate antagonists as seen in table 2.1. We reasoned that this would allow for easier 
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penetration via diffusion into the corneal epithelium to interact with the AMPA and Kainate 
receptors. PBS was used as a buffer solution for diluting the L-Glutamate and DNQX as it has 
minimal, if any, effect on the AMPA and Kainate receptors.  
Experimental Design 
In this study, 36 naive Sprague Dawley rats were used. Both male and female rats were 
randomly assigned to each of the 9 experimental and 2 control groups. Power analysis was 
conducted to determine the number of animals needed for each group (G Power). Each of the 
experimental groups had a topical dose of 10µL DNQX with a Rainin pipette at the respective 
dose five minutes before a second combination dose of 10µL DNQX and glutamate was given. A 
five minute wait period was to allow for adequate diffusion of DNQX across the epithelial layer 
to occur. The observational count of eye blinks, eye wipes, and eye scratching occurred for 30 
seconds immediately after the combination dose was given in the observational chamber (12in x 
11in x 10.25in; L x W x H). For the glutamate and PBS control, the observational recordings for 
a period of 30 seconds began once the respective dose was given. Water was used to wash out 
any remaining solution for all animals once the behavioral responses were counted by use of a 
wash bottle. Experimental doses were made at logarithmically increasing concentrations 
including 0.01µM, 0.033µM, 0.1µM, 0.33µM, 1.0µM, 3.0µM, 10.0µM, 30.0µM, and 100.0µM 
to determine an inhibitory dose response and IC50. Glutamate was used at 0.5M as determined 
from a dose response curve from previous work in our lab (Ibitokun, 2012). 
Statistical Analysis 
The Kolmogorov–Smirnov test was used to check for the normality of the dataset using 
GraphPad Prism (Version 7.03). All experimental groups had normally distributed data. One-
way Analysis of variance (ANOVA) using GraphPad Prism (Version 5.01) was conducted to 
determine statistical significance (p < 0.05) and post-hoc comparisons were performed using the 
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Newman–Keuls method to detect changes between the behavioral responses of experimental 
groups to the 0.5M L-Glutamate. GraphPad Prism (Version 7.03) was used to construct a log 
dose response curve. All DNQX data was averaged for each dose, transformed, then normalized. 
Nonlinear regression was used to determine the IC50.  
3. Results 
3.1. Corneal stimulation with glutamate 
Once the rats appeared to be habituated to the behavioral apparatus and passed health 
checks, the solutions were topically applied. As seen in table 2.1, the 0.5M glutamate only 
treatment and PBS only treatment yielded an average of 23 and 3 responses respectively. 
Application of 0.01, 0.033, 0.1, and 0.33µM DNQX + 0.5M glutamate did not significantly 
decrease the number of nocifensive responses when compared to 0.5M glutamate only. A 
significant decrease in nocifensive responses (p < 0.05) was observed at 1.0 and 3.0µM DNQX + 
0.5M Glutamate. To further evaluate if there was a further decrease in nocifensive responses, 10, 
30, and 100µM DNQX + 0.5M Glutamate were used. A further decrease in nocifensive 
responsive was observed (p < 0.01) until a plateau was reached at about 30µM. No data was 
removed from the dataset. No major adverse events occurred during the study, but a water 
washout period after the conclusion of analysis of each rat was included to decrease any potential 
side effects of the drugs.  
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Sample 
Size 6 12 12 12 12 12 12 6 6 6 6 
Mean 23.17 19.92 16.50 17.33 18.50 11.50 13.00 9.00 8.00 9.00 2.83 
Standard 
Deviation 6.97 9.29 6.04 8.08 6.83 5.45 5.26 2.83 6.93 5.40 0.98 
Standard 
Error of 
the Mean 2.85 2.68 1.74 2.33 1.97 1.57 1.52 1.15 2.83 2.21 0.40 
 
Figure 2.1: Bar graph of the behavioral responses in each of the respective DNQX treatment groups. Experimental 
groups logarithmically increased in concentration. The table underneath the graph displays the sample size, mean, 
standard deviation, and the standard error of the mean for each of the experimental and control groups. Statistical 
significance when compared to agonist of p ≤ 0.05 was displayed as *. Statistical significance when compared to 
agonist of p ≤ 0.01 was displayed as * *. 
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As seen in figure 2.2, a dose response curve was constructed to evaluate the half maximal 
inhibitory concentration (IC50) of the observed nocifensive responses. The IC50 was observed to 
be 1.18µM. 
 
Figure 2.2: Dose response curve for DNQX representing the nocifensive behavioral recordings in Figure 2.1.  
4. Discussion 
A significant decrease was detected in observed glutamate-induced nocifensive behaviors 
with topically applied DNQX to the cornea. Compared to previously published work (Gazerani, 
Dong, Wang, Kumar, & Cairns, 2010), the concentration of glutamate needed to elicit a 
nocifensive response was greater in the cornea when topically applied as compared to the 
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subcutaneous injection to the facial skin over the masseter. We theorize that higher 
concentrations were needed because the topical glutamate solution must dissolve through the 
protective corneal epithelial cell layer that has more tight junctions per area compared to any 
other body tissue (Eghrari et al., 2015). Despite the higher concentrations of both glutamate and 
DNQX, the glutamate elicited nocifensive response was dose dependently reduced by DNQX.  
Peripheral neuron terminals release glutamate that activate AMPA, Kainate, and NMDA 
receptors on nerve terminals in an autocrine or paracrine manner (Miller et al., 2011). During 
inflammation, an increase in the amount of glutamate receptors occurs on the terminals and the 
number of peripheral axons with iGluRs increases (Carlton & Coggeshall, 1999). As 
inflammation progresses, glutamate release can activate more receptors continuing the peripheral 
sensitization of primary afferents (Miller et al., 2011).  
Our results show a reduction of nocifensive responses, but not a total diminishing of the 
response. This could be in part due to the receptor specificity of the drug of choice. DNQX is an 
AMPA/Kainate antagonist (Fedele & Raiteri, 1996) that has little to no antagonistic 
characteristics for the NMDA receptors. To evaluate this, a non-specific iGluR antagonist or a 
combination of DNQX along with a NMDA receptor antagonist should be used. 
The Sprague Dawley animal model used is better at translating to a human model than a 
mouse model because the clinical implications are better translated (Iannaccone & Jacob, 2009). 
Furthermore, this study is a good example on how we can reduce and refrain from the extensive 
use of animals (Flecknell, 2002). We were able to randomly re-use each rat across more than one 
experimental group which greatly reduced the number of rats needed. We were not able to 
replace the Sprague Dawley rat model, however, with an in vitro model because human clinical 
implementation would have been lost.  
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Future studies should evaluate varying antagonists to determine if a larger molecular 
weight compound would still cross the corneal epithelial cell layer. As seen in table 2.1, an 
extensive list of glutamate receptor antagonists from Tocris were identified. Chemical name, 
common name, molecular weight, chemical formula, solubility, and antagonist site were 
included. DNQX has a relatively low molecular weight for the water soluble AMPA/Kainate 
antagonists. Further effectiveness in AMPA, Kainate, and NMDA specific antagonists should be 
evaluated, but one limitation of our study is that we were not able to antagonize specific 
glutamate receptor subunits because of the lack of subunit specific antagonists. Finally, some 
antagonists have a specific target to a specific receptor (Traynelis et al., 2010). Evaluation of the 
site specific AMPA, Kainate, and NMDA receptor antagonists would help compare the 
effectiveness to their effects in the CNS.  
Chemical Name Common Name 
Molecular 
weight Formula Solubility Antagonist site 
1,4-Dihydro-6-(1H-imidazol-1-yl)-
7-nitro-2,3-quinoxalinedione 
hydrochloride 
YM 90K 
hydrochloride 309.67 C11H7N5O4.HCl 
Soluble to 
10 mM in 
DMSO 
with 
gentle 
warming 
Selective AMPA 
antagonist 
1-(4'-Aminophenyl)-3,5-dihydro-
7,8-dimethoxy-4H-2,3-
benzodiazepin-4-one CFM-2 311.34 C17H17N3O3 
Soluble to 
100 mM 
in DMSO 
Non-competitive 
AMPA 
antagonist 
2,3-Dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo[f]quinoxaline-7-
sulfonamide NBQX 336.28 C12H8N4O6S 
Soluble to 
100 mM 
in DMSO 
Potent AMPA 
antagonist. 
More selective 
than CNQX  
4-(8-Methyl-9H-1,3-dioxolo[4,5-
h][2,3]benzodiazepin-5-yl)-
benzenamine dihydrochloride 
GYKI 52466 
dihydrochloride 366.24 C17H15N3O2.2HCl 
Soluble to 
50 mM in 
DMSO 
and to 10 
mM in 
water 
Selective non-
competitive 
AMPA 
antagonist 
(±)-4-(4-Aminophenyl)-1,2-
dihydro-1-methyl-2-
propylcarbamoyl-6,7-
methylenedioxyphthalazine SYM 2206 366.42 C20H22N4O3 
Soluble to 
100 mM 
in ethanol 
and to 
100 mM 
in DMSO 
Non-competitive 
AMPA 
antagonist 
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2,3-Dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo[f]quinoxaline-7-
sulfonamide disodium salt 
NBQX disodium 
salt 380.24 C12H6N4O6SNa2 
Soluble to 
100 mM 
in water 
Potent AMPA 
antagonist. 
More water 
soluble form 
of NBQX 
4-(8-Chloro-2-methyl-11H-
imidazo[1,2-
c][2,3]benzodiazepin-6-
benzeneamine dihydrochloride 
GYKI 47261 
dihydrochloride 395.71 C18H15ClN4.2HCl 
Soluble to 
100 mM 
in DMSO 
Non-competitive 
AMPA 
antagonist 
N-[3-[[4-[(3-
Aminopropyl)amino]butyl]amino]
propyl]-1-naphthaleneacetamide 
trihydrochloride 
Naspm 
trihydrochloride 479.91 C22H34N4O.3HCl 
Soluble to 
100 mM 
in water 
Ca2+-permeable 
AMPA receptor 
antagonist 
3-(2-Chlorophenyl)-2-[2-[6-
[(diethylamino)methyl]-2-
pyridinyl]ethenyl]-6-fluoro-4(3H)-
quinazolinone hydrochloride 
CP 465022 
hydrochloride 499.41 
C26H24ClFN4O.HC
l 
Soluble to 
10 mM in 
water and 
to 100 
mM in 
DMSO 
Selective, non-
competitive 
AMPA 
antagonist 
(S)-N-[7-[(4-
Aminobutyl)amino]heptyl]-4-
hydroxy-α-[(1-
oxobutyl)amino]benzenepropana
mide dihydrochloride Philanthotoxin 74 507.54 C24H42N4O3.2HCl 
Soluble to 
100 mM 
in water 
and to 
100 mM 
in DMSO 
GluR1 and GluR3 
AMPA receptor 
antagonist 
6-Cyano-7-nitroquinoxaline-2,3-
dione CNQX 232.16 C9H4N4O4 
Soluble to 
100 mM 
in DMSO 
Potent 
AMPA/kainate 
antagonist 
6,7-Dinitroquinoxaline-2,3-dione DNQX 252.14 C8H4N4O6 
Soluble to 
100 mM 
in DMSO 
Selective non-
NMDA 
antagonist 
6-Cyano-7-nitroquinoxaline-2,3-
dione disodium 
CNQX disodium 
salt 276.12 C9H2N4O4Na2 
Soluble to 
20 mM in 
water 
Potent 
AMPA/kainate 
antagonist. 
More water 
soluble form 
of CNQX 
6,7-Dinitroquinoxaline-2,3-dione 
disodium salt 
DNQX disodium 
salt 296.1 C8H2N4O6Na2 
Soluble to 
100 mM 
in water 
Selective non-
NMDA 
antagonist. 
Water-soluble 
salt of DNQX 
(αS)-α-Amino-3-[(4-
carboxyphenyl)methyl]-3,4-
dihydro-2,4-dioxo-1(2H)-
pyrimidinepropanoic acid UBP 282 333.3 C15H15N3O6 
Soluble to 
100 mM 
in 1eq. 
NaOH and 
to 25 mM 
in 1eq. 
HCl 
AMPA/kainate 
antagonist; 
distinguishes 
between 
motoneuron and 
dorsal root 
kainate 
receptors 
 (8R)-7-Acetyl-5-(4-aminophenyl)-
8,9-dihydro-8-methyl-7H-1,3-
dioxolo[4,5-
h][2,3]benzodiazepine Talampanel 337.37 C19H19N3O3 
Soluble to 
100 mM 
in DMSO 
Non-competitive 
AMPA/kainate 
antagonist 
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[[3,4-Dihydro-7-(4-morpholinyl)-
2,3-dioxo-6-(trifluoromethyl)-
1(2H)-
quinoxalinyl]methyl]phosphonic 
acid ZK 200775 409.25 C14H15N3O6F3P 
Soluble to 
100 mM 
in DMSO 
and to 50 
mM in 
ethanol 
Competitive 
AMPA/kainate 
antagonist 
D-(-)-2-Amino-4-
phosphonobutyric acid D-AP4 183.1 C4H10NO5P 
Soluble to 
100 mM 
in 1eq. 
NaOH 
Broad spectrum 
EAA antagonist 
DL-2-Amino-4-phosphonobutyric 
acid DL-AP4 183.1 C4H10NO5P 
Soluble to 
33 mM in 
water 
Broad spectrum 
EAA antagonist 
4-Hydroxyquinoline-2-carboxylic 
acid Kynurenic acid 189.17 C10H7NO3 
Soluble to 
50 mM in 
DMSO 
and to 
100 mM 
in 1eq. 
NaOH 
Broad spectrum 
EAA antagonist 
γ-D-Glutamylglycine γDGG 204.18 C7H12N2O5 
Soluble to 
100 mM 
in 1eq. 
NaOH and 
to 100 
mM in 
water 
with 
gentle 
warming 
Broad spectrum 
glutamate 
receptor 
antagonist 
DL-2-Amino-4-phosphonobutyric 
acid sodium salt 
DL-AP4 Sodium 
salt 205.08 C4H9NNaO5P 
Soluble to 
100 mM 
in water 
Broad spectrum 
EAA antagonist. 
4-Hydroxyquinoline-2-carboxylic 
acid sodium salt 
Kynurenic acid 
sodium salt 211.15 C10H6NNaO3 
Soluble to 
100 mM 
in water 
and to 50 
mM in 
DMSO 
Sodium salt 
of kynurenic 
acid  
(R)-3-Carboxy-4-
hydroxyphenylglycine   211.17 C9H9NO5 
Soluble to 
100 mM 
in 1eq. 
NaOH 
Ionotropic 
glutamate 
receptor 
antagonist 
2,4-Dihydroxyphenylacetyl-L-
asparagine   282.25 C12H14N2O6 
Soluble to 
50 mM in 
water 
Constituent of 
various spider 
toxins. Reported 
to be specific 
blocker of 
glutamate 
receptors.  
(RS)-1-(2-Amino-2-carboxyethyl)-
3-(2-carboxybenzyl)pyrimidine-
2,4-dione UBP 296 333.3 C15H15N3O6 
Soluble to 
10 mM in 
1eq. 
NaOH 
with 
gentle 
warming 
and to 10 
Selective, potent 
kainate 
antagonist; 
selective for 
GluR5-
containing 
receptors 
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mM in 
DMSO 
(S)-1-(2-Amino-2-carboxyethyl)-3-
(2-carboxybenzyl)pyrimidine-2,4-
dione UBP 302 333.3 C15H15N3O6 
Soluble to 
25 mM in 
1eq. 
NaOH and 
to 20 mM 
in DMSO 
with 
gentle 
warming 
Potent and 
selective kainate 
antagonist; 
active 
enantiomer 
of UBP 296  
2,3:4,5-Bis-O-(1-
methylethylidene)-β-D-
fructopyranose sulfamate Topiramate 339.36 C12H21NO8S 
Soluble to 
100 mM 
in DMSO 
and to 
100 mM 
in ethanol 
GluR5 
antagonist; 
inhibits carbonic 
anhydrase (CA) II 
and IV 
(S)-1-(2-Amino-2-carboxyethyl)-3-
(2-carboxy-thiophene-3-yl-
methyl)-5-methylpyrimidine-2,4-
dione UBP 310 353.35 C14H15N3O6S 
Soluble to 
100 mM 
in DMSO 
GLUK5 antagonis
t 
4,6-Bis(benzoylamino)-1,3-
benzenedicarboxylic acid NS 3763 404.38 C22H16N2O6 
Soluble to 
25 mM in 
DMSO 
Selective non-
competitive 
kainate 
antagonist; 
selective for 
GLUK5 
(S)-1-(2-Amino-2-carboxyethyl)-3-
(2-carboxy-5-phenylthiophene-3-
yl-methyl)-5-methylpyrimidine-
2,4-dione ACET 429.45 C20H19N3O6S 
Soluble to 
20 mM in 
3eq. 
NaOH 
Potent 
antagonist of 
GluR5-
containing 
kainate 
receptors 
(αS)-α-Amino-3-[(4-
carboxyphenyl)methyl]-3,4-
dihydro-5-iodo-2,4-dioxo-1(2H)-
pyrimidinepropanoic acid UBP 301 459.2 C15H14IN3O6 
Soluble to 
5 mM in 
DMSO 
with 
gentle 
warming 
Kainate receptor 
antagonist 
1-Aminocyclobutane-1-carboxylic 
acid ACBC 115.13 C5H9NO2 
Soluble to 
100 mM 
in water 
NMDA 
antagonist, acts 
at glycine site 
(R)-(+)-3-Amino-1-
hydroxypyrrolidin-2-one (R)-(+)-HA-966 116.12 C4H8N2O2 
Soluble to 
100 mM 
in water 
NMDA partial 
agonist/antagon
ist; acts at 
glycine site 
(S)-(-)-3-Amino-1-
hydroxypyrrolidin-2-one (S)-(-)-HA-966 116.12 C4H8N2O2 
Soluble to 
100 mM 
in water 
NMDA 
antagonist/parti
al agonist 
(R)-4-Carboxyphenylglycine   195.17 C9H9NO4 
Soluble to 
100 mM 
in 1eq. 
NaOH and 
to 5 mM 
in water 
Moderately 
potent NMDA 
antagonist 
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DL-2-Amino-5-
phosphonopentanoic acid DL-AP5 197.13 C5H12NO5P 
Soluble to 
10 mM in 
water and 
to 100 
mM in 
1eq. 
NaOH 
Potent, selective 
NMDA 
antagonist 
(E)-(±)-2-Amino-4-methyl-5-
phosphono-3-pentenoic acid CGP 37849 209.14 C6H12NO5P   
Potent and 
selective NMDA 
antagonist 
(2R*,4S*)-4-(1H-Tetrazol-5-
ylmethyl)-2-piperidinecarboxylic 
acid LY 233053 211.22 C8H13N5O2 
Soluble to 
100 mM 
in water 
and to 
100 mM 
in DMSO 
Competitive 
NMDA receptor 
antagonist 
3,5-Dimethyl-
tricyclo[3.3.1.13,7]decan-1-amine 
hydrochloride 
Memantine 
hydrochloride 215.77 C12H21N.HCl 
Soluble to 
100 mM 
in water 
NMDA 
antagonist; acts 
at ion channel 
site 
DL-2-Amino-5-
phosphonopentanoic acid sodium 
salt 
DL-AP5 Sodium 
salt 219.11 C5H11NNaO5P 
Soluble to 
100 mM 
in water 
Sodium salt 
of DL-AP5 
cis-4-[Phosphomethyl]-
piperidine-2-carboxylic acid CGS 19755 223.17 C7H14NO5P 
Soluble to 
25 mM in 
water 
Potent, 
competitive 
NMDA 
antagonist 
4-(Phosphonomethyl)-2-
piperazinecarboxylic acid 
PMPA (NMDA 
antagonist) 224.15 C6H13N2O5P 
Soluble to 
100 mM 
in water 
Competitive 
NMDA 
antagonist 
DL-2-Amino-7-
phosphonoheptanoic acid DL-AP7 225.18 C7H16NO5P 
Soluble to 
100 mM 
in 1eq. 
NaOH 
Specific NMDA 
antagonist 
(E)-(±)-2-Amino-4-methyl-5-
phosphono-3-pentenoic acid 
ethyl ester CGP 39551 237.19 C8H16NO5P 
Soluble to 
100 mM 
in water 
Potent, selective 
and competitive 
NMDA 
antagonist 
2-Phenyl-1,3-
propanedioldicarbamate Felbamate 238.24 C11H14N2O4 
Soluble to 
100 mM 
in DMSO 
and to 
100 mM 
in ethanol 
NMDA 
antagonist, acts 
glycine site 
(R)-3,4-Dicarboxyphenylglycine (R)-3,4-DCPG 239.18 C10H9NO6 
Soluble to 
100 mM 
in water 
AMPA 
antagonist/weak 
NMDA 
antagonist 
 D-4-[(2E)-3-Phosphono-2-
propenyl]-2-piperazinecarboxylic 
acid D-CPP-ene 250.19 C8H15N2O5P 
Soluble to 
100 mM 
in water 
Potent, 
competitive 
NMDA 
antagonist 
(2R*,4S*)-4-(3-
Phosphonopropyl)-2-
piperidinecarboxylic acid PPPA 251.22 C9H18NO5P 
Soluble to 
100 mM 
in water 
Competitive 
NR2A antagonist 
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3-((R)-2-Carboxypiperazin-4-yl)-
propyl-1-phosphonic acid (R)-CPP 252.21 C8H17N2O5P 
Soluble to 
100 mM 
in water 
Potent NMDA 
antagonist; 
more active 
enantiomer 
of (RS)-CPP 
(RS)-3-(2-Carboxypiperazin-4-yl)-
propyl-1-phosphonic acid (RS)-CPP 252.21 C8H17N2O5P 
Soluble to 
100 mM 
in water 
Potent NMDA 
antagonist 
 (2R,3S)-β-p-
Chlorophenylglutamic acid 
(2R,3S)-
Chlorpheg 257.67 C11H12ClNO4 
Soluble to 
100 mM 
in 1.1eq. 
NaOH 
Weak NMDA 
antagonist 
5,7-Dichloro-4-hydroxyquinoline-
2-carboxylic acid 
5,7-
Dichlorokynureni
c acid 258.06 C10H5Cl2NO3 
Soluble to 
100 mM 
in 1eq. 
NaOH and 
to 100 
mM in 
DMSO 
Potent NMDA 
antagonist, acts 
at glycine site 
2-Amino-2-(2-
chlorophenyl)cyclohexanone 
hydrochloride 
Norketamine 
hydrochloride 260.16 C12H14ClNO.HCl 
Soluble to 
100 mM 
in water 
Potent, non-
competitive 
NMDA 
antagonist; 
antinociceptive 
7-Chloro-3-(cyclopropylcarbonyl)-
4-hydroxy-2(1H)-quinolinone L-701,252 263.68 C13H10ClNO3 
Soluble to 
50 mM in 
DMSO 
NMDA 
antagonist, acts 
glycine site 
 N,N'-1,4-Butanediylbisguanidine 
sulfate Arcaine sulfate 270.31 C6H16N6.H2SO4 
Soluble to 
25 mM in 
water 
Competitive 
NMDA 
antagonist 
2-(2-Chlorophenyl)-2-
(methylamino)cyclohexanone 
hydrochloride 
Ketamine 
hydrochloride 274.19 C13H16ClNO.HCl 
Soluble to 
100 mM 
in water 
Non-competitive 
NMDA receptor 
antagonist 
 [3S-(3α,4aα,6β,8aα)]-Decahydro-
6-(phosphonomethyl)-3-
isoquinolinecarboxylic acid) LY 235959 277.26 C11H20NO5P 
Soluble to 
100 mM 
in water 
Competitive 
NMDA 
antagonist 
1-(1-Phenylcyclohexyl)piperidine 
hydrochloride 
Phencyclidine 
hydrochloride 279.85 C17H25N.HCl 
Soluble to 
40 mM in 
water 
Non-competitive 
NMDA receptor 
antagonist 
5,7-Dichloro-4-hydroxyquinoline-
2-carboxylic acid sodium salt 
5,7-
Dichlorokynureni
c acid sodium salt 280.04 C10H4Cl2NNaO3 
Soluble to 
100 mM 
in 1eq. 
NaOH 
Sodium salt 
of 5,7-
Dichlorokynuren
ic acid. Potent 
NMDA 
antagonist, acts 
at glycine site 
2-Amino-N-(1-methyl-1,2-
diphenylethyl)acetamide 
hydrochloride 
Remacemide 
hydrochloride 304.82 C17H20N2O.HCl 
Soluble to 
100 mM 
in water 
NMDA 
antagonist; 
blocks ion 
channel and 
allosteric 
modulatory site 
 (5R,10S)-(-)-5-Methyl-10,11-
dihydro-5H-
dibenzo[a,d]cylcohepten-5,10-
imine maleate 
(-)-MK 801 
maleate 337.37 C16H15N.C4H4O4 
Soluble to 
25 mM in 
water 
with 
NMDA 
antagonist, less 
active 
enantiomer 
  
 
41 
 
gentle 
warming 
(5S,10R)-(+)-5-Methyl-10,11-
dihydro-5H-
dibenzo[a,d]cyclohepten-5,10-
imine maleate 
(+)-MK 801 
maleate 337.37 C16H15N.C4H4O4 
Soluble to 
25 mM in 
water and 
to 100 
mM in 
DMSO 
Non-competitive 
NMDA 
antagonist; acts 
at ion channel 
site 
1,3-Dihydro-5-[3-[4-
(phenylmethyl)-1-2H-
benzimidazol-2-one TCS 46b 345.44 C22H23N3O 
Soluble to 
100 mM 
in DMSO 
and to 
100 mM 
in ethanol 
Orally active, 
subtype-
selective 
NR1A/NR2B 
antagonist 
α-(4-Chlorophenyl)-4-[(4-
fluorophenyl)methyl]-1-
piperidineethanol Eliprodil 347.86 C20H23ClFNO 
Soluble to 
25 mM in 
DMSO 
Non-competitive 
NR2B-selective 
NMDA 
antagonist 
(9α,13α,14α)-3-Methoxy-17-
methylmorphinan hydrobromide 
Dextromethorph
an hydrobromide 352.31 C18H25NO.HBr 
Soluble to 
40 mM in 
water 
NMDA receptor 
antagonist 
N,N'-1,10-Decanediylbisguanidine 
sulfate Synthalin sulfate 354.47 C12H28N6.H2SO4 
Soluble to 
5 mM in 
water 
Non-competitive 
NMDA 
antagonist 
7-Chloro-4-hydroxy-3-(3-
phenoxy)phenyl-2(1H)-
quinolinone L-701,324 363.8 C21H14ClNO3 
Soluble to 
100 mM 
in DMSO 
NMDA 
antagonist; acts 
at glycine site 
1-[2-(4-Chlorophenyl)ethyl]-
1,2,3,4-tetrahydro-6-methoxy-2-
methyl-7-isoquinolinol 
hydrochloride 
Ro 04-5595 
hydrochloride 368.3 C19H22ClNO2.HCl 
Soluble to 
15 mM in 
water and 
to 100 
mM in 
DMSO 
NR2B-selective 
NMDA 
antagonist 
(S)-α-Amino-2'-chloro-5-
(phosphonomethyl)[1,1'-
biphenyl]-3-propanoic acid SDZ 220-581 369.74 C16H17ClNO5P 
Soluble to 
25 mM in 
DMSO 
with 
gentle 
warming 
and to 
100 mM 
in 1.1eq. 
NaOH 
Competitive 
NMDA 
antagonist 
1-[2-(4-Hydroxyphenoxy)ethyl]-4-
[(4-methylphenyl)methyl]-4-
piperidinol hydrochloride 
Co 101244 
hydrochloride 377.91 C21H27NO3.HCl 
Soluble to 
100 mM 
in water 
and to 50 
mM in 
DMSO 
Highly selective 
NR2B antagonist 
(2S*,3R*)-1-(Phenanthren-2-
carbonyl)piperazine-2,3-
dicarboxylic acid PPDA 378.38 C21H18N2O5 
Soluble to 
50 mM in 
2eq. 
NaOH and 
to 100 
mM in 
Subtype-
selective 
NR2C/NR2D 
antagonist 
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DMSO 
trans-2-Carboxy-5,7-dichloro-4-
phenylaminocarbonylamino-
1,2,3,4-tetrahydroquinoline L-689,560 380.23 C17H15Cl2N3O3 
Soluble to 
25 mM in 
DMSO 
and to 
100 mM 
in ethanol 
Very potent 
NMDA 
antagonist 
(±)-1-(1,2-
Diphenylethyl)piperidine maleate   381.47 C19H23N.C4H4O4 
Soluble to 
10 mM in 
water 
NMDA 
antagonist, acts 
ion channel site 
(6aS,10aS)-3-(1,1-
Dimethylheptyl)-6a,7,10,10a-
tetrahydro-1-hydroxy-6,6-
dimethyl-6H-dibenzo[b,d]pyran-
9-methanol HU 211 386.57 C25H38O3 
Soluble to 
100 mM 
in DMSO 
and to 
100 mM 
in ethanol 
NMDA receptor 
antagonist; also 
NF-κB inhibitor 
4,6-Dichloro-3-[(1E)-3-oxo-3-
(phenylamino)-1-propenyl]-1H-
indole-2-carboxylic acid sodium 
salt Gavestinel 397.19 
C18H11Cl2N2O3N
a 
Soluble to 
40 mM in 
DMSO 
Potent and 
selective glycine 
site antagonist; 
orally available 
and active in 
vivo 
(1R*,2S*)-erythro-2-(4-
Benzylpiperidino)-1-(4-
hydroxyphenyl)-1-propanol hemi-
(DL)-tartrate 
Ifenprodil 
hemitartrate 400.49 
C21H27NO2.½C4H
6O6 
Soluble to 
15 mM in 
water 
with 
gentle 
warming 
Non-competitive 
NMDA 
antagonist. 
Also σligand 
(1S*,2S*)-threo-2-(4-
Benzylpiperidino)-1-(4-
hydroxyphenyl)-1-propanol 
hemitartrate 
threo Ifenprodil 
hemitartrate 400.49 
C21H27NO2.½C4H
6O6 
Soluble to 
25 mM in 
water and 
to 100 
mM in 
DMSO 
NR2B-selective 
NMDA 
antagonist; 
also σagonist 
4-[3-[4-(4-Fluorophenyl)-1,2,3,6-
tetrahydro-1(2H)-pyridinyl]-2-
hydroxypropoxy]benzamide 
hydrochloride 
Ro 8-4304 
hydrochloride 406.88 C21H23FN2O3.HCl 
Soluble to 
10 mM in 
water and 
to 100 
mM in 
DMSO 
NR2B-selective 
NMDA 
antagonist 
 [(1S)-1-[[(7-Bromo-1,2,3,4-
tetrahydro-2,3-dioxo-5-
quinoxalinyl)methyl]amino]ethyl]
phosphonic acid hydrochloride 
CGP 78608 
hydrochloride 414.58 
C11H13BrN3O5P.
HCl 
Soluble to 
100 mM 
in 2.2eq. 
NaOH 
Potent, selective 
glycine-site 
NMDA 
antagonist 
(S)-α-Amino-2',4'-dichloro-4-
hydroxy-5-(phosphonomethyl)-
[1,1'-biphenyl]-3-propanoic acid SDZ 220-040 420.19 C16H16Cl2NO6P 
Soluble to 
100 mM 
in DMSO 
Potent, 
competitive 
NMDA 
antagonist 
 4-[6-Methoxy-2-[(1E)-2-(3-
nitrophenyl)ethenyl]-4-oxo-
3(4H)quinazolinyl]benzoic acid QNZ 46 443.41 C24H17N3O6 
Soluble to 
10 mM in 
DMSO 
with 
gentle 
warming 
NR2C/NR2D-
selective NMDA 
receptor non-
competitive 
antagonist 
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(αR,βS)-α-(4-Hydroxyphenyl)-β-
methyl-4-(phenylmethyl)-1-
piperidinepropanol maleate 
Ro 25-6981 
maleate 455.55 
C22H29NO2.C4H4
O4 
Soluble to 
10 mM in 
water 
with 
gentle 
warming 
and to 
100 mM 
in DMSO 
NR2B-selective 
NMDA 
antagonist 
4,4'-
(Pentamethylenedioxy)dibenzami
dine bis-2-
hydroxyethanesulfonate salt 
Pentamidine 
isethionate 592.68 
C19H24N4O2.2C2
H6O4S 
Soluble to 
100 mM 
in water 
Antimicrobial 
that antagonizes 
NMDA receptors 
Conantokin-T   2683.8 
C110H175N31O45
S   
Non-competitive 
NMDA receptor 
antagonist 
Conantokin-R   3098.4 
C127H201N35O49
S3   
Potent non-
competitive 
NMDA receptor 
antagonist 
Table 2.1: List of Tocris glutamate receptor antagonists with pertinent information.  
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CHAPTER III 
 
IDENTIFYING THE LOCATION OF THE SIXTEEN CURRENTLY KNOWN GLUTAMATE 
RECEPTORS IN THE RAT CORNEA: A WESTERN BLOTTING AND 
IMMUNOHISTOCHEMISTRY STUDY 
 
Abstract 
Introduction: With further evaluation of glutamate receptor subunits in the central 
nervous system being conducted, a full evaluation is needed to determine the presence and 
localization of glutamate receptor subunits in the peripheral nervous system. Once an 
understanding of where each receptor subunit is located in the cornea and trigeminal root 
ganglion, more specific evaluation can occur. 
Aim: To identify and localize GluA1-4, GluK1-5, GluN1, GluN2A-2D, and GluN3A-3B 
glutamate receptor subunits in the Sprague Dawley rat cornea and trigeminal root ganglion. 
Methods: A total of 24 Sprague Dawley rats were used to identify the presence of 16 
glutamate receptor subunits by western blots and a total of 24 rats for immunofluorescence.  
Results: Each of the 16 glutamate receptor subunits were present in the Sprague Dawley 
rat cornea and trigeminal root ganglion with a differential distribution in the tissues across the 
glutamate receptor subunits. 
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Discussion: Glutamate receptors become functional when four receptor subunits form a 
tetramer. Identifying the presence and location of each of the subunits separately will further our 
knowledge on what possible functions a receptor has and what combination of subunits can 
combine to form a functional receptor in the peripheral nervous system. 
Introduction  
Currently four ionotropic glutamate receptor subtypes (iGluRs) have been classified: 2-
Amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA), Kainate, N-methyl-D-
aspartate receptor (NMDA), and Delta (Bleakman et al., 2006). These receptors are all activated 
by L-glutamate or a combination of L-glutamate and coagonist, e.g., glycine, with Delta 
receptors being an exception where the endogenous ligand is under current examination (Yuzaki 
& Aricescu, 2017).  
An iGluR requires a dimer of dimer of subunits within the same receptor class to 
construct a functional tetrameric receptor (Dingledine et al., 1999; Traynelis et al., 2010). Each 
iGluR has specific subunits included in their receptor class; AMPA: GluA1, GluA2, GluA3, and 
GluA4; Kainate: GluK1, GluK2, GluK3, GluK4, GluK5; NMDA: GluN1, GluN2A, GluN2B, 
GluN2C, GluN2D, GluN3A, and GluN3B; Delta: GluD1 and GluD2. Additional subunit variants 
have been described including flip and flop for AMPA and NMDA receptor subunits (Krampfl et 
al., 2002; Pachernegg et al., 2015; Y. H. Park et al., 2016; Pei et al., 2009). Certain subunit 
containing receptors have been described for specific functions such as GluK1 and GluN2B in 
relation to inflammatory pain (Abe et al., 2005; Bu et al., 2015; Vincent et al., 2016). 
Despite the extensive research conducted on iGluRs and their receptor subunits in the 
central nervous system, there is minimal identification of these iGluR subunits in peripheral 
tissues, for example the cornea (Carr, 2017). The cornea is the most innervated peripheral tissue 
in the body (Barry, Petroll, Andrews, Cavanagh, & Jester, 1995; Eghrari et al., 2015; He et al., 
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2010) and, during certain human surgery procedures such as Lasik surgery, pain can become 
debilitating during the recovery phase (Huang & Chen, 2008). With the identification of specific 
iGluR subunits in the cornea, more accurate targeting could accomplish specific results, e.g., 
decreased pain, faster healing, etc. A rat model was chosen for this study, because in many ways 
it is superior to the mouse model for correlation to human disease (Iannaccone & Jacob, 2009). 
 In our study, we aimed to determine the presence and location of the 16 currently 
recognized subunits that form the AMPA, Kainate, and NMDA GluRs in the Sprague Dawley rat 
cornea and trigeminal root ganglion. We hypothesized that some, but not all, of the glutamate 
receptor subunits will be present in the stromal nerve fibers and corneal epithelial cells and a 
similar immunoreactivity will be present in neuronal cell bodies of the ophthalmic division of the 
trigeminal root ganglion. With an understanding of potential subunit combinations in the cornea, 
we can begin to identify better tissue specific drugs for pain, dry eye, and epithelial healing 
following injury.  
Methods: 
Ethical Guidelines 
This experiment and experimental procedures were conducted in accordance to the 
guidelines from the National Institutes of Health (NIH Publications No. 80-23) and were 
approved by the Oklahoma State University Center for Health Sciences Institutional Animal 
Care and Use Committee. All experiments were structured so that the number of animals and the 
length of the study were kept to a minimum. This manuscript was written in accordance to the 
Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (Kilkenny et al., 
2010). 
Animals 
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A total of 48 naive male (n=24) and female (n=24) Sprague-Dawley rats (Charles River 
Laboratories, Wilmington, MA) at an age of 5-10 weeks were used in this study. The rats were 
housed 1-3 rats in each transparent plastic cage (17in x 9.25in x 8.5in; L x W x H) with a metal 
grated top. A 12-hour light/12-hour dark cycle was used at a temperature kept at 22-23 °C and 
humidity at 38% in a USDA approved animal facility with standard housing conditions (not 
specific pathogen free). The rats had free access to Teklad 18% protein rat pellets (Envigo, 
Huntingdon, United Kingdom) and purified water (Filter: Pentek C1 Carbon Filter Cartridge 2.5" 
X 9.75" 5 Micron). All cages were bedded with Teklad Sani-Chips (Envigo, Huntingdon, United 
Kingdom) to cover the bottom of the cage 1 inch deep. 
Western blot 
 A total of 12 male and 12 female (n=24/48, mean age: 9.54 months (age range: 10.28-
8.57 months)) naïve rats were euthanized by 5% isoflurane anesthetic (NDC 11695-0500-2, 
Henry Schein Animal Health) followed by decapitation once they became unresponsive. A total 
of 48 whole corneas, trigeminal root ganglia, and hippocampus were taken and combined in a 
1:1 Radioimmunoprecipitation assay (RIPA) buffer (50mM Tris HCl buffer (pH 8), 1% NP40, 
0.5% sodium deoxycholate, 0.1% SDS, 150mM NaCl, 10% glycerol) and lysis buffer (50mM 
Tris HCl pH 7.4, 1% triton X 100, 50mM NaCl, 10% glycerol). 1µL Halt Protease & 
Phosphatase Inhibitor Cocktail (x100, Thermo Scientific, Waltham, MA) solution was added to 
1mL RIPA/Triton X-100. The tissues in solution were stored at -80°C until used before 
homogenization. 
All samples were homogenized by a handheld homogenizer with pestles. Bio-Rad, 
Hercules, CA, Criterion TGX Precast Gels (26 well, 4-20%) at 100V for 10 minutes, 150V for 
10 minutes, and 180V for 1 hour 20 mins were used. All blots were transferred to a 
Polyvinylidene difluoride (PVDF) membrane (Cat. #162-0177). Each glutamate receptor was 
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examined for the cornea and trigeminal root ganglion. The hippocampus was used as a positive 
control. A Typhoon 9410 Variable Mode Imager was used to image the western blots. A 
Chemidoc MP imaging system (BIORAD, Hercules, CA) was used to image GluA2.  
Immunofluorescence 
 A total of 12 males and 12 females (n=24/48, mean age: 7.44 months, age range: 7.14-
8.85 months) naïve rats were used for evaluation of the 16 glutamate receptors with 
immunofluorescence. All animals were euthanized with 3mL of 2.5% Avertin and 1mL of 
100mg/mL Xylazine (NDC 59399-111-50, Akorn Animal Health, Lake Forest, IL). Rats were 
intracardially perfused with a fixative solution (75% picric acid, 0.2% paraformaldehyde, 0.1M 
phosphate buffer, pH 7.3) when corneal blink and tail flick responses were no longer present. 
Perfusion and tissue collection were done between 1200 to 1800 hours. Corneas, trigeminal root 
ganglia, and hippocampus were extracted from the rats and placed in the fixative solution for 4-6 
hours at 4°C. All tissue were transferred into 10% sucrose in phosphate buffered saline (PBS, 
pH: 7.3) for 12 to 48 hours at 4°C.  
Corneas were cut 3-4 times with a scalpel blade from the periphery to close to the center, 
but not enough to separate the tissue into different sections to help keep the tissue flat. Tissue 
were placed in Shandon M-1 Embedding matrix (Ref: 1310, Thermo Scientific, Waltham, MA) 
in an embedding mold and frozen into a square block with liquid nitrogen. To keep flat, the 
corneas were placed epithelium side down in a drop of embedding medium and frozen. 
Additional medium was placed on top of the frozen tissue and frozen again to allow for coronal 
sectioning. Tissue sections were coronally cut at 18µm using a Leica cryostat (CM1850) and 
thaw mounted on gel coated slides (VWR, 48311-600). All slides were placed tissue up on a 
slide warmer (Fisher Scientific, Waltham, MA, model: 77) for 1 hour at 37°C. The tissues were 
washed 3 times with PBS (pH: 7.3). The slides were incubated in 0.5% BSA, and 0.5% 
  
 
49 
 
polyvinylpyrolidone in PBS with 0.3% Triton (PBS-T). Sections were incubated for 48 hours at 
4°C in each of the primary antisera presented in table 3.1 which includes GluA1-4, GluK1-5, 
GluN1,2A-2B,3A,3B, PSD-95, stargazin, and glutamate. All primary antisera raised in goat or 
mouse were colocalized with PGP 9.5 raised in rabbit, all antibodies raised in rabbit were 
colocalized with Calcitonin gene-related peptide (CGRP) raised in mouse, and glutamate was 
single labeled without colocalization. The tissue was washed three times with PBS for ten 
minutes each. Alexa Fluor 488 secondary antisera for iGluRs, PSD-95, Stargazin, and 
Glutamate, and Alexa Fluor 555 secondary antisera for PGP9.5 and CGRP were added with 
PBS-T to 1:1000 for their respected species for 1 hour followed by three washes with PBS. 
Coverslips were placed over the tissue with Prolong Gold antifade reagent (Ref: P36930). All 
images were taken with a Leica DMI 4000B confocal microscope (Resolution: 2048 x 2048) 
with a 40X water objective. Images were saved as TIFF and the exposure times were iGluR 
subunit specific. All final images were a merge of 3-10 confocal images (Resolution: 2048 x 
2048) that best represented the particular field of view. Refer to table 3.1 for a full list of 
antibodies used along with the company, catalog number, species reactivity, monoclonal or 
polyclonal, and concentration used.  
Target Company 
Catalog 
Number Species Mono/Poly Concentration 
Primary antisera   
GluA1 Santa Cruz sc-7609 Goat Polyclonal 1:100 
GluA2 Millipore MAB397 Mouse Monoclonal 1:100 
GluA3 Santa Cruz sc-7613 Goat Polyclonal 1:100 
GluA4 Acris AP16819PU-N Goat Polyclonal 1:100 
GluK1 Santa Cruz sc-7617 Goat Polyclonal 1:100 
GluK2 Abcam ab53092 Rabbit Polyclonal 1:100 
GluK3 Abcam ab82148 Goat Polyclonal 1:100 
GluK4 Santa Cruz sc-8917 Goat Polyclonal 1:100 
GluK5 Santa Cruz sc-8915 Goat Polyclonal 1:100 
GluN1 Santa Cruz sc-1467 Goat Polyclonal 1:100 
GluN2A Santa Cruz sc-1468 Goat Polyclonal 1:100 
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GluN2B Santa Cruz sc-1469 Goat Polyclonal 1:100 
GluN2C Santa Cruz sc-1470 Goat Polyclonal 1:100 
GluN2D Santa Cruz sc-1471 Goat Polyclonal 1:100 
GluN3A Millipore 07-356 Rabbit Polyclonal 1:250 
GluN3B Upstate Cell Signaling 07-351 Rabbit Polyclonal 1:250 
PSD-95 Cell Signaling 2507X Rabbit Polyclonal 1:500 
Stargazin/Cacng2  Upstate Cell Signaling 07-577 Rabbit Polyclonal 1:100 
Glutamate Sigma G6642 Rabbit Polyclonal 1:1000 
Colocalized 
Antisera   
CGRP Santa Cruz sc-57053 Mouse Monoclonal 1:1000 
PGP 9.5 Cedarlane CL7756AP Rabbit Polyclonal 1:10,000 
Table 3.1: List of all primary antibodies used in this study. 
Statistical analysis 
 Because this was a descriptive study, no statistical analysis was conducted.  
Results:  
1.1 Western Blot 
 
Figure 3.1: Preliminary western blots of whole corneas. 
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Western blots of each of the iGluR subunits were conducted to support their presence or 
absence in the cornea. From our preliminary results, figure 3.1, shows that each of the iGluR 
subunits have some level of expression in the cornea. Because of many nonspecific bands 
present in the blots in figure 3.1, optimization steps for GluA2 were targeted for further western 
blot analysis. As represented in figure 3.2, both the whole cornea and trigeminal root ganglion 
were found to have bands at 130kd. Hippocampal control was found to be at about 110kd. 
                 Whole cornea       Trigeminal root Ganglion                        Hippocampus 
 
Figure 3.2: Western blot of GluA2. 
1.2 Immunohistochemistry 
All the glutamate receptor subunits, PSD-95, Stargazin, and glutamate were identified to be 
present in the corneal epithelium and cytoplasm in the cornea epithelial cells. The intensity of the 
fluorescence of the corneal epithelial cells made it difficult to identify epithelial nerve fibers. 
GluA2,3 and GluK1 were identified in the corneal epithelial nerve fibers, but all of the other 
subunits, PSD-95, Stargazin, and glutamate were undetermined. Perinuclear staining was only 
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identified in GluA2 and GluK1,4. Nuclear staining was identified in GluK3 and GluN2A,2B,2C. 
Stromal nerve fibers were undetermined in GluA4 and GluN2B, but, in all the other subunits, 
PSD-95, Stargazin, and glutamate immunofluorescent staining occurred in the stromal nerve 
fibers. All results are represented in table 3.2. 
 All glutamate receptor subunits, PSD-95, Stargazin, and glutamate were identified to be 
present in both the large and small neuronal cell bodies of the ophthalmic division of the 
trigeminal root ganglion. Furthermore, for GluA2,3, GluK1,2,4,5, and GluN2C,3B, the large 
neuronal cell bodies were dimly stained as compared to the brightly stained small neuronal cell 
bodies. Nuclear staining in the trigeminal root ganglion was not identified for GluA4, GluK2,5, 
GluN1,2D,3B, PSD-95, Stargazin, and glutamate. Nuclear staining was identified for GluA1,2,3, 
GluK1,4, and GluN2A3A, but more intense nuclear staining was identified for GluK3 and 
GluN2B,2C. All of the glutamate receptor subunits, PSD-95, Stargazin, and glutamate were 
identified in the nerve fibers of the trigeminal root ganglion. GluA1,3, GluK3,4, and 
GluN1,2C,2D, were identified as having satellite cell staining in the trigeminal root ganglion and 
the remaining subunits, PSD-95, Stargazin, and glutamate were identified as undetermined. 
GluN2C,2D,3A,3B were identified to have Schwann cell staining in the trigeminal root ganglion. 
GluK2,5 and GluN2A,2B were identified to have myelin sheath staining in the trigeminal root 
ganglion. All results are represented in table 3.2. 
 Figures 3.2-3.7 represent enlarged examples of the cornea for each of the characteristics 
identified. Figures 3.8-3.13 represent enlarged examples of the trigeminal root ganglion for each 
of the characteristics identified. Figures 3.14-3.32 represent each of the glutamate receptor 
subunits, PSD-95. Stargazin, and glutamate for the cornea and trigeminal root ganglion. 
  
 
53 
 
 
 
Table 3.2: Results of immunofluorescent reactivity for the cornea and trigeminal root ganglia. Green Y: Presence. 
Dark Green Y: Low presence. Bright Green Y: High presence. Yellow U: Unknown presence. Red N: No presence.  
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GluA1 Y Y N U Y Y Y Y Y Y N U
GluA2 Y Y N Y Y Y Y Y Y U N U
GluA3 Y Y N Y Y Y Y Y Y Y N U
GluA4 Y Y N U U Y Y N Y U N U
GluK1 Y Y N Y Y Y Y Y Y U N U
GluK2 Y Y N U Y Y Y N Y U N Y
GluK3 Y Y Y U Y Y Y Y Y Y N U
GluK4 Y Y N U Y Y Y Y Y Y U U
GluK5 Y Y N U Y Y Y N Y U N Y
GluN1 Y Y N U Y Y Y N Y Y N U
GluN2A Y Y Y U Y Y Y Y Y U N Y
GluN2B Y Y Y U U Y Y Y Y U N Y
GluN2C Y Y Y U Y Y Y Y Y Y Y U
GluN2D Y Y N U Y Y Y N Y Y Y U
GluN3A Y Y N U Y Y Y Y Y U Y U
GluN3B Y Y N U Y Y Y N Y U Y U
PSD95 Y Y N U Y Y Y N Y U N N
Stargazin Y Y N U Y Y Y N Y U N N
Glutamate Y Y N U Y Y Y N Y U N N
Cornea Trigeminal
Y Yes (Bright) Y Yes (Dim) N No
Y Yes U Unclear
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1.2.1 Corneal characteristics 
 
Figure 3.3: Image illustrating immunoreactivity in corneal epithelial cells (GluA2). Arrows illustrate the corneal 
epithelium.  
  
Figure 3.4: Image illustrating corneal epithelial nerve fiber staining (Green: GluK1, Red: PGP 9.5). 
 
20.0 µm 20.0 µm 
30.0 µm 
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Figure 3.5: Image illustrating corneal stromal nerve fiber staining (GluK5). 
 
 
Figure 3.6: Image illustrating corneal cytoplasmic staining (GluN2D). 
20.0 µm 
20.0 µm 
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Figure 3.7: Image illustrating corneal nuclear staining and enlarged in right panel (GluN2B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20.0 µm 10.0 µm 
  
 
57 
 
1.2.2 Trigeminal characteristics 
 
Figure 3.8: Image illustrating Trigeminal large (White arrows) and small (Blue arrows) immunoreactive neuronal 
cell bodies (GluA2). 
 
Figure 3.9: Image illustrating Trigeminal nuclear (arrows) immunoreactivity (GluK3) of large neuronal cell body. 
10.0 µm 
20.0 µm 
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Figure 3.10: Image illustrating Trigeminal nerve fiber (arrows) immunoreactivity (GluN3A). 
 
Figure 3.11: Image illustrating Trigeminal satellite (arrows) immunoreactivity (GluN2D). 
10.0 µm 
10.0 µm 
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Figure 3.12: Image illustrating Trigeminal Schwann (arrows) immunoreactivity (GluN3A). 
 
Figure 3.13: Image illustrating Trigeminal myelin (arrows) immunoreactivity (GluK5). 
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Figure 3.14: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluA1 (Green) and 
PGP9.5 (Red). Fig1A-C represent immunofluorescent images of GluA1 positive epithelial cells (“E”)), Stroma 
(“S”), and stromal nerve bundles (arrows) in the cornea. Fig1D-F represent immunofluorescent images of GluA1 
positive large neuronal cell bodies (thick arrow), small neuronal cell bodies (thin arrow), and satellite cells 
(arrowhead). 
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1.2.2 GluA2 
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Figure 3.15: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluA2 (Green and 
PGP9.5 (Red). Fig2A-C represent immunofluorescent images of GluA2 positive epithelial cells (“E”), Stroma (“S”), 
and stromal nerve bundles (arrows) in the cornea. Fig2D-F represent immunofluorescent images of GluA2 large 
neuronal cell bodies (thick arrow), and small neuronal cell bodies (thin arrow). 
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1.2.3 GluA3 
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Figure 3.16: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluA3 (Green) and 
PGP9.5 (Red). Fig3A-C represent immunofluorescent images of GluA3 positive epithelial cells (“E”), Stroma (“S”), 
and stromal nerve bundles (arrows) in the cornea. Fig3D-F represent immunofluorescent images of GluA3 positive 
large neuronal cell bodies (thick arrow), small neuronal cell bodies (thin arrow), and satellite cells (arrowhead).  
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1.2.4 GluA4 
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Figure 3.17: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluA4 (Green) and 
CGRP (Red). Fig4A-C represent immunofluorescent images of GluA4 positive epithelial cells (“E”), Stroma (“S”), 
and stromal nerve bundles (arrows) in the cornea. Fig4D-F represent immunofluorescent images of GluA4 positive  
large neuronal cell bodies (thick arrow), and small neuronal cell bodies (thin arrow). 
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1.2.5 GluK1 
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Figure 3.18: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluK1 (Green) and 
PGP9.5 (Red). Fig5A-C represent immunofluorescent images of GluK1 positive epithelial cells (“E”), Stroma (“S”), 
and stromal nerve bundles (arrows) in the cornea. Fig5D-F represent immunofluorescent images of GluK1 positive 
large neuronal cell bodies (thick arrow), and small neuronal cell bodies (thin arrow). 
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1.2.6 GluK2 
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Figure 3.19: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluK2 (Green) and 
CGRP (Red). Fig6A-C represent immunofluorescent images of GluK2 positive epithelial cells (“E”), Stroma (“S”), 
and stromal nerve bundles (arrows) in the cornea. Fig6D-F represent immunofluorescent images of GluK2 positive 
large neuronal cell bodies (thick arrow), small neuronal cell bodies (thin arrow), and satellite cells (arrowhead). 
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Figure 3.20: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluK3 (Green) and 
PGP9.5 (Red). Fig7A-C represent immunofluorescent images of GluK3 positive epithelial cells (“E”), Stroma (“S”), 
and stromal nerve bundles (arrows) in the cornea. Fig7D-F represent immunofluorescent images of GluK3 positive 
large neuronal cell bodies (thick arrow), small neuronal cell bodies (thin arrow), and satellite cells (arrowhead). 
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Figure 3.21: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluK4 (Green) and 
PGP9.5 (Red). Fig8A-C represent immunofluorescent images of GluK4 positive epithelial cells (“E”), Stroma (“S”), 
and stromal nerve bundles (arrows) in the cornea. Fig8D-F represent immunofluorescent images of GluK4 positive 
large neuronal cell bodies (thick arrow), small neuronal cell bodies (thin arrow), and satellite cells (arrowhead). 
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Figure 3.22: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluK5 (Green) and 
PGP9.5 (Red). Fig9A-C represent immunofluorescent images of GluK5 positive epithelial cells (“E”), Stroma (“S”), 
and stromal nerve bundles (arrows) in the cornea. Fig9D-F represent immunofluorescent images of GluK5 positive 
large neuronal cell bodies (thick arrow), and small neuronal cell bodies (thin arrow). 
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1.2.10 GluN1 
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Figure 3.23: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluN1 (Green) and 
PGP9.5 (Red). Fig10A-C represent immunofluorescent images of GluN1 positive epithelial cells (“E”), Stroma 
(“S”), and stromal nerve bundles (arrows) in the cornea. Fig10D-F represent immunofluorescent images of GluN1 
positive large neuronal cell bodies (thick arrow), small neuronal cell bodies (thin arrow), and satellite cells 
(arrowhead). 
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1.2.11 GluN2A 
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Figure 3.24: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluN2A (Green) and 
PGP9.5 (Red). Fig11A-C represent immunofluorescent images of GluN2A positive epithelial cells (“E”), Stroma 
(“S”), and stromal nerve bundles (arrows) in the cornea. Fig11D-F represent immunofluorescent images of GluN2A 
positive large neuronal cell bodies (thick arrow), and small neuronal cell bodies (thin arrow). 
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1.2.12 GluN2B 
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Figure 3.25: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluN2B (Green) and 
PGP9.5 (Red). Fig12A-C represent immunofluorescent images of GluN2B positive epithelial cells (“E”), Stroma 
(“S”), and stromal nerve bundles (arrows) in the cornea. Fig12D-F represent immunofluorescent images of GluN2B 
positive large neuronal cell bodies (thick arrow), and small neuronal cell bodies (thin arrow). 
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Figure 3.26: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluN2C (Green) and 
PGP9.5 (Red). Fig13A-C represent immunofluorescent images of GluN2C positive epithelial cells (“E”), Stroma 
(“S”), and stromal nerve bundles (arrows) in the cornea. Fig13D-F represent immunofluorescent images of GluN2C 
positive large neuronal cell bodies (thick arrow), small neuronal cell bodies (thin arrow), and satellite cells 
(arrowhead). 
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1.2.14 GluN2D 
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Figure 3.27: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluN2D (Green) and 
PGP9.5 (Red). Fig14A-C represent immunofluorescent images of GluN2D positive epithelial cells (“E”), Stroma 
(“S”), and stromal nerve bundles (arrows) in the cornea. Fig14D-F represent immunofluorescent images of GluN2D 
positive large neuronal cell bodies (thick arrow), small neuronal cell bodies (thin arrow), and satellite cells 
(arrowhead). 
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1.2.15 GluN3A 
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Figure 3.28: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of GluN3A (Green) and 
CGRP (Red). Fig15A-C represent immunofluorescent images of GluN3A positive epithelial cells (“E”), Stroma 
(“S”), and stromal nerve bundles (arrows) in the cornea. Fig15D-F represent immunofluorescent images of GluN3B 
positive large neuronal cell bodies (thick arrow), and small neuronal cell bodies (thin arrow). 
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Figure 3.29: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of Glu3B (Green) and 
CGRP (Red). Fig16A-C represent immunofluorescent images of GluN3B positive epithelial cells (“E”), Stroma 
(“S”), and stromal nerve bundles (arrows) in the cornea. Fig16D-F represent immunofluorescent images of GluN3B 
positive large neuronal cell bodies (thick arrow), and small neuronal cell bodies (thin arrow). 
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1.2.17 PSD-95 
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Figure 3.30: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of PSD-95 (Green) and 
CGRP (Red). Fig16A-C represent immunofluorescent images of PSD-95 positive epithelial cells (“E”), Stroma 
(“S”), and stromal nerve bundles (arrows) in the cornea. Fig16D-F represent immunofluorescent images of PSD-95 
positive large neuronal cell bodies (thick arrow), and small neuronal cell bodies (thin arrow). 
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1.2.18 Stargazin 
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Figure 3.31: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of Stargazin (Green) and 
CGRP (Red). Fig16A-C represent immunofluorescent images of Stargazin positive epithelial cells (“E”), Stroma 
(“S”), and stromal nerve bundles (arrows) in the cornea. Fig16D-F represent immunofluorescent images of Stargazin 
positive large neuronal cell bodies (thick arrow), and small neuronal cell bodies (thin arrow). 
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1.2.19 Glutamate 
              
Figure 3.32: Images illustrating Cornea and Trigeminal root ganglion immunoreactivity of Glutamate. Fig16A 
represent immunofluorescent images of Glutamate positive epithelial cells (“E”), and Stroma (“S”), in the cornea. 
Fig16B represent immunofluorescent images of Glutamate positive large neuronal cell bodies (thick arrow), and 
small neuronal cell bodies (thin arrow). 
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Discussion 
In our results, we have identified all the glutamate receptor subunits in both the cornea 
and trigeminal root ganglion, which directs us to accept the alternative hypothesis that all the 
iGluR subunits are present in the cornea and trigeminal root ganglion. Interestingly, we have 
identified differing distributions of immunoreactivity across many of the iGluR subunits, e.g. 
nuclear staining and Schwann cell staining. Many characteristics, however, were similar across 
the iGluR subunits, e.g. corneal epithelial cell staining. We identified all iGluR subunits, PSD-
95, stargazin, and glutamate in the large and small neuronal cell bodies in the trigeminal root 
ganglion. These results support that there are specific iGluR subunit combinations that could be 
responsible for painful responses when glutamate activates the iGluRs. When a noxious stimulus 
is introduced to a tissue, peripheral neuron terminals release glutamate that activates iGluRs on 
nerve terminals in an autocrine or paracrine manner (Miller et al., 2011). In skin, there is an 
increase of iGluR in the nerve terminals during inflammation. Furthermore, the number of 
peripheral afferents with iGluRs increase (Carlton & Coggeshall, 1999) to produce a more robust 
nociceptive response due to peripheral sensitization of primary afferents (Miller et al., 2011). 
With the results of the present study, it is now possible to evaluate if similar occurrences ensue 
during corneal inflammation. 
With immunoblotting, the GluA2 receptor subunit band was identified for the cornea and 
trigeminal root ganglion at a higher molecular weight than in the hippocampus. Previous studies 
have also reported findings similar to ours (Kaniakova, Lichnerova, Skrenkova, Vyklicky, & 
Horak, 2016; Lichnerova et al., 2015; Mollerud, Kastrup, & Pickering, 2016; Tucholski, Pinner, 
Simmons, & Meador-Woodruff, 2014; Tucholski et al., 2013). The differing number of 
glycosylation sites between the CNS and PNS can begin to explain the difference in size. Further 
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evaluation of the glycosylation of these receptor subunits should be conducted to identify further 
differences between the CNS and PNS. 
 One limitation to our evaluation is that only the presence or absence of staining of each of 
the iGluR subunits can be described, but we cannot determine if the iGluR subunits are present 
in a functional iGluR or if they are present in a nonfunctional aggregation of iGluR subunits 
(Coleman et al., 2016). Even though each of the iGluR subunits in the cornea and trigeminal root 
ganglion were detected, further evaluation is required to identify if these iGluR subunits are 
present in a functional receptor and what types of functions these receptors have.  
The Sprague Dawley rat model used has been identified as being a better representative 
model when translating to humans (Iannaccone & Jacob, 2009). We were able to reduce the 
number of animals by using multiple corneal sections from each animal for 
immunohistochemistry of more than one iGluR subunit (Flecknell, 2002).  A certain level of bias 
may have been introduced, howerve, in the process of identifying the best representative images 
for each of the iGluR subunits, PSD-95, stargazin, and glutamate. To preserve human clinical 
implementation of our study, we were not able to replace the Sprague Dawley rat model with an 
in vitro model.  
We identified the GluN2C,2D,3A,3B receptor subunits in the trigeminal root ganglion 
Schwann cells. Previous work has identified GluN2D and GluN3A in oligodendrocytes and 
myelin sheath in the optic nerve (Micu et al., 2016) which supports our results. Additional 
colocalization studies of other iGluR subunits to GluN2C,2D,3A,3B receptor subunits will help 
in a better understanding of which subunits are present in the Schwann cells and myelin sheath.  
Further studies are needed to understand how the events of peripheral sensitization 
(Latremoliere & Woolf, 2009) occur during cornea inflammation and injury. When a noxious 
stimulus is introduced to the cornea, phosphorylation of calcium impermeable GluA2 containing 
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glutamate receptors occurs and these receptors are endocytosed, so calcium permeable GluA1 
containing receptors can implant into the cell membrane for a more robust sensitization of nerve 
fibers (Latremoliere & Woolf, 2009). When topically applied Capsaicin is used as the noxious 
stimulus, this would support that the corneal epithelial cells could take part in the transduction of 
a noxious stimulus by autocrine and paracrine release of glutamate from the corneal epithelial 
cells (Miller et al., 2011). 
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CHAPTER IV 
 
APPLYING THE ARRIVE GUIDELINES TO PERIPHERAL IONOTROPIC GLUTAMATE 
RECEPTOR LITERATURE: A SYSTEMATIC REVIEW 
 
Abstract 
Introduction: High quality, basic science publications are needed to further the translational 
research from animals to humans along with conducting meta-analyses to search for true effects 
of animal modeled research.  
Methods: Two hundred seventy-four published research articles were identified using PubMed 
in which 169 were coded using the ARRIVE guidelines. Hand coding of each component of the 
ARRIVE guidelines was done.   
Results: Of the 169 studies analyzed, an underreporting of methodological components of the 
ARRIVE guidelines was observed. To identify the current trend of reporting, the 46 studies that 
were published after the publication of the ARRIVE guidelines were separately compared to the 
articles published before 2010. It was determined that there has been little change of efficiently 
reporting the components of the ARRIVE guidelines over time.  
Discussion: Many of the core components of the ARRIVE guidelines were underreported in the 
peripheral iGluR literature which corresponds to other systematic reviews of a similar 
assessment type. Better reporting is needed to increase the translation of research from animal 
models to humans.
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Introduction 
Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines were 
published in 2010 to improve research reporting and to decrease research redundancy with 
animal models (Kilkenny et al., 2010). In the interim 7 years, these guidelines often are under-
utilized within pre-clinical studies (Arora & Ivanovski, 2017; Gulin, Rocco, & Garcia-
Bournissen, 2015; Karp et al., 2015). With more evidence indicating inefficient translation of 
animal research to human studies, (Hackam & Redelmeier, 2006; Ting, Hill, & Whittle, 2015), 
there is need to increase animal research quality.  
In the current study, we examined the use of ARRIVE guidelines in the literature 
involving ionotropic glutamate receptors (iGluR) in relation to peripheral pain. The iGluRs are 
located on the peripheral terminals of nociceptive primary sensory afferents and the amino acid 
glutamate activates and sensitizes the primary sensory afferents by binding to iGluRs (Carr, 
2017; Miller et al., 2011). Decreasing pain intensity is a sought-out topic of research (Liu et al., 
2008; McRoberts et al., 2001; Medvedev et al., 2004; Zhou, Bonasera, & Carlton, 1996), so 
increasing the quality of reporting in animal research will undoubtedly aid in increasing 
translational research.  
We hypothesize that when investigating the study quality of the peripheral iGluR 
literature, the overall efficiency of reporting will not meet the current standards of the ARRIVE 
guidelines. Furthermore, we hypothesize that will be no significant change of reporting from pre- 
to post- ARRIVE guidelines publication. Our aim is to evaluate the iGluR literature for each of 
the ARRIVE guideline components and to compare the efficiency of reporting between pre- and 
post- ARRIVE guidelines publication. 
Methods 
Search String 
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 PubMed was used to search Medline to obtain the primary studies with the following 
search string: “((Excitatory amino acid receptors OR glutamate receptor OR GluA OR gluK OR 
gluN) AND Pain) AND (Behavior OR Behavioral) AND (Peripheral OR electrophysiology OR 
microdialysis)” on 2-26-2017. Two hundred seventy-four studies were located from the search 
and coded using the ARRIVE guidelines. Two on-staff librarians at Oklahoma State University 
Center for Health Sciences were consulted to identify the most concise yet inclusive search string 
possible.  
Identification of Included Articles 
 All identified articles were transferred to EndNote. Full text articles were identified and 
screened for inclusion or exclusion. Articles that included iGluRs and had a component 
evaluating the peripheral nervous system were included. All articles that were human, a review, 
not iGluR, not in English, or not retrievable were excluded. Table 4.1 displays an adapted 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram 
displaying the included and excluded articles.  
Quality assessment 
The primary author, B.K.C., reviewed and coded each full text article for each component 
of the ARRIVE guidelines. The reviewer determined that the publication either included or did 
not include the requirements for each of the coded components. All subcomponents of the 
ARRIVE guidelines were individually evaluated by the reviewer. If a single component had 
multiple requirements, all requirements had to be met to receive an included mark by the 
reviewer. Table 4.2 contains the 38 coded components with short descriptions.  
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Table 4.1: Adapted PRISMA flow diagram. 
Results 
After full text screening, a total of 169 studies were included in our study. A total of 46 of 
these studies were published the same year or after the ARRIVE guidelines were published 
(Kilkenny et al., 2010). Table 4.2 represents all the coded components and the percentage of 
reporting when all the 169 articles were combined, when only the articles from before 2010 were 
combined, and when all of the articles during or after 2010 were combined.  
Descriptive and organized abstract 
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 Presenting a descriptive and organized abstract based on each component of a scientific 
paper has increased before (8.9%) to after (30.4%) ARRIVE guidelines publication.  
Ethical statement 
 An ethical statement of animal usage was reported and increased before (83.7%) to after 
(100%) the ARRIVE guidelines publication.  
Experimental Procedures 
 Identification of all drugs and doses were highly reported across the articles, before 
(90.2%), and after (89.1%), but identifying the time of performing the experiment, before 
(12.2%) and after (8.7%), identifying in detail where the experiment was conducted, before 
(42.3%) and after (58.7%), and explaining the reason behind choosing the drug and dosages, 
before (9.8%) and after (4.3%), were underreported.  
Experimental Animals 
 Identifying the average weight and age along with the range of each was not reported, 
before (2.4%) and after (0.0%). Furthermore, the identification of the animals as naïve or if they 
participated in a previous experiment and where they were purchased, bred, or found was also 
underreported, before (7.3%) and after (0.0%).  
Housing and Husbandry 
 Identifying the type, or size, of the cage, bedding used, and the number of animals housed 
in each cage was underreported, before (7.3%) and after (2.2%). Full reporting of the light/dark 
cycle, temperature, and quality of food and water was underreported, before (7.3%) and after 
(2.2%).  
Statistics 
 The statistical methods were highly reported before (91.1%) and after (97.8%) the 
ARRIVE guidelines publication. Identifying the unit being assessed was moderately reported, 
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before (62.6%) and after (63.0%). Identifying if data meet the assumptions of statistical approach 
was underreported, before (3.2%) and after (15.2%).  
Outcomes and Estimation 
Identifying the standard error of the mean (S.E.M.) for each experimental and control 
group was underreported, before (26.8%), and after (19.6%). 
Interpretation/Scientific Implications 
 Identifying any bias and limitations to the animal model was underreported, before 
(2.4%) and after (2.2%). Describing replacement, refinement, and reduction was underreported, 
before (0.0%) and after (0.0%). 
  
ARRIVE 
item   
Reported 
(%)   
    
Total 
(n=169) 
Before 
2010 
(n=123) 
2010 to 
2017 
(n=46) 
Title 1 100.0 100.0 100.0 
Descriptive and organized 
abstract. 2 14.8 8.9 30.4 
Background a. Reference 
previous work to describe the 
motivation of current study. 3a 100.0 100.0 100.0 
Background b. Describe how the 
animal model of choice is the 
best and how it transfers to 
humans.  3b 21.9 24.4 15.2 
Objectives. Describe the 
objectives (hypothesis, aims, etc.) 4 89.3 89.4 89.1 
Ethical statement. Did they get 
approval or not? 5 88.2 83.7 100.0 
Study design a. Number of 
Experimental groups and Control 
groups. 6a 27.2 27.6 26.1 
Study design b. Was the study 
blinded and explain details of 
who was blinded and when. 6b 30.8 29.3 34.8 
Study design c. What was 
considered an experimental unit? 
Single animal? Group of animals? 6c 94.7 95.9 91.3 
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Experimental procedures a. List 
all drugs that were used 
(anesthesia, experimental, etc.) 
and the dose that was 
administered. Also, where was it 
administered. 7a 89.9 90.2 89.1 
Experimental procedures b. What 
time of the day was the 
experiment performed? 7b 11.2 12.2 8.7 
Experimental procedures c. 
Where was the experiment 
performed? Location of 
experiment (home cage, water 
maze, etc. 7c 46.7 42.3 58.7 
Experimental procedures d. 
Explain your reasoning of why 
you chose the drug, the area of 
administration, and the dose 
used. 7d 8.3 9.8 4.3 
Experimental animals a. List 
species, strain, sex, age (mean 
and range), and weight (mean 
and range) of animals 8a 1.8 2.4 0.0 
Experimental animals b. Are the 
animals naïve, previously tested, 
what company did they come 
from, strain of rat, etc. 8b 5.3 7.3 0.0 
Housing and husbandry a. Type 
of cage (housing), bedding 
material, number of animals in 
the cage. 9a 5.9 7.3 2.2 
Housing and husbandry b. 
Light/dark schedule, 
temperature, quality of food and 
water. 9b 5.9 7.3 2.2 
Housing and husbandry c. 
Welfare of animal before, during, 
and after experiment.  9c 1.8 2.4 0.0 
Sample size a. Number of animals 
in whole experiment and number 
in each group. 10a 11.2 9.8 15.2 
Sample size b. How was the 
number arrived at. 10b 0.0 0.0 0.0 
Sample size c. How many 
independent replications were 
there. 10c 0.6 0.8 0.0 
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Allocating animals to 
experimental groups a. How were 
the animals sorted into their 
groups? Randomized? Matching? 11a 8.3 8.1 8.7 
Allocating animals to 
experimental groups b. Describe 
the order in which the animals 
were treated and assessed. 11b 1.8 1.6 2.2 
Experimental outcomes.  What is 
the outcome that you looking 
for? Behavioral change, cell 
death, etc.? Be specific. 12 98.2 98.4 97.8 
Statistical methods a. Give 
specific details about all 
statistical methods used 
throughout the experiment.  13a 92.9 91.1 97.8 
Statistical methods b. Specify the 
unit that is being assessed. A 
group of animals, single animal, 
neurons, etc. 13b 62.1 62.6 63.0 
Statistical methods c. Did the 
data meet the assumptions of 
statistical approach? 13c 6.5 3.2 15.2 
Baseline data. For each group 
describe: health, weight, and 
drug/test naïve.  14 1.2 1.6 0.0 
Numbers analyzed a. Report 
absolute values of the number of 
animals in each group. Not 
percent.  15a 46.2 45.5 47.8 
Numbers analyzed b. Explain why 
any animals were taken out of 
analysis.  15b 0.0 0.0 0.0 
Outcomes and estimation. 
Report results for each analysis 
with standard error of the mean 
and/or confidence interval. 16 24.9 26.8 19.6 
Adverse events a. Give details 
about any adverse important 
events in each experimental 
group. 17a 0.0 0.0 0.0 
Adverse events b. Were there 
any modifications done to the 
experimental protocols made to 
reduce adverse events.  17b 0.6 0.8 0.0 
  
 
108 
 
Interpretation/scientific 
implications a. Interpret the 
results and consider the aims, 
current theory, and other 
literature. 18a 100.0 100.0 100.0 
Interpretation/scientific 
implications b. Comment on the 
sources of bias, any limitations of 
the animal model, and the 
imprecision associated with the 
results. 18b 2.4 2.4 2.2 
Interpretation/scientific 
implications c. Describe the 
replacement, refinement, or 
reduction of the use of animals in 
research based off of your study.  18c 0.0 0.0 0.0 
Generalizability/translation. 
Comment on how the results 
translate to other species 
including humans.   19 28.4 30.9 21.7 
Funding. Was this study funded? 
List all grants and the roles of the 
funder(s) in this study. 20 56.8 54.5 63.0 
 
Table 4.2: Table representing each graded component with description of the ARRIVE guidelines and percentages 
of articles that met criteria. All articles combined, articles before 2010, and articles during or after 2010 are 
represented separately.  
Discussion 
We found that there were certain components that were well, moderately, or poorly 
reported. Critical components that were poorly reported include the time of day experiments 
were performed, identification of the animal origin and if they were naïve, how the experimental 
animal number was determined, if the data meet the assumptions of statistical approach, and 
reporting specific standard error of the mean (S.E.M). In many cases the S.E.M. was reported as 
bars on each data point in a graph, but the numerical value of the S.E.M. of each data point was 
not located in the published work. With an impetus for conducting meta-analyses in pre-clinical 
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trials ("Collaborative Approach to Meta analysis and Review of Animal Data from Experimental 
Studies," 2014), reviewers conducting a meta-analysis would not be able to obtain accurate 
results when estimating the S.E.M. from graphs. Furthermore, reporting the time of the day an 
experiment was performed will provide a better understanding of particular factors of the 
light/dark cycle. Our results indicate that the exact number of animals in specific group often is 
underreported. Instead of reporting exact values, it was common to find a range of animals for 
each group. Additionally, how each published work determined the number of animals needed 
rarely reported. 
In our study, we determined that there is low methodological reporting in aspects of 
animal usage, randomization, blinding, etc. This lack of information may greatly decrease the 
reproducibility of these preclinical studies. This is a disturbing trend because animals being used 
in non-reproducible studies are not translated to human research and are difficult for translation 
to the same or other species of animals in different labs. Increasing the efficiency of reporting 
and increasing the sample number, for example in the first study conducted in a series, can 
decrease the amount of subsequent replication and overall reduction of the number of animals 
used.  
In human clinical trials, there are multiple clinical trials registries to enroll research 
before a study begins and to be updated during and after completion ("ClinicalTrials.gov," 2013). 
Negative findings can be available to other researchers in these registries. Although clinical trials 
registries are commonly left unused (Sinnett et al., 2015; Yerokhin, Carr, Sneed, & Vassar, 
2016), the concept is one that would bring great benefit to the animal literature. With benefit, 
risk may follow. For example, introducing an animal trials registry for public use could increase 
the quality of reporting, but prevention of “research idea theft” might be difficult (Wieschowski, 
Silva, & Strech, 2016).  
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Our study contains limitations including determination of the research quality of a 
publication, but indicates only the efficiency of reporting in a published manuscript. Our study 
had a more extensive number of articles than similar systematic reviews (Arora & Ivanovski, 
2017; Ting et al., 2015), but the total number of articles published after the ARRIVE guidelines 
were published were still limited (n=46).  
 In conclusion, our study identified the under-utilization of the ARRIVE guidelines in the 
peripheral pain iGluR literature, particularly in methodology. We support the use of the ARRIVE 
guidelines in the pain literature in hope to increase the quality of the published literature. This 
increase in quality is an important goal to increase the number of preclinical trials that can be 
translated to human studies and to decrease the potential harm in human research when 
translational research takes place.  
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CHAPTER V 
 
CONCLUSION 
Various environmental exposures can damage or activate the corneal primary sensory 
afferents producing intense pain. The corneal sensory afferents can be damaged or activated by 
abrasions, drying, and chemicals. For example, autoimmune diseases like Sjogren’s syndrome 
facilitate drying of the cornea (Pedersen & Nauntofte, 2001) leading to primary sensory afferent 
damage. In each of these cases, it is presumed that glutamate is produced and released as the 
excitatory neurotransmitter of both the peripheral and central nerve terminals (Miller et al., 
2011). Glutamate acts as a ligand to the glutamate receptors which include the AMPA, Kainate 
and NMDA receptors. When present in peripheral afferent nerve terminals, these receptors 
participate in the sensitization of primary sensory afferents which in turn increases the rate of 
neuronal firing. This signal proceeds through the primary, secondary, tertiary, and quaternary 
neurons to ultimately be perceived in the cortex as intense pain (Basbaum et al., 2009).  
 Currently, there are several pharmaceutical drugs that help alleviate the pain of an 
irritated cornea. For example, non-steroidal anti-inflammatory drugs (NSAIDS) can help reduce 
pain, but side effects may occur such as delayed epithelial regeneration (Aragona & Di Pietro, 
2007). Opiates also can be used, but can produce respiratory depression, constipation, and 
addictive properties that may be more harmful for the patient than the benefits of pain relief 
(Alam & Juurlink, 2016). A new drug option, therefore, is needed for corneal pain and glutamate 
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receptor antagonists may be well suited for this need. Glutamate antagonists could alleviate pain 
by competitively or non-competitively antagonizing glutamate receptors in specific ways. 
Identifying the right drug along with appropriate solubility, molecular weight, and antagonistic 
site are all important in determining if a glutamate antagonist will be effective as a 
pharmaceutical analgesic.  
 In this study, we focused on corneal and trigeminal root ganglion glutamate receptors. 
We have evaluated for the functional presence of AMPA and Kainate receptors with behavioral 
assays, performed immunohistochemistry and preliminary Western blotting for the 16 currently 
recognized glutamate receptor subunits, and conducted Western blotting to support the presence 
of GluA2 in the cornea. Finally, we evaluated the literature of iGluRs and peripheral afferents 
with the ARRIVE guidelines to understand the current reporting of results in the peripheral pain 
iGluR literature. In previous studies in our lab, we examined GluK1, GluK5, and GluN1 for 
presence in the cornea using immunohistochemistry and determined the origin of trigeminal root 
ganglion neuronal cell bodies using retrolabeling with fluorogold (Ibitokun, 2012). These studies 
demonstrated the presence of these iGluR subunits in both in nerve fibers in the cornea and 
neuronal cell bodies in the trigeminal root ganglion (Ibitokun, 2012). This indicated that 
trigeminal root neurons project to the cornea and express specific iGluR subunits.  Additionally, 
our lab determined the glutamate dose response for eliciting nocifensive behavior and 
determined that an effective topical dose was 0.5M (Ibitokun, 2012). The high dose for eliciting 
behavior responses, compared to CNS receptor binding studies, is most likely due to two main 
reasons. First, the cornea always has a layer of tear film that will dilute the exogenously applied 
glutamate on contact. Secondly, the network of tight junctions between the corneal epithelial 
cells (Eghrari et al., 2015) will reduce the glutamate that contacts ligand binding sites on 
peripheral afferents.  
  
 
113 
 
 In chapter 2, the results that we present support that DNQX is an effective antagonist 
when topically applied to the cornea and that functional AMPA and Kainate receptors are present 
in the cornea. We first studied how an AMPA/Kainate antagonist can effectively reduce the 
glutamate-induced nocifensive response, such as eye blinking, wiping, and shaking. Although 
glutamate receptor antagonists produce many side effects when given systemically (Bleakman et 
al., 2006; Traynelis et al., 2010), we believe that a topical application to the cornea may have 
fewer severe side effects because of the lack of vasculature of the cornea (Eghrari et al., 2015). 
Still, there could be some adverse effects that need to be evaluated because of the vasculature in 
the sclera (Sit & McLaren, 2011). We further reviewed a comprehensive list of drugs, table 2.1, 
that have the potential to have similar antagonistic effects. Three unique characteristics of 
DNQX caused us to choose it for our behavioral studies: a small molecular weight, specificity 
for the AMPA and Kainate receptors, and water solubility. With these characteristics, we 
hypothesized that this drug could diffuse across the corneal epithelium to antagonize the 
AMPA/Kainate GluRs.  
 We then aimed to determine the presence and location of all the specific iGluR subunits 
in chapter 3. Our immunohistochemistry findings supported that all iGluR subunits are present in 
the cornea. One limitation that needs further research is to determine if these receptor subunits 
heterotetramerize into a functional glutamate receptor or if they form a nonfunctional aggregate 
of receptor subunits (Coleman et al., 2016). One step is to use more specific iGluR subunit 
agonists and/or antagonists to determine if the receptor subunits are functionally active in the 
cornea. A major limitation to this is the lack of potent subunit specific iGluR antagonists, as 
displayed in table 2.1, and the incomplete understanding of the functions of certain receptor 
subunit combinations. Furthermore, there is a lack of specific AMPA and Kainate specific 
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antagonists in general. As more specific iGluR antagonists are discovered, further analysis in this 
field can be conducted.  
We further evaluated the glutamate receptor subunits for Western blot analysis. Our 
preliminary data showed presence in each of the iGluR subunits, but many nonspecific bands 
were present, also. We further optimized detection of the GluA2 subunits by blocking the PVDF 
membrane with 2.5% bovine serum albumin (BSA) instead of 5% non-fat dried cow milk. After 
this, GluA2 had a molecular weight that was greater than what was determined for the 
hippocampus. The most likely explanation for this finding is that the peripheral tissues, in 
comparison to the CNS, have a greater number of glycosylation sites (Kaniakova et al., 2016; 
Lichnerova et al., 2015; Mollerud et al., 2016; Tucholski et al., 2014; Tucholski et al., 2013). 
This would support the claim that the Western blot band with the higher molecular weight is the 
band of interest for GluA2. Further analysis should be conducted to determine if these subunits 
are also at an increased molecular weight as compared to the hippocampal iGluR subunits and to 
further support the presence of the subunits in the cornea and trigeminal root ganglion.  
 While in the process of identifying a dissertation research project, we became aware the 
ARRIVE guidelines. These guidelines consist of a set of quality assessment components that aim 
to help researcher in designing experiments and writing manuscripts as efficiently and effectively 
as possible. In chapter 4 we used these guidelines to conduct a systematic review of the 
peripheral pain, iGluR literature. We have identified other similar systematic reviews (Arora & 
Ivanovski, 2017; Gulin et al., 2015; Ting et al., 2015), but not in this field and not as inclusive. 
We identified 169 articles and determined that, in many cases, the reporting was insufficient for 
important aspects that allows for reproducibility of preclinical studies. Furthermore, in the age of 
meta-analyses, the exact number of animals used per group and the specific S.E.M. were seldom 
reported. This suggests that changes in scientific publishing must occur in the way data is 
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reported and/or how journals review and present data. One way to increase the quality of 
reporting is to require registration of animal trials registries so study updates can be described. 
 
Figure 5.1: Figure representing a noxious stimulus being applied to the corneal epithelial layer and the subsequent 
release of glutamate to activate corneal primary afferents. (From (Ibitokun, 2012)). 
 Finally, our study describes the location of glutamate production, release, and activation 
in the cornea. As seen in figure 7.1, glutamate has been described in this dissertation to be 
produced in the corneal epithelial cells. When a noxious stimulus interacts with the corneal 
epithelial cells, glutamate may be released via exocytosis to further stimulate the corneal 
epithelial cells and to activate the primary sensory afferents. This model, therefore, hypothesizes 
that the corneal epithelial cells would be a transducer of noxious stimuli into activation of 
primary sensory nerve terminals. This is supported by the expression of nociceptive-specific 
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transducer proteins, TRPV1, in cornea cells (Mergler et al., 2014). Furthermore, the presence of 
iGluRs in both epithelial cells and nerve terminals indicates that the complexity of the cornea is 
much greater than previously thought. The cornea is one of the most densely innervated tissues 
for sensation in the body (Eghrari et al., 2015). iGluRs subunits are in many corneal afferents, 
but an understanding of iGluR subunit composition is lacking. The findings in this dissertation 
should lead to future research examining the various functionalities of the iGluRs in the cornea, 
e.g., nociception, wound healing (Por, Choi, & Lund, 2016).  
Future research 
 With the interesting findings of the location of the iGluR subunits in the cornea and 
trigeminal root ganglion, many future experimental possibilities arose. First, specific iGluR 
subunits are present at higher levels (immunoreactive intensity) in the small neuronal, TG cell 
bodies compared to the large neuronal cell bodies, e.g. GluA2-3, GluK1-2, 4-5, and GLUN1, 2C, 
3B. We theorize that specific combinations of these receptor subunits are for nocifensive 
behavior. Colocalizing and immunoprecipitation studies could be conducted to support this 
theory. A full understanding of the subunit composition of functional nociceptive iGluRs will 
help identify specific drugs that can act on particular combinations of receptor subunits to 
decrease the painful response, possibly with much fewer side effects than current drugs.  
In chapter 2, we examined the effects DNQX has when topically applied to the cornea. 
Further research should be conducted to evaluate the effectiveness of DNQX when given 
topically to the cornea when combined with a potent NMDA antagonist. This may further reduce 
the number of nocifensive responses seen when glutamate is used as an agonist or a faster 
reduction of nocifensive responses when compared to DNQX alone. 
 To further examine corneal epithelial cells as transducers of a noxious stimulus, capsaicin 
can be topically applied to the cornea to activate the transient receptor potential channel (TRPV) 
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receptors to produce autocrine and paracrine release of glutamate for activation of the glutamate 
receptors (Miller et al., 2011). In our preliminary results, figure 5.2, we examined capsaicin as an 
effective noxious stimulus. Furthermore, in figure 5.3, we examined KCl, which is a noxious 
stimulus that will depolarize nerve fibers. We plan to examine the effects of these two chemicals 
on the recruitment of glutamate receptors and to examine the antagonistic effects of DNQX with 
capsaicin and KCl, along with further combinations of DNQX and NMDA receptor antagonists.   
***
****
****
****
 
Figure 5.2: Capsaicin behavioral response and log dose response. (p= <0.001***, <0.0001****) 
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*
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Figure 5.3: Potassium Chloride (KCl) behavioral response and log dose response. (p= <0.05*, <0.001***, 
<0.0001****) 
 Furthermore, we identified GluN2C,2D,3A,3B on the Schwann cells in the trigeminal 
root ganglion. These data support previous findings that the GluN2D and GluN3A receptor 
subunits are present in optic nerve oligodendrocytes and myelin sheath (Micu et al., 2016). Our 
results provide the first report that these subunits occur on peripheral glial cells. Further studies 
conducted to colocalize iGluR subunits to the Schwann cells would help in a better 
understanding of which iGluR subunits actively participate in Schwann cell function.  
 In this dissertation, we showed that glutamate is present in the corneal epithelial cells. 
Future studies could examine the presence of glutamate synthesizing enzymes such as 
glutaminase and aspartate aminotransferase. Glutamate, being the ligand to the iGluRs, is 
transported into cells by glutamate transporters (Hediger & Welbourne, 1999). Further 
evaluation of specific glutamate transporters including EAAT, GLT1, and GLAST will be 
conducted to evaluate the similarities and differences between the corneal epithelial cells to the 
trigeminal root ganglion and CNS neurons. Vesicular glutamate transporters were detected only 
in corneal nerve fibers and not in corneal epithelial cells (Ibitokun, 2012). The presence of 
glutamate transporters, therefore, can serve as an export (release) mechanism of the corneal 
epithelial cells when they are activated by an external nociceptive stimulus.  
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Conclusion 
  Evaluating the iGluR in the human cornea has been studied (Feng, Price, McKee, & 
Price, 2015; A. Lee et al., 2014; Oswald et al., 2012; Seigel et al., 2003; Sloniecka et al., 2015; 
Staines, 2008), but is ultimately still lacking. Furthermore, a complete evaluation of iGluR 
subunits in a single tissue has not been conducted. With our results presented in this dissertation, 
we have examined and worked to fill this gap. With an examination of an AMPA/Kainate 
antagonist on the cornea and a full examination of all iGluR subunits in a single tissue, our work 
can help direct researchers to additional iGluR subunits that may not have been considered to 
have a role in corneal pain. Finally, with the evaluation of peripheral pain iGluR literature using 
the ARRIVE guidelines, we can begin to produce higher quality publications that makes it easier 
to reproduce and translate to a human model.   
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CHAPTER VI 
 
WESTERN BLOT PROTOCOL 
 
Equipment and materials: 
 Male rat (age between 2-5 months) 
 Female rat (age between 2-5 months) 
 Plastic rat home cage and top 
 Rat bedding 
 Rat chow 
 Water in rat dispensable bottle 
 Two generic green cards and one specifically colored card for you. 
 
• Rat selection 
o 8-10 weeks is good, but no actual age range restriction. (I use 6-8 week rats). 
• Tissue collection in surgery room: 
o Anesthesia machine: 
 Set up: Place the blue surgical cloth present in the surgery room over the 
table with the plastic rat housing cage on one end of the table and the 
guillotine on the other. You will collect your tissue in the area in between. 
Place paper towels on either side of the guillotine to absorb the blood.  
 Set up for tissue collection: Obtain a tub of ice and a metal plate for tissue 
collection. Also, make sure you have enough 1-2 mL tubes for the all of 
your tissue collection (Use larger sizes for bigger tissues.) 
 Radioimmunoprecipitation Assay buffer (RIPA buffer) -Add 1 mL of 
RIPA buffer into a 2 mL tube, remove 1 µL of the RIPA buffer, and add in 
1 µL of the protease/phosphatase inhibitor. The final concentration of the 
protease/phosphatase will be 1:1000. 
 There are 2 metal gas tanks (1 for carbon dioxide and one for oxygen) and 
an anesthesia machine for isoflurane in the surgery room.  
 Check the isoflurane level on the anesthesia machine. Add more if needed. 
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 Make sure the oxygen is plugged into the anesthesia machine and turn the 
knob until the metal ball on the anesthesia machine is up to the mark 
(about 5).  
 Make sure the rubber tube on the anesthesia machine is plugged into the 
plastic box that the rat will be placed in.  
 Place the rat into the box and close the lid before turning on the anesthesia 
machine.  
 Turn the knob on the anesthesia machine up to 5. This will deeply 
anesthetize the rat (use 2.5 with a “rat gas mask” if you want to keep the 
rat anesthetized for a longer period of time.  
 Once the rat appears unconscious; Typically about 3-5 minutes. (INFO: 
The rat will most likely become hyper aroused as it goes through the 
stages of anesthesia).  Turn the anesthesia machine off and take the rat out 
of the chamber and close the lid to prevent gas leakage into the room. 
 Immediately place the rat head under the blade of the guillotine, make sure 
all your appendages are away from the blade, and firmly and quickly force 
the blade through the neck of the rat. (You will need a lot of force to do 
this; the first time you try it, make sure to slam the blade to feel how it 
works. Keep fingers, etc., away from the blade!!!!!). 
• If you have to readjust the head of the rat, gently grab the nose of 
the rat with your thumb and index finger and move the head where 
you want it. This will prevent your fingers from ever going under 
the blade. 
 Take the head and put it on ice and the body in the sink if it begins to 
move too much.  
• Tissue Collection: 
o CORNEA 
 Once the head of the rat is removed and on ice, remove one eye as fast as 
possible with an 11 sized scalpel blade (the smaller one). Use fine tipped 
forceps to aid with the process. 
• Note: When removing the eye, place the tip of the 11 sized scalpel 
blade on the side of the cornea and press straight down without 
cutting into the eye. Rotate the blade around all the eye to cut all 
tissue keeping it in place. Use forceps to lift the eye and cut any 
remaining tissue. 
 Take the eye and place it on the metal plate. Hold the eye with the fine 
tipped forceps and use the 11 (small) sized scalpel blade to puncture the 
top side of the cornea next to the sclera.  
 You should be able to obtain a better grip when grabbing the optic nerve, 
or where the optic nerve was, after a puncture has been made.  
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 Once a puncture is made, continue to cut along the cornea sclera line until 
the cornea is completely off. Trim any excess sclera off of the cornea  
 Place the cornea in the 99 µL of RIPA buffer and 1µL of 
Protease/Phosphatase inhibitor solution.  
 Homogenize the tissue.  
 If saving the tissue for later: Place the eyes of the rat into liquid nitrogen 
to flash freeze the corneas for storage.  
 Place in -80ºC freezer until analysis 
o TRIGEMINAL ROOT GANGLION 
 Once the eyes are removed, use a scalpel to cut the skin on the top of the 
skull. Pull the skin back and cut into the muscles around the skull and pull 
them back as well. 
 Take a pair of large rongeurs and break the bone in between the eyes were.  
 Take the large rongeurs, place rongeur tines on the left and right sides of 
the skull, and GENTLY crack the skull top (watch movement of the 
sutures). 
 Once the skull top is cracked, you can gently place the rongeurs under the 
skull where the eyes were to pull off the entire skull cap. Remove any 
other bone around the skull and gently begin lifting the brain away from 
the base of the skull.  
 If done correctly, the brain will come up with ease, but you will have to 
cut or break the optic nerves as the brain is lifted.  
 Continue lifting the brain and remove any bone that it becomes caught on. 
The brain should fall out of the skull base. 
 Place the brain on ice for the next step (Hippocampus removal). 
 On the skull base, there will be two large nerves. These nerves appear to 
have an enlargement and this is the trigeminal root ganglion. 
 Use the 11 (small) sized scalpel to cut through the nerve rostral to the 
ganglion, cut along both of the long sides of (next to) the ganglion to 
separate it from the connective tissue, and cut the nerve connected to the 
caudal side of the ganglion. You should be able to pick the ganglion up 
with the scalpel tip or a fine tipped forceps.  
 Place the ganglion in the 99 µL of RIPA buffer and 1µL of 
Protease/Phosphatase inhibitor solution.  
 Homogenize the tissue.  
 If saving the tissue for later: Place the trigeminal root ganglion of the rat 
into liquid nitrogen to flash freeze the tissue if you want to store it.  
 -80 freezer until analysis 
o HIPPOCAMPUS 
 Place the brain that was previously collected on the metal plate located on 
the ice. 
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 Cut the cerebellum and brainstem from the brain and place it on ice for the 
spinal trigeminal nucleus step.  
 With the brain, cut about one fourth of the way from the front of the brain 
and about one fourth from the back of the brain with the 11 (small) scalpel 
blade. You should be left with the middle section of the brain.  
 Turn it over and begin to separate the cerebral hemispheres.  
 You should see the corpus callosum (white section) that you can cut 
through. Underneath is the hippocampus. 
 Keep spreading the cortical hemispheres back until you expose the 
hippocampus as much as possible.  
 Cut around the hippocampus with the 11 (small) scalpel blade and retrieve 
the hippocampus.  
 Place the hippocampus in the 99 µL of RIPA buffer and 1µL of 
Protease/Phosphatase inhibitor solution.  
 Homogenize the tissue.  
 If saving the tissue for later: Place the hippocampus of the rat into liquid 
nitrogen to flash freeze the tissue if you want to store it.  
 -80 freezer until analysis 
o SPINAL TRIGEMINAL NUCLEUS 
 With the remaining cerebellum and brainstem from the previous section, 
place it on the metal plate. 
 Remove the cerebellum and disregard it. 
 Orient yourself to the brainstem and identify the closed and open medulla. 
You will want to closed medulla section, so use the 11 (small) scalpel 
blade to cut at the top of the closed medulla and disregard the open 
medulla. 
 Trim the bottom part of the brainstem (may not have to depending on the 
location of the decapitation) to about 25 mm below the beginning of the 
closed medulla.  
 Place the section upright and obtain the dorsal section of the tissue.  
 This will have the spinal trigeminal nucleus in it.  
 Place the spinal trigeminal nucleus in the 99 µL of RIPA buffer and 1µL 
of Protease/Phosphatase inhibitor solution.  
 Homogenize the tissue.  
 If saving the tissue for later: Place the spinal trigeminal nucleus of the rat 
into liquid nitrogen to flash freeze the corneas if you want to store them.  
 -80 freezer until analysis 
• Homogenizing the tissue 
o Set up: You will need a green or blue homogenizer plastic rod and the 
homogenizer machine. The homogenizer machine is a handheld device that will 
twist and vibrate the homogenizer rod for you.  
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o Take tissue out of the -80 freezer if you stored them. 
o If you are using fresh samples that you just collected, it is already in the 
RIPA/protease inhibitor solution, so you will go to the homogenizing step. 
o In the tube that is ON ICE, you will smash and twist the tissue to break up and 
dissolve the proteins in the tissue.  
o Place a clean homogenizer rod into the homogenizer machine and gently place the 
tip into the tube to smash your tissue.  
o Press the button to begin the vibrations to aid in the protein extraction.  
o The goal is to press the rod hard enough on the bottom of the tube that you do not 
cause frothing (bubbling) of the fluid in the tube.  
o Use the rod to the bottom of the tube and balance between pressing too hard that 
the vibrations will stop and letting up a little bit that the vibrations will start again.  
o Continue with this method for about 1 minute then let the sample sit on ice for 
about 10 minutes. 
o Repeat steps 3-5 times until the tissue is completely homogenized. (The stroma of 
the whole cornea will not fully homogenize because of very high collagen 
content.)  
o Be sure to use a new rod for each sample and clean the rods that you use after you 
are finished! 
o Once all of the tissue is dissolved into the liquid, bring all of the labeled tubes to a 
cold microcentrifugation unit.   
o Make sure there is nothing in the rotor.  
o Place the rotor lid on the rotor, close the lid, set the temperature at 4°C, and push 
the button that says speed cool. This will cool the machine for you before you use 
it.  
o Bring your homogenized tissue to the centrifuge that you have prepared. Push the 
off button to end the cooling cycle so you can open the lid. 
o Open the lid and place all of your tubes into the centrifuge. Make sure there is a 
blank tube across from each of the tubes that you place into the centrifuge. Use a 
loading control tube located next to the centrifuge if you have an odd number of 
tubes. Pick a tube with a similar amount of fluid in it, but you do not have to be 
exact.  
o Place the lid back on the rotor, shut the centrifuge and have it spin for 10 minutes 
at 10,000RCF at 4 degrees Celsius.  
o Once the cycle is complete, take out only the supernatant with a 200 µL pipette 
and place it into a tube labeled accordingly. Either save the pellet in the -80 
degree Celsius freezer, or trash them.   
 Trouble shooting tip: If you are not getting a band of interest after all is 
done, try running the pellet.  
• Suspend the pellet in loading dye, and load it into the gel per 
normal protocol after boiling.  
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o Place all of the tubes in the -80 degree Celsius freezer for storage or continue 
directly into the protein quantifying step.   
• BCA assay quantification.  
o Once all of the tissues are homogenized, spun down, and the supernatant is placed 
into a different identically labeled tube, you are ready to quantify the protein in 
your tissues. Keep samples on ice! 
o Obtain an equal amount of autoclaved PCR tubes and label each as you labeled 
them on the supernatant tubes.  
o Prepare the solutions for the quantification: 
 Obtain a BCA protein assay kit. 
 Obtain a 50 mL plastic tube and place 49 mL of the reagent A into the 
tube. 
 Obtain 1 mL of reagent B and put it in the tube for a final volume of 50 
mL. This should make it turn green. 
 Obtain a vial of known protein (2 mg/mL vial). 
 Break the glass by applying pressure to the white line away from your 
body. 
 Take out 1 mL of the fluid and place it into a small tube. Add 1 mL of 
deionized water to make a final concentration of 1 mg/mL. Mix. 
 Place the broken vial in the broken glass box. 
o You want to dilute a sample of the supernatant for this quantifying step. Here are 
some examples: 
 5 times diluted: Take 20 µL of deionized water and place into each of the 
tubes for the 5x dilution. Place 5 µL of your supernatant into the tube as 
well for a total volume of 25 µL. Mix. (You will also need to make a tube 
for the RIPA/Protease inhibitor only solution, as well) 
 8 times diluted: Take 14 µL of deionized water and place into each of the 
tubes for the 8x dilution. Place 2 µL of your supernatant into the tube as 
well for a total volume of 50 µL. Mix. (Will also need to make a tube for 
the RIPA/Protease inhibitor only solution) 
 10 times diluted: Take 45 µL of deionized water and place into each of the 
tubes for the 10x dilution. Place 5 µL of your supernatant into the tube as 
well for a total volume of 50 µL. Mix. (Will also need to make a tube for 
the RIPA/Protease inhibitor only solution) 
o Now that the solutions are prepared, it is time to obtain a 96 well plate that is 
clean and not cloudy. As seen in the image below, each of the wells will have 
some solution in it via triplicates (3 wells will have the same “stuff” in it). 
o For the first three columns, follow what is shown in the image. 
 The first row of the first three columns will have nothing in it except air. 
 The second row of the first three columns will have 200 µL of the reagent 
A/B mix (referred as the green solution from now on). 
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 The third row of the first three columns will have 198 µL of the green 
solution and 2 µL of the 1 mg/mL solution. 
 Continue down the first three columns as the image states.  
 The last nine columns will contain your samples in triplicates.  
 To do this, you will take a multichannel pipette and place 195 µL of the 
green solution in all of the wells of columns 4-12. 
 You will then add in 5 µL of your sample to each of the wells in triplicate 
(triplicate means 3 wells will have the exact same material in each of the 
wells so you can compare and average the difference to account for pipette 
error). 
 Make sure to label what sample you put in which well with the example 
plate printout that you see below.  
 You will begin to see the green solution turn purple over time. (More 
purple, the more protein is in the well).  
 Take the multichannel pipette and take in some of the leftover green 
solution and pipette it back into the container to wet the pipette tips.  
 Go through the wells that you just loaded and mix all of them thoroughly 
by drawing into and out of the pipette tips. Change tips after each triplicate 
and re-wet the new tips before placing them in the well for mixing.  
 Incubate the plate in the 37°C incubator for 30 minutes. (Make sure to 
place a lid or Parafilm over the plate before placing it in the incubator). 
 Once finished incubating, pop any bubbles in the wells with a tip of a 
Kimwipe. Carefully just touch the bubble and pop it, do not suck up the 
solution with the Kimwipe. 
 Bring the plate to the Synergy 2 machine in Dr. Champlin’s lab for 
quantification. 
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• Reading the plate for protein concentration 
o Take the plate to the plate reader, the Synergy 2 machine. 
o To turn it on, you will need to turn on the power to the right of the machine and 
the switch at the front bottom left portion of the machine. 
o Launch Gen5 1.11 program on the computer that it is connected to. (Picture 
Below). 
o Click on “read a plate” when the program is running. (Picture Below). 
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o Click on read and you will be able to enter your wavelength. (Picture Below). 
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o Enter 562 as the wavelength then hit ok. (Picture Below). 
 
o Click on ok again. (Picture Below). 
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o You are now ready to read the plate. Click on READ. (Picture Below). 
 
o This will trigger the ability to identify a location to put your saved results. 
(Picture Below). 
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o Find or make your folder under the lab that you are in. Name your file. Save your 
file in your folder. 
o Hit save. 
o A warning pop up will appear to make sure your plate is in the machine. (Picture 
Below). 
 
o At this point, place your plate on the machine and hit ok.  
o The machine will take in your plate and read it. 
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o Hit the layout part on the top and change it to 562 to see your results. (Picture 
Below) 
 
o Hit the export to excel button to get your results into an excel file. (Picture Below. 
Look at red box for excel button). 
 
o An excel sheet will open and you can save this file to your folder and/or your 
flash drive. This is what you need to quantify your protein.  
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• Determining amount of protein to add to electrophoresis gel wells (BCA protein 
estimation) 
o After you have scanned your 96 well plate, the excel sheet should look like this: 
 
o From this you can prepare a standard curve from the first three columns, (Yellow 
highlight) and make a graph (Purple and Blue highlights). (Follow instructions in 
image to get Average-Blank numbers for the graph). 
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o Add a trendline: 
 
o Add equation, R squared, and polynomial trendline (Red boxes): 
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o Use the formula to get this number: 
 
o Multiply and divide appropriately. *5/*10 is where you will multiply the previous 
cell by the dilution factor. *200 is to multiply by 200 since you used a total 
volume of 200µL for each well. The mg/mL is for dividing by 1000 for a 
conversion factor. The 50µg is where you take 50 and divide by the previous cell 
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to determine how many microliters you need to add in each well to get 50µg of 
total protein in each: 
 
 
o Once you have the total protein, you can begin to determine how much loading 
dye and water to add. If you have 30µL wells to load into, using the first set of 
green boxes from buffer 1, you can load 10µL of water, 10µL of 5x loading dye, 
and 9.8µL of protein, in this order; just in case you mess up, you will not lose 
your sample.  
 In this case, the loading dye is at a higher concentration, but it is ok to 
have a little extra, but you do not want to go under the recommended 
amount or too much in the extreme either.  
• Preparing gel for Western blot 
o If using a pre-cast gel, obtain from the refrigerator and bring it to the 
electrophoresis unit (Protean or Criterion).  
 Protean 
• Can do one or two gels at one time. If doing one, you will need a 
blank piece of plastic made to mimic a gel so you can pour running 
buffer between plates. 
• Remove the pre-cast gel from the plastic and REMOVE THE 
BOTTOM GREEN TAPE ON THE GEL!!!! 
• Put in a blank glass plate where a second gel can be placed in the 
and the actual gel on the other side. 
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o The smaller glass plate of the gel must be facing inward! 
This will keep running buffer on top of the gel at all times. 
• Firmly press down on the plates and place the apparatus in the 
hinge portion of the device.  
• Press firmly and inwardly rotate the colorless plastic pieces to lock 
in the plates. 
• Place the gel and apparatus in the electrophoreses box and add 
running buffer in between the plates. 
o Troubleshooting tip: If it leaks, take the apparatus out, pour 
the running buffer into the plastic cell, then place the 
apparatus on a hard surface. 
o Undue the colorless plastic hinge, then very firmly and 
forcefully press on the taller glass plate. You should feel 
about a millimeter drop in height. This will fix your leaking 
issue.  
• Gently place two thumbs on the green well comb and apply steady 
force upward until the comb exits the gel. Use a well loading 
pipette tip to fix any wells that might have collapsed.  
 Criterion 
• Take a precast gel out of its package, remove the tape at the 
bottom, and place it in one slot of the Criterion electrophoresis 
unit.  
• Add Running buffer to the reservoir at the top of the gel cassette 
and fill the criterion with running buffer to the arrow on the unit.  
• Much more user friendly than the Protean.  
o Making your own gel: 
 Mix together these solutions to make the concentration you want 
(Example is 12% gel) 
o All of this is on the sheet from 5-15% gels: 
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Polyacrylamide gel % 
  5 6 7 7.5 8 9 10 12 13 15 
30% 
Acrylamide 
solution 
2.5 3 3.5 3.75 4 4.5 5 6 6.5 7.5 
4x 
Resolving 
Buffer 
3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75 
Deionized 
Water 
8.75 8.25 7.75 7.5 7.25 6.75 6.25 5.25 4.75 3.75 
10% APS 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
TEMED 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
 
Stacking gel 
30% 
Acrylamide 
solution 
4x 
Resolving 
Buffer 
Deionized 
Water 
10% 
APS TEMED 
0.65 1.25 3.05 0.025 0.01 
 
• 6 mL of 30% Acrylamide/Bis Solution 29:1 in refrigerator in main 
lab.  
• 5.25 mL of Deionized water 
• 3.75 mL of 4x resolving buffer (1.5 M Tris pH 8.5 + 20mL 10% 
SDS). 
• 50 µL of 10% APS. 
• 10 µL of TEMED (once added, must finish gel quickly since it will 
begin to set). 
• Here is the full list of gels: 
 Get the green stand ready on hard surface and place the smaller plate on 
the front.  
 Place a small rubber piece on the gel casting stand, then place the green 
stand with the glass plates on top of the rubber piece. 
 Lock the green stand in onto the casting stand and check for leaks by 
placing a small (about 1mL) of water in between the plates. 
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• Troubleshooting: If your gel casting stand is leaking, place a 
regular pen behind the clamp on top of the casting stand. This will 
apply additional pressure to the glass and prevent leakage. 
 Remove water by using filter paper. Make sure the plates are dry.  
 Mix the solution together by inverting the tube a couple of times and then 
begin to place about 7.5mL of the solution between the plates with a 
pipette. 
• Troubleshooting: If you are having issues with the gel setting too 
fast, decrease the amount of TMED used. If you are having issues 
with the gel casting too slow, increase the amount of TMED. 
 Place water on top of the solution between the glass plates very slowly to 
remove bubbles. Once solidified, remove the water with filter paper. 
 Let solidify and prepare for the stacking gel (Amount in chart above). 
 Place 2 mL of it on top of the previous gel. 
 Place a green comb in between the glass starting with the right most well 
then rotate the comb between the gel until all of the wells are in. Make 
sure to prevent a lot of air bubbles from going in between the wells.  
• Troubleshooting: decide how much of the sample you need and 
how many samples you have. You can choose the number of wells 
with varying sized combs.  
 Let solidify and the gel is ready to use like the precast gels (without the 
tape on the bottom).  
• Once in the apparatus, you will have to use a pipette and blow out 
any extra debris in the wells. To do this, take in running buffer that 
is on top of the plate in the apparatus, then gently expel the running 
buffer into the wells. This will get the debris out of the wells and 
they will sink to the bottom of the cell so they will not interfere 
with the movement of the loaded proteins  
 You can wrap the gels with saran wrap and place in the 4° C refrigerator 
for up to three days.  
o Make the running buffer (100 mL of 10x running buffer into 900 mL of deionized 
water. 
o Set up the apparatus with the short plate on the inside and a plate to hold in the 
running buffer in between the plates.  
o Pour the running buffer in between the glass plates and let it overflow.  
o Take a 1 mL pipette and suck in some of the running buffer and use it to flush out 
all the wells to remove debris. 
• Preparing sample for western blot 
o Label 500 µL tubes the same name as your samples. 
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o You want 30 µL total, so: Example= if need 8 µL of sample, load 12 µL 
deionized water, 10 µL blue dye, and 8 µL sample in that order. Total volume is 
30 µL.  
 Blue dye is in the freezer in the box that says Loading Butter (5x) SDS 
and 10% APS. 
o Once you have your samples prepared, bring to the Perkin Elmer DNA Thermal 
Cycler to boil the samples at a constant temperature of 100°C.  
 Turn switch on—PRESS: file—1—enter—step—100—enter—enter—
start. Let it run for 10 minutes then PRESS: Stop—stop.   
• Can also do this step in mildly boiling water on a hot plate for 10 
minutes.  
o Be careful when removing the tubes. Grab the tube by the cap/body joint to lift 
them up, NOT THE CAP ITSELF. They may pop open and you will lose your 
sample.  
o Spin the samples down using the small centrifuge for all the tubes for about 3 
seconds each.  This should bring any evaporated fluid to the bottom of the tube. 
o Turn down the speed on a vortex machine and gently vortex all of the samples for 
about 1 second. DO NOT ALLOW THE SAMPLE TO FROTH (make bubbles)! 
o Prepare the gel so you can load your samples.  
• Loading gels 
o Take a 100 µL pipette and have it set to take up about 40 µL of fluid. 
o Place a well loading pipette tip on the pipette and move your entire sample; try to 
prevent the intake of bubbles.  
o Bring the pipette tip into the well were you want your sample and, up on top of 
the well, expel any bubbles that may be present. Once gone, enter further into the 
well and pipette out your sample into the well.  
 Troubleshooting: Be careful not to load your sample behind the glass 
plate. Gently press the pipette tip on the larger plate and slide into the well 
to prevent loss of sample. 
 Make sure the tip is above the sample in the well. You can bring the tip up 
as the well fills.  
o Continue loading all your samples. 
o Once all the samples are loaded, use the last remaining well to load 8 µL of a 
protein ladder which will tell you how large your protein is (You can place the 
ladder in any well you want as long as it is only the ladder and not your sample. 
 Protein ladder is in the freezer section in room E453. It is called Spectra 
Multicolor Broad Range Protein Ladder. Product number: 26634. 
 Troubleshooting: You can do a curtain gel by using multiple samples and 
ladders. You can cut the final membrane into multiple sections after your 
transfer is complete. This way you can stain for multiple antibodies by just 
doing one gel. 
  
 
141 
 
• Conducting a Western blot (Electrophoresis step) 
o Once all your protein is loaded and it is in the cell, place the lid on the cell (red to 
red, black to black), plug the lid into the powerpac, and turn it on. 
o Set the powerpac to ten minutes to pass 100 volts until the protein has gone 
through the stacking gel and has entered the bottom gel. Once all the protein has 
entered the gel, you can turn up the powerpac to 150 volts for 1 hour 20 minutes 
to allow the protein to travel faster down the gel.  
o For the Criterion, begin with 100 volts for ten minutes, then 150 volts for 10 
minutes, then 180 volts for 1hour 20 minutes or until your ladder is in the location 
you want it. 
 Troubleshooting: This step varies with your protein of interest and other 
variables. Make sure you understand what voltage you need for your 
protein of interest beforehand to prevent unnecessary work. Easiest way is 
to just keep checking the gel and stop the powerpac when your bands are 
where you want them. Record the time and repeat thereafter. 
o Watch the ladder travel down the gel. Depending on your protein, you may want 
one of two of the colored bands from the ladder to go all the way to the bottom 
and through the bottom of the gel. 
o For me, I allow the bottom green and blue bands to exit the gel. This will allow 
me to visualize my protein of interest (about 100 kilo Daltons) clearly.  
• Blotting onto the membrane 
o Once the ladder is just where you want it to be on the gel, turn off the powerpac to 
prevent excess protein from exiting the gel.  
o To prepare for the blotting step, prepare a transfer buffer by: 
 Add 200 mL of methanol, 700 mL of deionized water, and 100 mL of 10x 
transfer buffer, then mix. (Can mix with a gloved hand over the top of a 
1L graduated cylinder and invert a couple of times.) 
o Pour about 200mL of the transfer buffer into a container.  
 Place 2 black sponges, 4 sheets of filter paper that you cut that is a little 
larger than your gel, and plastic blotting piece into this transfer buffer for 
about 5 minutes in a separate container.  
o Cut a PVDF membrane from a roll about the size of the gel that you just ran. 
o Also, cut a small section of the top left corner of the PVDF membrane. This will 
help you determine what side your protein is on.  
o Obtain a small container to fit your cut PVDF membrane and place enough 
methanol in it to cover the PVDF membrane. Once the methanol is in the 
container, place the PDVF membrane and allow it to soak for about 5 minutes.  
o Once soaked, take the PDVF membrane out of the container, and place it into the 
container with transfer buffer along with the filter paper, etc. Allow it to soak for 
about 5 minutes. DO NOT TOUCH THE PVDF MEMBRANE!!!! Only use a flat 
head tweezers to transport.  
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o Take the gel out of the glass plates by taking it out of the apparatus and use a 
green glass plate opener to pry the edges apart.  
 Self made gel: you can reuse the glass plates, so do not break them when 
you pry. 
 Pre made gel: you cannot reuse the plastic plates, so you will have to pry 
harder to break the plastic between the plates.  
 Place the gel in transfer buffer to soak for about 5 minutes. Do not allow it 
to touch the PVDF membrane. 
o Take the plastic blotting piece out of the buffer and hold it in your hand where the 
colorless/red piece is in your palm and the black piece is on your fingers. (You 
may have a special container for this step; if so, place the plastic piece on the 
increasing wall of the tray instead of your hand. Have transfer buffer in this 
portion as well.) 
o Place one sponge on the black portion of the plastic blotter piece.  
o Place two pieces of filter paper from the tub on top of the sponge. Roll out any 
bubbles. 
o Place the gel on top of the filter paper. Roll out any bubbles. 
o Place the PVDF membrane on the gel and make sure there are no bubbles under 
the membrane by rolling them out with a roller. 
o MAKE SURE THE PVDF MEMBRANE IS PLACED FACE DOWN!!! (The cut 
corner will be on the top right when placed down properly.) 
o Place two more pieces of filter paper on the PVDF membrane.  
o Place the final sponge on top, close the plastic blotting piece and place it in the 
transfer cell.  
 Troubleshooting: You need to make sure there are no bubbles in this step 
or they will show up in your image at the end. Also, make sure the whole 
sandwich stays wet. Do not let it dry, so do not take a lot of time putting it 
together if it is not submerged in a specialized western blot sandwich 
maker. 
o Pour the remaining transfer buffer in the soaking container into the transfer cell. 
o Place your 2 sandwiches, or your 1 sandwich and an extra plastic piece into the 
transfer cell. 
o Use the remaining transfer buffer in the 1L graduated cylinder to make sure your 
sandwich is covered. 
o Place a stir bar into the cell and check to make sure it will spin using a stir bar 
plate. If it does, you are good to go; if not, you need to get a smaller one, but not 
too small. 
o Place an ice pack into the cell. 
o Place the lid of the cell with the black colored wire on the black electrode, and the 
colorless portion of the plastic blotting piece towards the red electrode. 
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o Obtain a large container that the cell can fit in. Fill the container with ice (Can use 
a spare transfer container to place the ice around, so you will mold the ice for 
your own.). Place your transfer cell with your sandwich in the ice. Use some more 
ice and cover the top of the cell as well.  
 Troubleshooting: The Criterion runs hotter than the Protean. Pouring cold 
water into the container with ice will increase the ability to extract the 
extra heat from the cell. This will decrease the overall amps you will have 
when transferring. (The amps typically stay at around 0.65, if done right.) 
 Troubleshooting: To further make sure your amps will be low, have the 
transfer cell with transfer buffer in the ice bath for 1 hour before you place 
the sandwich and ice pack in. 
o Turn the powerpac to 110 Volts. 
 Troubleshooting: If the voltage does not go up to 110, and/or the amps 
max out or are very high, your transfer buffer has gone bad. Pour out the 
10 X stock transfer buffer and make a new batch. 
o Allow it to sit for 1 hour with precast gel, 1 hour 30 minutes for 10% self-made 
gel. (You want to see all the bands transfer out of the gel and onto the PVDF 
membrane. You may need to adjust the time to your liking.). 
 Troubleshooting: If you are looking for small weight proteins, you can use 
2 PVDF membranes. If the protein passes through the first one, they 
hopefully can be seen on the second one.  
o Make blocking buffer: Can try nonfat dry milk or Bovine Serum Albumin (BSA): 
 Make 5% milk (2.5 grams of dried milk into a 50 mL tube. Bring to 50 mL 
mark with TBST) and place about 10 mL of it into a 50 card trading card 
container (Or go to Vintage Stock and buy a plastic trading card container 
for a fraction of the price to put it in. Same thing.)  
 Make 2.5% BSA (add 2.5 grams of dried milk into about 70mL of 
deionized water in a 200mL beaker. Bring the final volume to 100 mL 
using a graduated cylinder. Distribute 50mL into one 50mL conical tube 
and 50mL into a different 50mL conical tube. Add 25µL of TWEEN 20 
into one conical tube and mix by inverting. Label each tube respectively as 
BSA-T and BSA. Place about 10 mL of BSA-T into a perfect Western 
container (Or go to Vintage Stock and buy a plastic trading card container 
for a fraction of the price to put it in. Same thing. Costs 49 cents compared 
to 15 dollars.) 
o Place your PVDF membrane that was just blotted FACE UP into the container 
with the 5% milk or 2.5% BSA (Cut corner will be on the top left when placed 
properly.). (You may need to trim the membrane to make it fit into the container. 
Be sure to cut only the sections of the PVDF membrane where you are sure there 
are no bands or protein.). 
• Primary antisera 
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o Remove the PVDF membrane from the blotting machine and place it in a 50 card 
trading card container FACE UP (Cut corner will be at the top left of the PVDF 
membrane; cut if needed with scissors) with 5% milk (2.5 grams of dried milk 
into a 50 mL tube; bring to 50 mL mark with TBST) or BSA-T.  
o Place on shaker at about 4-5 speed (somewhat gentle) for 2 hours. Should see the 
membrane sliding back and forth with the flow of the milk or BSA-T. 
o After 2 hours, remove the milk or BSA-T and replace it with another 10 mL of 
milk or BSA (I just use BSA, not BSA-T here). Measure this time with the 
electronic pipette. 
o You typically want a 1:1000 dilution of your primary antiserum, but the 
concentration of antiserum will depend on how much you need to add to the 5% 
milk or BSA. 
 Example: For Santa Cruz antisera, they typically come in a concentration 
of 200µg/mL, or 0.2µg/µL. You want the final concentration to be 
1µg/µL, so you will need to x5 your concentration. Instead of using 10µL, 
you will need to use 50µL in this case. 
o Pipette CALCULATE µL of your primary antiserum of interest and place it next 
to the PVDF membrane to allow for it to diffuse across the membrane. Place in 
the cold room overnight on the rotator machine.  
• Secondary Antisera 
o Take the PVDF membrane in the 50 card, trading card case submerged in the 
primary antibody out of the cold room.  
o Let it sit for about 1 hour to stabilize at room temperature. 
o Pour the milk/primary antibody out of the container and replace with TBST. 
o You will want to wash with TBST 1 time at “0” minutes (Place in, swirl, pour 
out) and then 4 times for 15 minutes each. 
o Once washed, prepare 5% milk (2.5 g of dried milk and bring up to 50 mL with 
TBST) and place 10 mL on the membrane with the electronic pipette.  
o Add 10 µL of the secondary antiserum in the milk next to the membrane and 
allow for it to diffuse over the membrane on the rotator machine.  
 Ex: if your primary antiserum was rabbit anti-Kainate receptor subunit, 
you will need a rabbit secondary antiserum.  
 Ex: if your primary antiserum was mouse anti-Kainate receptor subunit, 
you will need a mouse secondary antiserum.  
 Note: Depending on the way you would like to image your blot will 
determine which secondary antisera you will use. 
• Chemifluorescence: Has alkaline phosphatase enzyme conjugated 
to the secondary antibody. This protocol follows 
Chemifluorescence.  
• Chemiluminescence: Has horse radish peroxidase enzyme 
conjugated to the secondary antibody. 
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o Once the secondary antiserum is added, allow rotatory shaking for 2 hours. 
o Once the 2 hours are finished, remove the milk and wash four times with TBST 
for 15 minutes each. 
o Obtain tweezers that have a square flat head (flat head tweezers), a tube with 1mL 
substrate labeled ECF substrate for WB RPN5785, and a 1 mL pipette set at 
0.5mL. 
o Take your PVDF membrane over to the imaging machine. (Typhoon).  
o “Wake up” the computer by moving the mouse and double click on Typhoon 
Scanner Control v5.0. 
o Open the machine lid and spray a little bit of isopropyl alcohol on the bottom left 
portion of the glass piece under the lid and wipe withKimwipes to clean. 
o Let dry for a couple of seconds and then apply 0.5 mL of substrate to the area on 
the bottom left that you washed in an area you think will fit your membrane. 
(Drag the pipette tip in a “wave motion” as you eject the substrate). 
o Earlier, the top left corner of your membrane was cut. That is face up. The 
membrane must be faced down, so place the membrane down in a way that has 
the cut on the top right. This has to be done on the substrate placed on the 
machine and it must be done quickly. Use the flat head tweezers and run the 
membrane through the substrate once to soak it and then lift it. Gently place the 
end way from your tweezers on the glass plate and gently allow the membrane to 
make contact with the glass/substrate. Make sure you prevent bubbles from being 
caught underneath the membrane. It helps if you do not have any bubbles when 
pipetting the solution.  
o Once on the glass, (should take no more than 1 minute, aim for about 30 seconds) 
close the lid and open the Typhoon Scanner control v5.0. 
o You will see this picture and you want to click on the setup box highlighted by the 
red box: 
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o Once pressed, you will want it to look like this. Change all of the components to 
match this if you are using alkaline phosphatase secondary antibodies that are 
excited at 488nm: 
 
o Press OK, and you will get a message saying that you are changing the laser away 
from the default. Click yes. 
o Once finished, you want to change the orientation of the image to properly view 
your membrane. Click and hold on the R button and move your arrow to the R 
that has a red box around it: 
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o Once finished, press the SCAN button. It has a blue box around it in the previous 
image. You will get a box to save your data. Find the folder that says DATA. You 
should see a lot of folders with names on them. Right click on a portion of the 
window and click on new folder. Name it (your name) and click off of it. Double 
click it and you should open your folder. Press the save button.  
o It will take about 5 minutes to scan your membrane. 
• Stripping and reblotting (Primary antibody) 
o After you have finished the imaging step, bring the PVDF membrane back into 
the lab and apply about 10 mL of stripping buffer. 
o Place the container that has your PVDF membrane on the shaker for 20 minutes. 
o Remove the fluid after 20 minutes and wash with TBST 3 times with no waiting 
time. 
o Continue to wash the membrane with TBST for 5 minutes each time until you 
have eliminated the odor of the stripping buffer. 
o Remove from the final wash (once the smell is gone) and block the membrane a 
second time with 2.5% milk or BSA-T for 2 hours. 
o After 2 hours, replace the milk with 10 mL of 2.5% milk with an electric pipette, 
and place 10 µL (1:1000) of antiserum next to the membrane so it can diffuse 
across.  
o Place on a rotatory shaker overnight in the cold room. 
• Stripping and reblotting (Secondary antiserum) 
o Take the PVDF membrane in the 50 card trading card case submerged in the 
primary antiserum out of the cold room.  
o Pour the milk/primary antiserum out of the container and replace with TBST. 
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o Wash with TBST 3 times for 20 minutes each. 
o Once washed, prepare 5% milk (2.5 g of dried milk and bring up to 50 mL with 
TBST) and place 10 mL on the membrane with the electronic pipette.  
o Add 10 µL of the secondary antiserum in the 5% milk next to the membrane and 
allow for it do diffuse over the membrane on the rotator machine.  
 Ex: if your primary antiserum was rabbit anti-Kainate receptor subunit, 
you will need a rabbit secondary antiserum.  
 Ex: if your primary antiserum was mouse anti-Kainate receptor subunit, 
you will need a mouse secondary antiserum.  
o Once the secondary antiserum is added, allow rotatory shaking for 2 hours. 
o Once the 2 hours are finished, remove the milk and wash four times with TBST 
for 15 minutes each. 
o Obtain flat head tweezers, a tube of 1 mL substrate out of the freezer in the box 
labeled ECF substrate for WB RPN5785, and a 1 mL pipette set at 0.5mL. 
o Take your PVDF membrane to the imaging machine next to the cold room.  
o Wake up the computer by moving the mouse and double click on Typhoon 
Scanner Control v5.0. 
o Open the machine lid and spray a little bit of isopropyl alcohol on the bottom left 
portion of the glass piece under the lid and wipe with Kimwipes to clean. 
o Let dry for a couple of seconds then apply 0.5 mL of substrate to the area on the 
bottom left that you washed in an area that you think will fit your membrane. 
(Drag the pipette tip in a wave motion as you eject the substrate). 
o Earlier, you cut the top left corner of your membrane. That is face up. We want 
you membrane to be faced down, so place the membrane down in a way that has 
the cut on the top right. This has to be done on the substrate that you just put on it 
and has to be done fast. Use the tweezers with the square flat head and run the 
membrane through the substrate once to soak it and then lift it. Gently place the 
end way from your tweezers on the glass plate and gently allow the membrane to 
make contact with the glass/substrate. Make sure you prevent bubbles from being 
caught underneath it. It helps if you do not have any bubbles when pipetting the 
solution.  
o Once on the glass, should take no more than 1 minute, aim for about 30 seconds, 
close the lid and open the Typhoon Scanner control v5.0 on the computer. 
o You will see this picture and you want to click on the setup box highlighted by the 
red box: 
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o Once pressed it, you will want it to look like this. Chance all of the components to 
match this: 
 
o Press OK, and you will get a message saying that you are changing the laser away 
from the default. Click yes. 
o Once finished, you want to change the orientation of the image to properly view 
your membrane. Click and hold on the R button and move your arrow to the R 
that has a red box around it: 
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o Once finished, press the SCAN button. It has a blue box around it in the previous 
image. You will get a box to save your data. Find the folder that says DATA. You 
should see a lot of folders with names on them. Right click on a portion of the 
window and click on new folder. Name it and click off of it. Double click it and 
you should open your folder. Press the save button.  
o It will take about 5 minutes to scan your membrane. 
o To save your result gel results as an image, open the program ImageQuant 5.1. 
o Go to file then open and find the gel you wish to take to an image. 
o Open the file then go back to file then save as.  
o Name the file and change the “Save as type:” portion to TIFF Files. 
o Save to your designated folder of interest and you have an image file to use. You 
can open this file on your own computer now.  
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Making solutions 
10X TBS 
• 60.6g of Tris HCl pH 7.6 
• 87.7g of NaCl 
• Bring to 1L of water 
Making TBST 
• A concentrated solution of TBST is already made. It is 10 times more concentrated than 
need. 
• Take the bottle labeled 10x TBS and measure 100 mL using a graduated cylinder and 
place the fluid in a 1 L bottle. Add water up to the 1 L mark (900 mL). 
• Add 1 mL using a 1 mL pipette of TWEEN 20. 
• Swirl to mix and it is ready to use.  
Making 5% nonfat dry milk 
• Weigh out 2.5 grams of milk powder and pour it into a 50 mL tube. Add TBST up to the 
50 mL mark (50 is a plastic line, not a marked black line on the tube.). 
Making 2.5% Bovine serum albumin (BSA). 
• Weigh out 1.25 grams of BSA and pour it into a 50 mL tube. Add TBST up to the 50 mL 
mark (50 is a plastic line, not a marked black line on the tube.). 
Making 10x Running Buffer 
• 144g Glycine  
• 30.3g Tris HCl 
• 10g SDS 
• Bring to 1L of water 
Making 10x Transfer Buffer 
• 30.3g Tris HCl 
• 144g Glycine 
• 20% methanol 
• Bring to 1L of water 
5x Loading buffer 
• 1g Sodium dodecyl sulfate (10%) 
• 1.67 mL of 1.5M tris-HCl (pH 6.8. 
• 5mL of glycerol 
• 50µL of BME per 1mL of loading buffer. 
• 0.001% bromoethanol blue 
• Bring to 10mL of water. 
1x RIPA buffer 
• 50mM Tris HCl buffer (pH 8) 
• 1% NP40 (Can use 1% triton X 100) 
• 0.5% sodium deoxicholate 
• 0.1% SDS 
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• 150mM NaCl 
• 10% glycerol 
• Add protease inhibitor 
1x Lysis buffer (Triton X-100) 
• 50mM Tris HCl pH 7.4 
• 1% triton X 100 
• 50mM NaCl 
• 10% glycerol  
APS 
• 1g APS. 
• Bring to 10mL of water. 
 
 
 
LEGEND: 
Set up 
Making a solution 
Set up 
Information for a different method 
Important step 
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CHAPTER VII 
 
IMMUNOHISTOCHEMISTRY PROTOCOL 
 
Immunohistochemistry 
• Rat selection 
o 8-10 weeks is good, but no actual age range restriction. (I use 6-8 week rats). 
• Preparing gel coated slides (wear gloves and lab coat). 
o Obtain a slide metal rack. Do not use rack if rusted. 
o Obtain a square or rectangular glass container that will fit the metal rack. 
o Place glass slides in all the slots of the metal container. Try to get all the slides 
facing the same direction. 
o Place the metal rack with all the glass slides into the glass container and place 
under the hood. 
o Obtain the chromic acid solution (recipe provided below) which is in the cabinet 
under the hood and pour it on the slides in the glass container until the slides are 
fully submerged. 
o Allow the acid to remain on the slides for 20 minutes. (The acid solution will 
make holes in your clothes if it gets on you.) 
o Once finished, bring out the metal rack and slides with a bent clothes hanger 
(attached to the left side of the hood).  
 The hanger is made in a way that you can squeeze it and place the ends in 
the holes of the metal rack for transport. Be careful not to drop the metal 
rack with the slides. 
o Place the metal rack with the slides into another empty glass container for 
transport. 
o Turn on the hot water in the sink and allow the water to wash the slides in the 
metal rack for 10 minutes. (Keep the hot water flowing over the slides for the full 
time). 
 Take a ceramic filter that has a flat inside portion for a filter paper to fit in. 
I have made a template filter paper so you can use it to cut out the right 
size. 
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 Place the filter with the filter paper on a 1000mL Büchner flask (vacuum 
flask) and hook up the vacuum with a tube in the cabinet to the left of the 
hood. You may need to seal the connection between the flask and the filter 
by applying parafilm to the connection. 
 Turn on the vacuum and place a little bit of the chromic acid solution on 
the filter paper to wet it. This ensures it will go through the filter paper and 
not around and underneath it. 
 Once wet, gently pour the rest of the solution into the filter. 
 Pour the filtered solution back into its original bottle and place it back in 
the cabinet under the hood. 
 Throw away the filter paper and rinse clean the vacuum filter with water.   
o Once the 10 minutes has passed, remove the rack and gently shake any excess 
water from the rack with slides. 
o Take the gelatin slide coating solution (also located in the cabinet under the hood) 
and pour it into another glass container that fits the metal rack and slides. (The 
same glass container can be used that held the chromic acid solution after filtering 
the solution and placing it back in its original bottle and after the container has 
been rinsed clean with water.) 
o Dip the metal rack with the slides 5 times into the gelatin solution. (Nothing 
special here, just dip once every 3 seconds for 5 times. Takes less than a minute to 
do.). Drain the solution from the rack by tilting one edge of the rack against the 
inside lip of the glass container.  
o Place the metal rack with the slides in the 37°C incubator for 12-24 hours. Filter 
the slide coating solution with the filter and new filter paper. 
o After 12-24 hrs, remove the slide rack form the oven. Run your finger across the 
top part of the white portion of the slide to disconnect the slides from the metal so 
the next coat can be applied evenly. 
o Pour the gelatin slide coating solution into a glass container. Dip the metal rack 
with the slides 5 more times, drain, and allow the slides to remain in the 37°C 
incubator for another 12-24 hours.Once again, filter the slide coating solution. 
o The slides can be left in the 37°C incubator over the weekend if needed. 
o Remember to clean up after yourself after each step. 
Making the Acid Cleaning Solution 
o 100 Grams of Potassium Dicromate or Bichromate 
o 850mL of DD H2O. 
o 100mL of 95% H2SO4. 
 Mix the Potassium Dichromate with deionized H2O while stirring on low 
temperature setting until it is completely in solution. This should be done 
in the hood. 
 Let cool to room temperature. 
 Add the acid and stir. Bring to 1000 mL with DD H2O. 
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Making the Slide Coating Solution 
o 7.5g of Gelatin 
o 0.75g of Chrom Alum (Chromium Potassium Sulfate -12 H2O). 
o 0.01 g of Sodium Azide. 
o 900 mL of DH2O. 
 Dissolve gelatin in water by heating to about 50°C, but do not exceed 
58°C. 
 Let it cool to room temperature. 
 Add the Chrom Alum (Chromium Potassium Sulfate -12 H2O). 
 Bring to 1000 mL with deionized H2O. 
 Filter and skim off any bubbles with filter paper. 
• Solution preparation for rat transcardial perfusion: 
o Each rat will need about 100 mL of calcium free Tyrodes buffer and about 240 
mL Picric acid, 81 mL 0.4 M phosphate buffer, and 4 mL of paraformaldehyde. 
Before you continue, determine how many rats you will use and make the 
solutions accordingly.  
o Calcium free Tyrodes buffer 
 Obtain a large flask (1 L for fewer rats, 2 L for more rats) and place a stir 
bar in it to mix the solution well without hitting the sides of the glass.  
 Using a graduated cylinder, measure 800 mL of deionized water. 
 Pour the water in the beaker or flask, place a stir bar in the flask, and turn 
on the stir plate to mix the water. 
 For one liter, weigh and place the following chemicals in the beaker or 
flask: 
• 6.8 g of NaCl 
• 0.40 g of KCl 
• 0.15 g of MgCl2. 
• 0.10 g of MgSO4-7H2O. 
• 0.19 g of NaH2PO4-2H2O. (Or use 0.098 g of anhydrous NaH2PO4-
2H2O). 
• 1.00 g of Glucose. 
• 2.20 g of NaHCO3. 
 Completely mix. 
 Pour the solution into a 1 L graduated cylinder and add deionized water to 
the 1 L mark.  
 Pour back into the flask and mix. 
 Using a pH probe attached to a pH meter, add NaOH to raise the pH and 
HCl to decrease the pH until the solution reaches 7.31-7.35. 
 Place a piece of Parafilm over the top of the flask (or place in a capped 
bottle) and a piece of tape describing what is in the flask with the date and 
your name on it.  
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 Store at room temperature overnight. 
 Check the pH right before use on the next day and adjust pH back to 7.31-
7.35 if needed. 
o Paraformaldehyde (This should be done in the hood.) 
 Obtain a 100mL beaker, a thermometer, and 2 hot plates. Place these items 
in the ventilated hood. 
 Place the beaker on top of the hot plate with 40 mL of deionized water in 
it. 
 Place the thermometer in a metal bar holder and place the tip into the 
water. 
 The temperature should be kept between 50-55 degrees Celsius. DO NOT 
GO OVER 55 DEGREES CELSIUS!!!! 
 Place a small stir bar into the 100mL beaker and turn on the stirring and 
heating functions.  
 Measure 8 grams of paraformaldehyde under the hood.  
 Bring the temperature up to 50°C. 
 Once the temperature reaches 50°C, place the 8g of paraformaldehyde in 
the beaker and allow to mix. 
 Once the temperature again reaches 50°C, place the beaker on a different 
hotplate and only turn on the stirring function.  
 Place the paraformaldehyde into the 100mL beaker with the water.  
 Obtain about 8 pellets of sodium hydroxide (NaOH) and place into the 
100mL beaker.  
 After about 30 seconds of mixing, place the 100mL beaker back on the 
hotplate with the thermometer and bring the temperature back up to 50°C.  
 Once at 50°C, remove the 100mL beaker and place back on the stirring 
only plate.  
 Repeat moving the 100mL beaker back and forth until the solution has 
cleared. (You will move the solution back and forth about 3 times and the 
solution will not be perfectly clear, but close). 
 Once the solution is clear, let it sit until it has reached room temperature. 
 Obtain a funnel, graduated cylinder, and a round piece of filter paper.  
 Fold the round piece of filter paper in half twice and separate the edges 
from each other to be able to place it into the funnel. 
 Place the funnel with the filter paper in on top of the graduated cylinder.  
 Pour the paraformaldehyde solution and let it filter through the paper.  
 You will filter deionized water with the same filter paper after the 
paraformaldehyde is all filtered out. 
 You want the final volume to be 50mL. 
 After filtered, your solution should be completely colorless and not 
cloudy.  
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o 0.4 M phosphate buffer 
 Obtain a 1000mL beaker and add 900mL of deionized water into it. 
 Place a stir bar in the beaker and begin mixing. 
 Add these chemicals together in the beaker: 
• 43.6g of NA2HPO4 (Anhydrous) to the beaker. 
• 12.8g of NaH2PO4 (Anhydrous) to the beaker. 
 Allow for the chemicals to completely dissolve. 
• It will take some time to dissolve. The chemical mixture becomes 
hard when it hits the water. 
 Place the 900mL with the dissolved chemicals into a 1000 mL graduated 
cylinder and bring the volume to 1000mL with deionized water.  
 Pour the 1000mL back into the beaker for mixing. 
 The 0.4 M phosphate buffer is ready to use.  
o Picric acid 
 Under the hood are plastic rectangle jugs of a yellow solution. This is 
picric acid. You will need 240 mL of picric acid per rat 
 Obtain a 1 L vacuum flask, a large ceramic funnel with multiple holes, and 
a filter paper cut to fit the funnel.  
 Once the filter paper is in and it does not look like it will leak around the 
edges, place the tubing on the nozzle of the flask and turn on the vacuum 
until you see the filter paper settle onto the funnel.  
 Begin to pour the picric acid in the center of the filter paper and be careful 
not to pour in too much, too fast. If the filter paper moves and the solid get 
into the flask, you must start over filtering the solution. 
 Keep pouring in as much as needed (240 mL per rat) and then place it in a 
large graduated cylinder to determine the exact volume collected.  
 Once you have obtained the volume needed, pour all of the picric acid into 
a large bottle and place a stir bar in the bottle as well.  
 Pour 81 mL of 0.4 M phosphate buffer PER RAT into the picric acid. 
• NOTE:  Do not use Sorenson’s phosphate buffer or you will get a red 
precipitate when mixing it with the picric acid. 
 Pour 4 mL of Paraformaldehyde PER RAT into the picric acid.  
 pH the solution to about 7.31-7.35. 
 Store at room temperature overnight. 
 Check the pH right before use on the next day and adjust pH back to 7.31-
7.35 if needed. 
o 2.5% Avertin 
 Take out 1 mL of 2-methyl-2-butanol and place into a 10mL beaker. 
 Take 1g of 2,2,2-Tribromoethanol and place into the same 10mL beaker. 
 Place a very small (micro) stir bar into the 10mL beaker and stir. 
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 Allow the chemicals to dissolve completely (about 10 minutes) and place 
into a microcentrifuge tube.   
 Take 350µL of the solution and put into 10mL of phosphate buffered 
saline (PBS) to make the final concentration of 2.5%. (You will need 3 
mL per rat, so make the solution for the number of rats needed.  
• Anesthesia and euthanasia of the animals 
o Obtain the rat for perfusion.  
o Obtain 3mL of Avertin, with a 5mL syringe. 
o Remove the rat from its cage and place a towel over its head and front feet.  
o Turn over rat and use your hip to hold its tail against the counter as you apply 
pressure with your hand to cross the front feet and keep it still. You may need to 
try a few times until you get the rat in the right position. 
o Once positioned correctly, quickly penetrate the needle through the abdominal 
skin and into the peritoneal cavity of the rat. Inject the rat and then quickly 
remove the needle.  
o Place the rat back into the cage and it will slowly be anesthetized.  
o Take up 1mL of Xylazine with a 1mL syringe. 
o Once again, quickly penetrate the peritoneal cavity of the rat, inject, and remove 
the needle. 
o Weigh the rat and then place back into the cage. 
o Regularly check the rat by touching its eye to check for the eye blink reflex and 
pinch its tail and hind paws for a flick response. 
o If there is no response when these tests are done, move on to the next step. 
• Perfusion of the animals 
o Place a flat plastic container into the hood to collect the blood and other solutions.  
o There also should be a metal grate that can go on top of the plastic container. 
(Thick metal, not thin and flimsy). (Image below) 
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o Turn on the perfusion machine (a pump) and get familiar with it. Play around with 
some water and see which tube will take in water and which will push out water.  
o Place a cannula on the side that expels water. 
o Once ready, place the side of the tube that sucks the fluid, into a beaker 
containing the calcium free Tyrodes buffer.  
o Let the machine operate to get out any bubbles until all the water and bubbles 
have come out.  (Do not waste too much of your calcium free Tyrodes).  
o Turn off the pump until you have the cannula in the left atrium of the rat.  
o Place the rat on its back on the metal grate and test for any reflexes in the cornea, 
hind paw, and tail: 
                     Touch Cornea                                                     Pinch Hind paw 
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                         Pinch Tail 
 
o If you observe any reflexes, wait another minute then retest for reflexes. Do not 
continue with the perfusion until all three reflexes are not present.  
o Feel for the bottom of the rib cage and pinch the skin and muscle to pull it up. 
With scissors, cut the fur, skin, and muscle below the rib cage.  
o Once through the tissue, you should see the xiphoid process.  
o Take a hemostat and clip onto the xiphoid process. (Image below) 
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o Pull up to allow an opening and continue to cut on the two peripheral sides of the 
rat. You must cut through the diaphragm.  
o Cut through the ribs and you will eventually see the heart. (Image below) 
 
o Expose the heart without cutting it and place the hemostat that is on the xiphoid 
process in a way to hold the cut ribcage up.  
o If the head of the rat is facing to the left, incise the portion of the heart that is 
further from you and at the base (The left ventricle).(Image below) 
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o Take the cannula connected to the perfusion tube and insert it through the incision 
that you made in the left ventricle. Push the tip into the left ventricle and clamp it 
in place with a hemostat at the site of incision of the ventricle. (Image below) 
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o Slowly turn on the pump to a very low setting. 
o Wait about 3 seconds and cut open the right atrium with surgical scissors. (This 
allows the blood to make a full passage through the rat systemic circulation and 
exit at the entrance to the right atrium. Make sure to do this, otherwise the vessels 
will rupture and cause a mess.). (Image below) 
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o Slowly turn on the pump to about a rate of 3.5 to 4. 
o Allow about 100mL of the calcium free Tyrodes buffer to flow through the 
vasculature of the rat to clear the blood (watch the “clearing” of the liver). At this point, 
the rat tissues should be turn white/colorless. Look at the eyes and they should be 
transparent.  
o Turn off the pump and gently move the tube from the calcium free Tyrodes buffer 
into the picric acid/paraformaldehyde solution (watch out for bubbles getting into 
the tubing). 
 Troubleshooting: If you get a large bubble in the tube, you can keep the 
cannula in the heart, but remove the tube. Let the fluid flow through until 
the bubble is gone, then put the tube back on the cannula.  
o Turn the pump back on to about 3.5 to 4 and allow about 240 mL of picric 
acid/paraformaldehyde to flow through the rat. 
o Once finished, drain excess fluid out of the rat and bring the carcass to a cutting 
board for tissue collection.  
o Place each piece of tissue into a labeled microcentrifuge tube containing picric 
acid/paraformaldehyde fixative. 
o Place tubes on ice. 
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o Place the remains in a Ziploc bag and put into the used animal freezer for 
disposal. 
o Return to the pump and flush the tubes with water by placing the intake tube into 
a beaker water and running the pump for a little while. (About 30 seconds). 
o Place the intake tube back into the calcium free tyrodes and flush the water out. 
o You are now ready to move on to the second rat. 
o Continue until you have finished all the rats for your experiment.  
• Preparing the tissue 
o Once you have the tissue collected on ice, bring tubes to the refrigerator for 4 
hours at 4°C. 
o Prepare a 10% sucrose, phosphate buffered-saline solution. 
 Take 5g of sucrose and add to a 50mL tube. 
 Fill with PBS until the 50mL mark is reached. 
o After the tissue has undergone “post-fixation”, use a plastic pipette to remove the 
picric acid/paraformaldehyde solution from each tube. 
o Fill tubes with 10% sucrose solution and place in the refrigerator overnight (Can 
keep for about 3 days). 
• Preparing cornea in frozen matrix block 
o Turn temperature of the cryostat to -20°C, twist the knob to 18 micrometers, and 
turn on the light. The temperature should drop to -20°C by the time you prepare 
your tissue. 
o Take the tubes with tissue and obtain a cutting board, embedding liquid, and 
embedding plastic containers, and liquid nitrogen. 
o For the cornea, grab the optic nerve area with forceps and cut off the cornea with 
a small scalpel. Cut about 3 to 4 radial cuts into the cornea to make it lie flat.  
 Do not cut the cornea into multiple section. Keep it all together.  
o Place one drop of embedding matrix into the plastic embedding mold. 
o Place the cornea with epithelial side down in the embedding matrix in the plastic 
embedding mold.  
 You can place up to 6 corneas in one medium sized plastic embedding 
mold. 
o Place some liquid nitrogen into a small Styrofoam container. Should be enough 
liquid nitrogen to surround the plastic embedding piece but not enough to cover it 
completely.  
o Holding the embedding mold with forceps, freeze the corneas in the plastic 
embedding mold. 
o Fill the plastic embedding mold with additional embedding matrix until it is full.  
o Wait about 5 seconds for the previous frozen embedding matrix to melt a little bit, 
but the corneas are mostly still frozen.  
o Freeze the corneas in the embedding matrix for a second time. 
o The block is ready to bring to the cryostat for cutting.  
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• Cutting the cornea at 18 µm sections 
o Bring the block to the cryostat (temperature was turned down to -20 degrees 
Celsius and the black knob turned to 18 µm). Place the block in the cryostat and 
let the temperature equilibrate.  
o Take the cornea block out of the plastic embedding matrix mold. 
 Troubleshooting: Easy way to make sure you get it out without breaking 
the block is to blow on the plastic piece of the mold until the frozen 
condensation melts. The block will still be completely frozen, but it will 
come out with ease.  
o When ready, freeze the cornea block to a round “chuck” in the cryostat. 
 You do this with placing some of the Optical Cutting Temperature (OCT) 
Embedding Compound (TissueTec #4583) located by the cryostat onto the 
round portion of the chuck and then place the back of the cornea block 
OCT.  
o Place it back into the cryostat to freeze. 
o Tighten the chuck post into the microtome. You can slightly move the whole 
metal piece with the block in it to make it cut straight.  
o Due to the epithelium being the first portion that will be cut, be careful not to hit 
the knife edge to cube at an angle.  
o Make sure when you are cutting to see the whole (or most) of the block being cut 
evenly before starting. 
o Once ready, cut the sections into sheets and collect by placing a gel coated slide 
face down onto the tissue to make it adhere to it.  
o Determine how many pieces you want on one slide.  
o To use the least amount of antibodies as possible, place the tissue as close to the 
bottom of the gel coated slide as possible. 
 Troubleshooting: If your corneas do not cut all evenly at the same time, 
you can take certain sections that you want out of a cut with paint brushes 
and mount that where it belongs on the slide. 
o Five slides can fit into one mailer, so 5 slides are used for each antibody that you 
are interested in.  
 Troubleshooting: If you use less than 5 slides, you can use blank slides 
and blank plastic pieces that go in between the blank slides. I will typically 
try to get everything on 3 slides and as close to the bottom as possible 
(about 1cm from the bottom of the gel coated slide.). This way I can add 
in two blank slides and two blank plastic pieces. With this, I will only 
need 2mL of solution to completely cover the tissue.  
o Continue to cut and place at the end of the slide until you have what you need. 
o Once your slides are cut, place on the warm plate (long black warm plate) in the 
lab. Turn on the dial to about 2.5 for 1 hour. 
• Primary antibodies 
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o Take all the slides from the warm plate and place them in mailers (Plastic glass 
slide holders that hold 5 slides each). 
o Place each one in a glass rectangular container and place paper towels around the 
mailers to prevent them from falling. 
o Add PBS to each of the mailers and let it wash for 15 minutes. 
 Troubleshooting: If you find that your tissue has fallen off the slide, the 
gel coating was not sufficient.  
o Repeat 2 more times so each mailer has been washed 3 times for 15 minutes each. 
o Make PBS-T-BSA-PVP 
 PBS-T: Take 
• To make PBS-T, obtain a 100mL beaker with a stir bar and a 1000 
µL pipette. 
• Add 63mL of PBS to the 100mL beaker and begin stirring. 
• Use the 1000mL pipette and take out 188µL of Triton X-100. (It is 
very thick, so slowly take it out and allow the pipette tip to stay in the 
Triton X-100 for about 10 seconds before removing it. 
• Quickly bring the solution over to the 63mL of PBS in the 100mL 
beaker and dispense the Triton X-100 into the beaker. 
• Allow for it to mix, and the solution is ready to use. 
 PBS-T-BSA-PVP: Take 20 mL of PBS-T and add 0.10 g of BSA and 0.10g 
of PVP. Mix carefully since it will bubble. 
 Diluent: We want PBS-T with 0.5% bovine serum albumin (BSA), 0.5% 
PVP.  Take 0.05 g of BSA and PVP to each 10mL you need. In this case use 
(0.5g)/(100ml) = (xg)/(20ml) → x = 0.10g bovine serum albumin (BSA) and 
polyvinylpyrolidone (PVP).  Take 20ml PBS-T and add 0.10g of BSA and 
0.10g of PVP.  Mix, but will bubble if mixed too hard. 
o Place 2 mL of the PBS-T-BSA-PVP solution into a 15mL tube. (This will be 
added to the mailers, so depending on how far your tissue is up the slide will 
determine if you need to use more or less PBS-T-BSA-PVP. 
o For each mailer, prepare an additional 15 mL tube with 2 mL of the PBS-T-BSA-
PVP solution in it. 
o You will want to add in your primary antibodies into each 15mL tube with the 
PBS-T-BSA-PVP in it. If you are using 2 antibodies and one of them is the same 
antibody across all of the mailers, you can add in that antibody into the 20 mL 
solution directly and mix. 
 Example: if you are using PGP 9.5 at a 1:10,000 dilution, you can place 
2µL of PGP 9.5 into 20 mL of PBS-T-BSA-PVP and distribute 2 mL to 
each of the 15 mL tubes. 
o For the second antibody, make sure it was raised in a different species without 
cross reactivity. 
 For example, the PGP 9.5 is an anti-rabbit antibody. You can use a GluA1 
antibody if it is anti-goat. 
 Example: GαGluA1 
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• Dilute RαGluA1 to 1:250. (xμl)(1/1) = (2,000μl)(1/250) → x = 8µl 
GαGluA1 into 2mL of rαPGP 9.5 PBS-T-BSA PVP. 
o Each dilution will be different depending on what antibody you are using. Know 
the dilution before you start, do a dilution curve, or guess and hope for the best. 
o Once all the 15 mL tubes with 2 mL of PBS-T-BSA-PVP have all of the 
antibodies that you are interested in staining for, gently mix each tube by 
inverting and rotating. 
o Pour out all the fluid from the washed mailers and pour 1 tube into each of the 
mailers.  
o Label the mailers by what antibodies were in the 15mL tube that you poured into 
the mailer. 
o Once labeled, place Parafilm over each of the tops of the mailers and bring it to 
the cold room.  
o Place the mailers in the glass container, with your name and date on it with a 
piece of tape, on the rocker in the cold room and turn, if it is not already, to a 
speed that will mix the solution but not throw off your slides.  
o Incubate for 72-96 hours. 
• Secondary antibodies 
o Rinse each of the mailers with PBS 3 times for 10 minutes each. 
o Prepare another set of 15 mL tubes with 2 mL PBS-T in each of them (Again, 
tissue location on slide determines the amount of PBS-T needed). 
o Depending on what primary antibodies you used, will determine which secondary 
antibodies you need to use. 
 Example: Continuing the previous example, we used anti-rabbit PGP9.5 
and anti-goat GluA1. 
 To get the right secondary antibodies, you will need anti-goat Alexafluor 
555 1:1000 (2 µL Ab into 2mL PBS-T) and anti-rabbit Alexafluor 488 
1:1000 (2 µL Ab into 2mL PBS-T).  
 Once each of the 15 mL tubes with 2 mL of PBS-T has the secondary 
antibodies in it, and the washes are finished, you can completely empty the 
mailers of fluid and replace with the 2 mL of secondary antibody solution. 
 Let the secondary antibodies incubate for 1 hour in room temperature on a 
shaker. 
 Wash 3 times with PBS. 
• Cover slipping the slides 
o Once washed, you will need to pull out each slide individually with forceps and 
cover slip each slide individually and label each slide individually. 
o Take a slide out of the mailer and dry the sides and back of the slide. (Do not 
wipe your tissue off the front!!!) 
o Take a 25 µL pipette (or any other pipette that can take out about 25 µL) and 
place, in a drop wise manner, Prolong Gold on your tissue. 
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o Gently take a glass coverslip that will completely cover your tissue and touch the 
end of it to the Prolong Gold, but not the tissue itself. 
o The Prolong will come across the slide and you can gently place the coverslip to 
the end of the slide, apply slight pressure and gently bring the coverslip across the 
tissue and the rest of the slide.  
o You can get a slight bend in the coverslip, this will help prevent bubbles from 
accumulating as you place the coverslip on the slide.  
o Look for any bubbles that may have become stuck under the coverslip and gently 
use the forceps to push the bubbles out. Do not go over the area where your tissue 
is located to avoid possible scratching. 
o You can also wrap the coverslip with a Kimwipe and gently apply pressure across 
the coverslip to remove any bubbles or excess prolong gold.  
o Soak up any excess prolong gold with a Kimwipe. 
o Place in a cardboard slide holder overnight in a dark drawer to let the prolong 
gold harden. 
• Confocal Microscope. 
o After the prolong gold has hardened overnight, you can view your slides with the 
confocal microscope. 
 You will need personal training to use the microscope. Do this before 
you start your experiment. After training, activate your card to get 
access to the room 
o Sign up for the confocal microscope on the calendar. 
o MOST IMPORTANT STEP!!!! 
 When you walk into the microscope room you will take off the plastic 
cover from the confocal microscope. 
 Look at the microscope and make sure everything looks like it should.  
 You need to make sure the objectives are all the way down!!!!! 
• The confocal microscope will calibrate itself when you turn it on 
automatically, if the stage is not all the way down, the stage will 
catch one of the objectives, put deep scratches in the objective and 
tear up the stage. This is a VERY expensive mistake. 
 You need to make sure the objective that is in the useable position is 
an empty slot!!!!! 
• The water and oil lenses are always placed in and taken out for 
each experiment, so the empty slot where one of those will be 
located should be in the useable position when the confocal 
microscope goes through its calibration steps.  
o Turning the microscope on. 
 There are pieces of tape labeled 1-5 on each of the pieces of machinery 
that needs to be turned on. 
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 Turn on the machine by starting with 1 and wait 3-5 seconds, then 2, then 
3, then 4, then 5. 
 Once the computer is turned on, select SPE_User. 
 Then double click on LAS AF. 
 Make sure the program is in Machine No Stage (Orange box) mode then 
click OK (Red outline): 
 
 The confocal microscope will go through its calibration steps.  
• Takes about 1-2 minutes.  
 Click on Configuration (Red box) and click on each laser (Blue box): 
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 Identify the settings you need for your fluorophore(s) (Blue box). You can 
also save your settings if you will be using it a lot: 
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o Placing the objective in the confocal microscope. 
 The 40X Water lens is in a box in the desk. It also has a number written on 
it. The number indicates the objective location where it belongs. Make 
sure to put it in the right spot. 
 Unscrew the objective container next to the microscope and on top of the 
table the microscope is on. Do not take the objective out just yet. Leave 
the cap loose.  
 Move back the top of the confocal microscope. This is on a hinge system 
that is not protected. Make sure you firmly grasp the top of the confocal 
microscope and slowly bring it back until it is all the way back. If you do 
not guide it, you will damage the microscope.  
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 Unscrew the cap that is on the objective location for the objective you plan 
to use.  
• If you do not plan to use the water or oil lens, you do not have to 
do this. 
• Once again, leave the cap unscrewed on top of the hole that the 
objective screws into. 
o If dust and other debris manages its way into the objective 
position hole or in the objective itself, your images will be 
blurry and it is another expensive mistake. 
• Take the objective out of its casing and unscrew it. 
• After the cap is off the objective, remove the cap on the hole that 
the objective attaches to the confocal microscope and then screw 
the objective in.  
o Minimize the time that the transfer happens, but do not 
slam the objective into its spot.  
• Place the cap in the objective container then screw the cap back on.  
 Placing your slide on the stage. 
• Place a drop of autoclaved water on the 40X water objective. 
• Take the slide you want to view with the confocal microscope and 
wipe it off with water and a Kimwipe. 
• Bring you slide and place it face down (Coverslip down) on the 
stage. 
o Place your slide on the right side of the stage and bring the 
left side to the edge of your slide. 
o If you have your tissue all the way at the bottom of the 
slide, you will not be able to fully bring the left side of the 
stage to your slide. Just make a judgement and place it 
where it keeps the stage horizontal over the objectives, but 
it also does not block the view of your tissue.  
• Slowly bring the 40X water objective up to your slide until the 
water contacts your slide. 
• You can move the stage at this point to place the objective at the 
tissue of interest. 
• Carefully bring the arm (Top of the microscope) back in its 
downright position.  
• You are ready to view your slide. 
 Viewing your slide. 
• Press the top left button on the confocal microscope (The one that 
looks like an eye). 
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• Press the laser that is at the proper wavelength that will excite the 
fluorophores that are attached to your secondary antibody. 
o FITC= Excitation: 490, Emission: 525 
o Rhodamine= Excitation: 555, Emission: 565 
o DAPI= Excitation: 350, Emission: 470 
o Texas Red= Excitation: 596, Emission: 615 
• Press the center SHUTTER button to view the slide. 
• Focus on your tissue of interest and identify what you would like 
to photograph. 
o You will not be able to photograph the whole field of view 
you are examining. Place the most interesting part in the 
very center of what you see. 
• Press the SHUTTER button again to close the shutter. 
o Troubleshooting: You do not want to overexpose the 
fluorophore of the secondary because of photobleaching.  
 Taking a Z-Stack photoset. 
• Press on Live to view your tissue on the computer.  
• Slightly adjust the stage to where you want, so you get the image 
that you want. 
• Adjust the gain to where you want, so you best display the color 
intensity you are interested in. 
o If you are looking for a good image, gain does not really 
matter too much. 
o If you want to quantify your images, keep the same gain 
and laser intensity no matter what. Be sure to record what 
you use. 
• If the tissue is double labeled, you can switch filters by clicking on 
scan 2. 
o You will have to readjust everything for the second 
fluorophore.  
• Click on the yellow box, scroll down with the scroll wheel on the 
mouse (Blue Box) to the point where you want to start taking 
images, and click on the banner to the left (Red box left). Click on 
the yellow box again, scroll up to where you want to finish taking 
images, and click on the banner to the right (Red box right): 
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• Select the resolution for your images (Blue Box): 
 
• Click on Start on the bottom right of the left screen. 
• Click start (Blue box, where it would indicate start) and you can 
see the two fluorophores and the combined image by clicking this 
(Red box): 
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 Naming and saving experiments 
• Click on the experiments tab: 
o PICTURE 
• Click on the experiments tab (Blue box), right click and rename 
your experiment with the antibody or antibodies you used: 
 
o Also, right click and rename each image set that is located 
under the main experiment. Add the tissue type and 
experimental number to the name (Purple box, above 
image). 
 All the names here will transfer over to your final 
images. Make sure that you typed it in right before 
you move on. 
• Find the folder where you will save your images: 
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• Save your experiment in the folder you made for it (Red highlight): 
 
• Export the image set as a tiff file to the folder you made for it: 
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• You must save your image two separate times if you have a co-
labeled tissue section. One for the single images, one for the 
combination of the single labeled to make co-labeled images. 
o Single images 
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o Co-labeled images 
 
• Once all your images are in the correct folder, you can move on to 
formatting and/or analyzing. 
 Cleaning up after yourself!!!! 
• You will need to return and properly turn off everything on the 
confocal microscope. If this is not done correctly, another 
expensive error may occur.  
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• After you have saved everything, turn off the program on the 
computer. 
• Go to the start menu and click on shut down computer.  
• Once the computer is completely turned off, you can begin to turn 
off the confocal microscope. 
o Turn off the machine in the right order: 4, then 3, then 2, 
then 1. 
• Carefully guide the top of the confocal microscope back. 
• Place your slide back in your slide box. 
• Bring the objectives back to their lowest position!!! 
• Take the cap back out of the objective container. 
• Unscrew the 40X water lens. Directly after, set the cap over the 
hole. Do not screw it in yet.  
• Screw the 40X water lens back into the top of the objective 
container, then screw it back into the objective container. 
• Finish by screwing in the cap over the objective lens hole. 
• Gently bring the top of the microscope back into the downright 
positon. 
• Check to make sure the objectives are in the furthest down 
position, then cover the confocal microscope with its plastic dust 
protector.  
• Place the 40X water lens back into the cardboard box and place it 
back in the desk drawer.  
• Sign the log with the time that you started and finished in the log 
book and identify any issues that may have occurred. If you find 
the confocal microscope in a position or if something was out of 
place, make a comment in the log. Place it back where it should be, 
not where you found it.  
o Troubleshooting: There are more functions that the 
confocal microscope has. Learn about them and try to 
expand.  
• Image processing 
o Once you have the images, you will need to download and bring the images to 
Image J Fiji. 
 You will also need to go to the website and add the deconvolution lab 
plugin. 
o First, you will need to identify the images that you want to deconvolute and 
merge. 
o Make sure you know where you saved your images on your computer and make a 
new folder for each of the filters and one for the merged images. 
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 Make a copy of the images you want to deconvolute and merge and 
separate them into their respective folders. 
 You will not need the folder with the combined images since you will 
make another combined image with the program. 
o Copy the images that you will work on into their respected folders. 
o Open Image J Fiji. 
o Go to file/import/image sequence. 
o Find one of the filter folders and select the first image in the set and select open. 
o The program will tell you how many images you have in the folder. Press ok. 
o Go to file/import/image sequence again and select your second filter set. 
o Continue until you have all the filters that you are working with for that single set 
of images. 
o Now you should have two or more image stacks open for the same image, but in 
different colors (filters).  
o Go to Plugins/Deconvolution Lab/Deconvolution lab and press ok. 
o Now you should have the add on in Fiji image J for the deconvolution lab open. 
o Select Tikhonov-Miller from the dropdown box to find the deconvolution method 
that we use.  
 We use the default features which include 10 iterations. 
o Click on the image stack that you would like to deconvolute first and select Run. 
 The program is set to conduct commands based from the last image that 
you clicked on. Keep this in mind. 
• Note: If you have multiple images open, the last one that you 
clicked on is the one that will go through the deconvolution. Be 
sure to deconvolute each image set by clicking on the next set and 
redoing the deconvolution after the previous one has concluded.  
o Press Run, then ok. This will start the deconvolution. 
o This may take a while depending on how many images you have. You must wait. 
o Redo this method for the remaining image stacks. 
o You will have a greyscale image stack once this is complete.  
o Now, you will want a total of 3 images if you have two filters. 
 One being the green filter, one being the red filter, and one being the 
combination. 
• There are also other colors, change according to your liking or 
what it was originally. 
o First you will combine your stacks to make one image.  
 This will layer all the images on top of one another to allow you to see all 
the images at once. 
• Note: You can try this with any images that are not similar to see 
what is going on. Try taking an image of a tree and a separate 
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image of a building and see what it looks like when combined. 
This will give you an understanding of what the program is doing.  
o ‘X’ out of the deconvolution lab window. 
o Select the grey image set that you are interested in combining.  
o Go to Image/Stacks/Z Project then press ok. 
o You will notice that you can no longer scroll through the images on the stack 
window. This is because all the images are in a final single image. 
 This image is still greyscale. 
o Repeat for the remainder of the filters. 
o Go to Image/Color/Merge Channels. 
o There will be a window that asks which image belongs to which filter (channel). 
o Identify and select the greyscale image in the correct channel and select ok. 
o Click on the merged image and go to file/Save As/PNG. Name your image and 
save it where you want it. 
o Click on the merged image to make it active, then you can split the channels by: 
 Image/Color/Split Channels. 
o This will split the images that you just combined, but they will be in color. 
o Click on the one you want to save first, then select file/Save As/PNG to save it. 
o Continue saving all the split images. 
o Now you can make a montage if you want. 
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